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"Somewhere, something incredible is waiting t o be known."

Dr Carl Sagan

Steroid hormones, such as oestrogen, mediate their effects via activation of oestrogen
regulated genes using nuclear receptors. Selective oestrogen receptor modulators
(SERMs), such as Tamoxifen, are used to treat oestrogen responsive breast cancers,
hctioning to act as oestrogen antagonists, preventing the oestrogen receptor biding
DNA and blocking gene expression. However, Tamoxifen has been identified as an
oestrogen agonist in other tissues which can often lead to secondary tumors in the years
following the treatment. Identification of the genomic regions where SERMs can act as
oestrogen agonists can possibly lead to the development of gene targeted therapies or
other alternatives to prevent this from occurring.
Investigations of a previously constructed ERE reporter library were directed towards
the isolation of SERM responsive plasmids. Identified SERM responsive plasmids
were compared to oestrogen responsive reporter piasmids on the basis of their ability to
mediate trauscription in conjunction with other nuclear -tors

and coactivators to

establish potential novel interactions. ERa mutation analysis was performed to attempt
to identify the mechanism by which these sequences have the ability to be activated

with the addition of SERMs. It was found that SRC-3, a member of the SRC family of

coactivators, had the ability to corepress SERMs via oestrogen receptors, a response not
documented previously.

Further to results obtained from the investigations of the SERM responsive reporter
plasmids, DamID technology was employed to attempt to construct two libraries of
sequences that associated, indirectly, with SRC-1A or SRC-3, via ligand bound
oestrogen or progesterone. Gateway technology was used to transfer cloned sequences

in to reporter plasmids to enable the luciferase assay to be employed in order to
determine the functionality of the isolated sequences.
- ~...
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Transactivation assays suggested that the attempt to direct the SRC-1A:Dam fusion
protein to bind to DNA via either ligand bound oestrogen or progesterone failed,
however following reporter plasmid sequencing bioinformatical studies were performed
q d a number of possible transcription factor binding,motifs were identified in the
sequences. Further transactivation assays indicated SRC-1A:Dam had, in a subset of
the reporter plasmids, bound via the orphan nuclear receptors RORa and COUP TFI.

Results suggest that SRC-1A may mediate this association and coactivate gene
transcription; the mechanism behind this novel finding remains to be elucidated.
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1.1. Gene Expression
The expression of a genome is the mechanism whereby information contained in the
genome is synthesised into a gene product.
Steroid hormones mediate their functions by activating the expression of specific
subsets of genes to elicit a physiological response. The activation and expression of
genes is a highly regulated series of events which depend on the interaction of RNA
Polymerase Il with the genome. The interaction of RNA Polymerase I1 with the
genome in response to steroid hormones is mediated by nuclear receptors. The
interaction of nuclear receptors with the genome is hindered by the chromatin
environment which can be altered to either enhance the genomic interaction of inhibit it
via activators and inhibitors, w-enhancers and co-repressors (Reviewed in McKenna
and O'Malley, 2002).

1.2. Steroid Hormones
Steroid hormones are generally synthesised by cholesterol in the gonads or adrenal
glands. Being synthesised from cholesterol they are lipophilillic and can readily
transverse the cell membrane (Olefsky, 2001) and combine with a specific protein
receptor which, when activated by the steroid hormone, interacts with the cellular
tmmaiption machinery or specific genomic elements to either activate or inhibit a

target gene. Steroid hormones are transported through the body via the circulatory
system bound to specific carrier proteins.

1.2.1. Oestrogen and Progesterone
The ovarian steroids, oestrogen and progesterone, are steroid hormones which function
to regulate a variety of aspects of female reproduction. Oestrogen is produced from
developing ovarian follicles, the corpus luteum, the placenta during pregnancy and in
smaller amounts by other tissues (secondary tissues; important source of oestrogen in

post menopausal females) such as liver, adrenal glands and mammary glands.
Progesterone, on the other hand, is produced in the ovaries, the brain and also in the
placenta during pregnancy.

Levels of oestrogen and progesterone in menopausal

females vary depending on the stage of the cycle (Figure 1.1.).
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Figure 1.1. Fluchding levels of esiivgen dprogesterone daring the menshual cycle.

Positive and negative regulation of these steroid hormones are controlled by a series of

feedback mechanisms incorporating the pituitary hormones: follicle stimulating
hormone (FSH) and luteinizing hormone (LH) (Biology of Human Reproduction, R
Pinon).

1.2.2. Sex Hormone Synthesis
Oestrogen occurs natural1y in three major forms; oestrone (El), oestrodiol (E2) and
oestriol (E3) (Figure 1.2.). Estradiol is widely considered to be the principal form
present in nonpregnant females.

Oestmne (El)

Figure 1.2. Molecular structure of Oeshone, Oestradiol and Oestriol

Estrogens are present in both males and females, usually at a significantly higher level

in females of reproductive age.

All forms promote the development of female

secondary sex characteristics, such as mammary development and growth of body hair,
and also in aspects of regulating the menstrual cycle, such as thickening of the
endometrium. Oestrogen also has functions in males including regulation of sperm
maturation and release (Hess et al. 1997).

Progesterone (Figure 1.3.) has a number of physiological roles all of which are
augmented in the presence of oestrogen. Progesterone converts the endometrium to its
secretory stage to prepare the uterus for the arrival of a developing embryo in case
fertilization occurs, it also accelerates the movement of the oocyte or embryo to the
uterus and causes enlargement of mmmqy glands (in combination with other steroid
hormones such as estradiol).

Pqe8temne

Figure 1.3. Molecular structure of Progesterone

Follicular theca and granulosa cells in the ovary are the most important site of oestrogen
synthesis in females of reproductive age where production is stimulated by FSH and LH
(Figure 1.4.) (Wang et al. 1980; Simpson et al. 1994; Michael et al. 1995; Bulum et 01.

2000).
Earfy Folllcular Phase

Figure 1.4. Synthesis of Oeshogen (Adaptedfiomfigure in Biology of Human Reproduction,

Pinon)

Follicular maturation is characterized by the proliferation and functional differentiation
of ovarian granulosa and theca cells. In the early stage of follicular development
granulosa cells undergo rapid proliferation with limited capacity for hormonal
production. As the follicles grow and develop the cells demonstrate an increased ability
to secrete hormones (Gougeon, 1993). Cross-talk between granulosa and theca cells is
essential for the maintenance of the physiologic function and structure of follicular cells
and for the production of the ovarian hormones ( ~ a d et
a al, 1999).
Synthesis of oestrogen is initiated by increasing levels of the pituitary hormones LH and

FSH.

Oestrogen is synthesized from androstenedione, a substance of moderate

androgenic activity, which is synthesized from cholesterol (Figure 1.5.).

Figure 1.5. IIIustration Outlining Oestradiol Synthesis (Ray el al, 2006)

Cholesterol is the 'building block' of all steroid hormones and undergoes double
oxidation to produce 20,22-dihydroxycholesterol to initiate the synthesis of both
oestrogens and progesterone, this is then further oxidized with loss of the side chain
starting at position C-22 to produce pregnenolone. These conversions occur in ovarian
mitochondria. 17a-hydroxypregnenolone is then formed by the action of a smooth
endoplasmic reticulin enzyme, 17a-hydroxylase. Dehydroepiandrosterone is formed by
another shooth endoplasmic reticulin enzyme, 17,20 lyses, which is converted to
androstenedione by 3P-hydroxysteroid dehydrogenase which is then converted to
estrone by aromatase.

Alternatively, dehydroepiandrosterone is converted to

androstenediol by 17P-hydroxysteroid dehydrogenase and then to testosterone by 3Phydroxysteroid dehydrogenase which is then converted to estradiol by aromatase.
Oestrone and oestradiol can further be converted to estriol in the liver and placenta.
Theca cells convert cholesterol to androgens under LH stimulation from the pituitary;
however theca cells lack the enzyme aromatase and so cannot convert the androgens to
oestrogens. The androgens produced in the theca cells diffuse to the granulosa cells
which then convert them to oestrogens, primarily oestradiol, under FSH stimulation.
Therefore, the ability of the ovarian follicle to produce oestrogens is dependant firstly
on the androgen producing ability of the theca cells, followed by the aromatase activity
of the granulosa cells.
Intracellular cyclic adenosine monophosphate (CAMP) regulates aromatase expression
in the ovary. Upon FSH binding to its G-protein-coupled receptor located in the
granulosa cell membrane, intracellular cAMP levels increase which functions to
enhance binding of two critical transcription factors (steroidogenic factor-1 (SF-I) and
cAMP response element binding protein (CREB)), to the proximal promoter I1 of the

aromatase gene. This results in aromatase expression and consequently oestrogen
secretion h m the preovulatory follicle (Bulum et al, 2000).
Progesterone is also synthesised h m cholesterol, production being stimulation by LH
in vivo (Carlson et al., 1971) and in vitro (Armstrong and Black, 1966) (Figure 1.6.).
Oestrogen action on both the pituitary and the hypothalamus is required for the LH
surge that occurs at the end of the follicular phase. FSH and oestrogen action on the
granulosa cells initiates the synthesis of LH receptors and the combination of LH and
FSH action on the granulosa calls triggers the initiation of progesterone synthesis.

Lab Follfcular Phase
(beginning of luleiniration)

Fignre 1.6. *thesis

of Oestrogen ond progesterone (Adapted from figure in Biology of

Human Reproduction, Pinon)

Similarly, progesterone synthesis begins with the conversion of cholesterol to
pregnenolone by a cholesterol side chain cleavage enzyme present in the mitochondria

(Figure 1.5.). Pregnenolone is then converted to pmgesterone by 3p-hydroxysteroid
dehydrogenase. Progesterone can also be converted to oestrogens by 17a-hydroxylase

convertion to 17a-hydroxy progesterone and subsequent convertion to androstenedione
and testosterone by 17,20 lyases and 17P-hydroxysteroid dehydrogenase.
The major sites of oestrogen biosynthesis in postmenopausal women include
extraglandular tissues such as skin and adipose tissue.

Aromatase expression is

controlled by the cytokines interleukin OL)-6, IL-11, tumor necrosis factor alpha

(TNFa)and also glucocorticoids in adipose tissue and skin fibroblasts (Simpson et al,
1994). The major precursor of oestrogen in adipose tissue and skin is androstenedione
of adrenal origin (Bulum et al, 2000). Androstenedione is then converted to oestradiol
by 17P hydroxysteroid dehydrogenase (17p-HSD) (reductase) activity in these
peripheral tissues.

During pregnancy the placenta becomes the main source of progesterone.

1.3. Nuclear Receptors
Oestmgen and progesterone carry out their functions by interacting, via their specific
receptors, with promoter elements in the genome thereby inducing gene transcription
and pmtein production. The specific oestrogen and progesterone receptors are just two
of a major group of protein receptors known as the 'nuclear receptor superfamily'.
These receptors are responsible for detecting lipophilic hormones and certain other
molecules in the cell cytosol.

Lipophilic hormones, such as oestrogens and

progesterone, have the ability to transverse the cell membrane (Olefsky, 2001), in

contrast to hydrophilic hormones which are unable to cross the cell membrane.
Hydrophillic hormones generally interact with cell surface receptors which cause a

conformational change inside the cell initiating a cell signalling pathway inducing gene
transcription of repression.
Lipophillic hormones however, enter the cell cytosol, b i d to the appropriate nuclear
receptor which causes dissociation of receptor bound heat shock proteins and induces
dimerization, translocation to the nucleus and DNA binding to specific motifs in, or
close to, the promoter element of the target genes (Beato, 1989) (Fignre 1.7.).
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F i g m 1.7. The activation of Steroid Receptors. Steroid h o n e s enter the cell c y t o p l m
and bind to nuclear receptors which induce a confonnationnl change in the receptor and
dissociation of nuelem receptor msociaied herd shock proteins.

Ligand b o d nuclear

receptors dimerize which enables irmlocation to the nucleus and interaction with specific
mot13 in the promoter regions of target genes.

This biding can act to either induce or repress gene transcription. Therefore, the
nuclear receptor superfamily can act as ligand-dependant transcription factors.

Members of the nuclear receptor superfamily work with other proteins to coordinate and
control gene expression, and in effect play an important role in the growth,
differentiation, metabolism, reproduction and morphogenesis in higher organisms and
humans (Aranda ei al, 2001).
The nuclear hormone receptor superfamily includes receptors for thyroid and steroid
hormones, retinoids and Vitamin D and also a subgroup of transcription factors, orphan
receptors, for which the ligands have not yet been identified (Aranda et al, 2001).

1.3.1. Oestrogen Receptors
Oestrogen receptors (ERs) refer to a group of receptors that are activated by oestrogens.
These include the well known ER, members of the nuclear hormone family of
intracellular receptors which has up to 60 members (Lander et al, 2001) as well as a
trans-membrane intracellular receptor known as GPR30 (G-protein coupled receptor)
(Revankar, 2005).
ERs are localized to many sites within the cell including the nucleus and the plasma
membrane as well as cellular mitochondria (Chen et al, 2004) and endoplasmic
reticulum (Revankar, 2005).
There are two known nuclear hormone oestrogen receptors, ERa and ERP. Each are
encoded by separate gene; ERa by ESRl gene located on chromosome 6 (q24-q27)
while ERP is encoded by ESR2 gene located on chromosome 14 (q21-q22). There are 8
isoforms of ERa and P (Figure1.8.) (Matthews and Gustafsson, 2003).
ERa and ERB are Class I nuclear receptors that bind to elements in the 5' flanking
regions of DNA as homodimers. The main function of the oestrogen receptor is as a

DNA bindiig transcription factor that regulates the expression of genes controlled by

-

oestrogen. However, the oestrogen receptor has been found to have additional functions
which are independent to DNA biding.
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Figure 1.8. Representation of human ERa and /Iand their respective isofom. Both hER$2
and hER$A.5 can have either the h E ~ long
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evidence offul-length hEw4 or hER$5. The d~ferentfill patterns of the 3' end of hEw2, 4,

and 5 represent the divergent C-terminal regions of these isofom. (Matthews and Ghtqtison,

The binding of oestrogen to ERa or EM either activates or represses gene transcription.
The action carried out is a result of the steroid-receptor complex binding to specific
regions in the promoters of target genes, known as oestrogen responsive elements
(EREs). The resulting protein products determine the cell biological actions of the sex
steroid.
There is also a second mechanism of action for oestrogen receptors which involves the
interaction of nuclear estradiol (E2) oestrogen receptor complexes with transcription
factors, such as activator protein 1 (AP-I), that in turn bind their specific DNA binding
elements (Kushner et al, 2000). DNA binding via EREs or AP-1 elements leads to

chromatin remodelling, histone unwinding, recruitment of basal transcription factors
and co-activators, displacement of co-repressors and f d l y gene transcription and
protein expression (discussed in review by Levin, 2005).
Additionally, a small amount of ERs localize to the plasma membrane whereby a
response is elucidated via cellular signalling mechanisms such as kinase cascades,
calcium, and other second messenger signalling pathways which function to regulate
hmswiption (Qii et al, 2004, Watters et al, 2000).
GPIUO is uniquely localizedto the endoplasmic reticulum, where it specifically

bidsoestrogen (Revankar, 2005). Upon oestrogen binding intracellular calcium is
mobilized and phosphatidylinositol3,4,5-trisphosphate (PIP3: involved in the PIP2 lipid
signalling second messenger) synthesis is activated in the nucleus where it initiates

many non-genomic signalling events.
Human ERa has a molecular weight of 66 to 70 kDa,comprising of 595 amino acids
( P a m et al, 2001). ERa was isolated in 1962 by Jensen et al, in 1968 it was found to
be a ligand activated transcription factor (O'Malley et al, 1968) and it was cloned in

1986 by Greene et al (Greene et al, 1986). ERa is localised in central nervous system,
cardiovascular system, mgential tract,bone and breast (Gustafsson, 1999). It is also
the major ER subtype in the liver and the uterus (Gustafsson, 1999; Taylor et al, 2000)

(Fig-

1.9.).

ERp was discovered in 1996 by Kuiper et al in rat prostate and ovary and cloned in
1997 by Enmark et al. Full-length E M is 530 amino acids in length and has a
molecular weight of 58 to 62 kDa although it has been shown to be produced in
multiple isoforms, EM1 and EM2 (Figure 1.8.) (peterson et al, 1998). E M is seen at

highest levels in the ovary and prostate with lower expression levels seen in the
cardiovascular system, bone, breast, uterus and testis (Mosselman et al, 1996; Tremblay
et al, 1997; Kuiper et el, 1997; Gustafsson, 1999). It is also the major ER subtype in the
gastrointestinal tract, brain and prostate (Figure 1.9.) (Gustafsson, 1999; Taylor et al,

2000).
Centd nervous system: ERa. ERP

Breast: ERa. ER

Cnrdiovascular

Gnstrointestinnl

Figure 1.9. Overall distribution of ER in d~yerenttissues (Gustafson, 1999)

E R a has 6 main structural and functional domains (named A-F from N to C terminus)
(Figure 1.10.): a variable or regulatory domain containing a transcriptional activation
function (AIB), a DNA binding domain (C), a hinge region (D), a ligand binding
domain (E) and a region that plays a role in distinguishing agonists vs. antagonists (F).
In vitro site mutagenesis assays, deletion mutation studies and domain swapping
experiments have confirmed the functional roles of these domains (Green et al, 1987;
Kumar et al, 1986; Kumar et al, 1987)
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Figure 1.10. Functional Domains of Human ERa (Pavao et al, 2001)

The regulatory A/B domain (aa 1-184) of ERa exhibits very little conservation between
species (Krust et al, 1986) and among other nuclear receptor superfamily members
(Seagraves, 1991). This domain shows promoter- and cell-specific activity and is likely
to contribute to the specificity of action among isoforms and that it could interact with
cell type specific factors (Aranda et al, 2001). A portion of this N-terminal regulatory
domain AIB (aa 41-150) is known as the Activation Function-l (AF-1) domain,
associated with the modulation of transcriptional activity (Klinge, 2000). The AF-1
domain of ERa is phosphorylated at serine or threonine residues via the mitogenactivated protein kinase (MAPK) in vitro, and in cells treated with growth factors that
stimulate the Ras-MAPK cascade, and this phosphorylation has been shown to enhance
transcriptional activity (Kato et al, 1995; Patrone et al, 1996; Aranda et al, 2001).
The DNA binding domain, located in region C (aa185-263), is a highly conserved
region (Kumar et al, 1987) containing two zinc fingers. The zinc fingers (both 1 and 2)
are responsible for the direct interaction with the DNA double helix (Kumar et al,

1987). Each zinc finger contains four cysteine residues that coordinate the binding of a
zinc atom. The 'P Box' is a term given to three amino acids at the base of the first zinc
finger and is responsible for DNA binding specificity (Nelson et al, 2005), the three
amino acids at the base of the second zinc finger is known as the 'D Box' and is

involved in dimerisation (Aranda et al, 2001). The core DBD contains two a-helices:
the recognition helix located at the third conserved cysteine residue which binds the
major groove of DNA making contact with specific bases and a second which spans the
COOH terinus of the second zinc finger forming a right angle with the recognition helix
(Aranda et al, 2001).
The hinge region, region D (aa 264-302) serves as a hinge between the DBD and the
ligand binding domain (Aranda et al, 2001) containing sequences for receptor
dimerisation and nuclear localization (Klinge, 2000).
The ligand binding domain (aa 303-553) (region E) is located in the C-terminal section
of the receptor. This is a multifunctional domain that, in addition to ligand binding,
mediated homo- and hetero-dimerisation, interaction with heat shock proteins, liganddependant transcriptional activity and in some cases hormone reversible transcriptional
repression (Aranda et al, 2001). A portion of this domain (aa 530-553), AF-2 (a second
activation functional domain), is also associated with transcriptional regulation via
association with co-regulatory proteins (Henderson et al, 2003).
Region F (aa 554-595), (Figure I.IO.), is located at the C-termal region. Its function is
currently unknown but it shows very little sequence conservation similar between
receptor isoforms (Mosselman et al, 1996). However, it is thought to play a role in
distinguishing agonist vs. antagonist binding to the receptor (Pavao et al, 2001;
Henderson et al, 2003).
Both ERa and ERP share similar domain structure, ERP also containing 6 functional
domains (A-F). However, the AB domain (aa 1-148) contains a repressor domain
rather than an AF-I activation domain. The A/B domain is the least conserved of the
domains between ERa and ERP with only 30% similarity at the amino acid level

(Pavao et al, 2001). DNA biding domain is 96% and the ligand biding domain (aa
304-500) (containing a diierisation domain, transactivation domain and a nuclear
translocation domain) is 58% homologous, with an identical 'P Box', to the ERa
sequence (Mosselman et al, 1996). There is a nuclear translocation domain located
between the DNA bindiig domain and Hinge region. The E region (aa 304-500)
contains a (dimerisation domain, tramactivation domain and a nuclear translocation

domain). The F region is found between amino acids 500 - 530.

1.3.1.1. Physiological Roles of Oestrogen Receptors
Oestrogen Receptors control a wide variety of physiological processes (Figrre I.lI.),

and therefore, are implicated in many diseases. Below is a brief overview of the major
roles of the oestrogen receptors.

Reproduction

Oestrogens are essential for fertility, ERs being involved in ovulation, implantation,
pregnancy maintenance and childbirth.

It has been proposed the ERa mediates

proliferative effects while E@ mediates the differentiating effects of oestrogen within
the follicles.
Additionally, during p
u
w
,the lobular portions of the mammary terminal ducts are

highly responsive to oestrogen. In breast tissue, oestrogens function to stimulate the
growth and differentiation of the ductal epithelium, induce mitotic activity of ductal

cylindric cells, and stimulate the growth of connective tissue (Gruber et al, 2002). ERa
and ERfl have distinct mles and distributions in the mammary glands. The density of

oestrogen receptors in breast tissue is highest during the follicular phase of the
menstrual cycle and gradually decreases following ovulation (Gruber et al, 2002).
Oestrogen receptors also have a role in male reproduction, ERa being the primary
receptor responsible being localised in the efferent ductal epithelium. Its roles include
the regulation of fluid reabsorbtion in the efferent ductules and maintaining a
diffetenciated epithelial morphology. ERa lmockout mice display dilation of cauda
epididymal spenn, disruption of sperm morphology, inhibition of sodium transport and
subsequent water reabsorption and eventual decreased fertility (Hess, 2003).

F&we 1.11. Physiological Role of Oeshogen Receptors (Gruber et ~1,2002)

Skeletal System
Oeshogens have an important role in bone metabolism and homeostasis (reviewed in

Turner et al, 1994) with effects on skeletal growth and also bone maturation.
In adolescence oestrogens are involved in the bone modelling, initialling pubertal bone
growth and limiting longitudinal bone growth in women (Migliaccio et al, 1996). In

adults oestrogens are important in bone maintenance by promoting bone formation
through the stimulation of osteoblasts, and repressing bone resorption by repressing

osteoclasts. ERa is involved in the growth promoting effects of oestrogens and ERP is
involved during puberty, limiting longitudinal and radial bone growth in females
(Nilsson et al, 2001).
The action of oestradiol on bone maintenance and homeostasis is evident in women
during menopause as decreasing oestrogen levels is associated with a higher incidence
of oaeoporosis (Turner et al, 1990; 1992).

Central Nervous System

Oestmgens are also thought to have neumprotective actions (Behl and Holsboer, 1999).

In brain tissue h m adult rats, estrogens induce synaptic and dendritic remodeling and
cause glial activation. In neurons of the hippocampus, an area involved in memory,

estrogens increase the density of N-methyl-D-aspartate receptors and increase neuronal
sensitivity to input mediated by these receptors. In cultured human n e u r o b h m a cells,
estrogens have neuroprotective effects and reduce the generation of beta-amyloid

peptides (reviewed in Gruber et al, 2002).

Vascular Effects
Oestrogens act as natural vasoprotective agents, and this is ER dependant (Baku et al,
2000). Oestrogens cause short-term vasodilation by increasing the formation and
release of nitric oxide and pstacyclin in endothelid cells (reviewed in Gruber et al,
2002).

1.3.2. Progesterone Receptors
There are two natural isoforms of the progesterone receptor: PR-A (94 kDa) and PR-B

(104 kDa) (Horwitz & Alexander, 1983) (Figure 2.22.).

One gene, PGR on

chromosome 11 position q22, codes for both isoforms of the progesterone receptor,
unlike the oestrogen receptor, which uses separate promotors (both oestrogen receptor
inducible) and translational start sites to generate the two isoforms (Kastner et al, 1990).

Figure 1.12. Sequence similarities between human PR-A andPR-B

'Ihe progesterone receptor has multiple discrete, differentially conserved structural and

function regions, designated A-F, similar to the oestrogen receptors (Beato, 1989). The
non-conserved region A B contains the transcription activation function region 1 (AF-I)
which is present in both PR-A and PR-B. Region C contains the DNA binding domain

(DBD), consisting of 2 zinc fingers that function to b i d to DNA and enable recognition
of the progesterone responsive element (PRE)located in the promoter elements of

progesterone responsive genes. Region E contains the hormone binding domain (HBD)
which functions to prevent the DBD from binding to the responsive element. Ligand
binding induces receptor dimerization prior to DNA binding and creates an 'active
surface', within the HBD, thus generating a second transcriptional activating function
(Webster et al., 1988, 1989; Tora et al., 1989). Region D is a hinge region, and Region
Fs function is currently unknown, both described in more detail in Section 1.2.1.
Transcription of one gene from multiple promoters provides advantages in gene
expression; one or more of the resultant transcripts may be truncated causing the
different transcripts to convey a variety, and sometimes opposing, biological actions.
Thereby one gene is used to transcribe a number of isoforms, which'can be expressed by
different transcription factors, the products of which elicit a number of varied biological
responses.

The progesterone receptor gene is oestrogen inducible yet the promoter

regions for PR-A and PR-B do not contain consensus oestrogen responsive elements
(EREs), however the PR-A promoter region does contain a half-palindromic ERE site
which may be involved in the oestrogen responsiveness of PR-A (Kastner et al, 1990).
PR-B differs from PR-A by an additional stretch of 164 amino acids at the N-terminal
end of PR-B, known as the PR-B specific domain which encodes a third transactivation
function domain (AF-3) which is absent from PR-A (Figure 1.12.) (Sartorius et al,
1994; Wen et al, 1994).

Additionally, they both share important structural and

functional domains, with similar DNA and ligand binding affinities yet they are not
functionally identical and have been shown to exhibit functionally distinct
transcriptional activation properties specific to cell types, ligands and promoters (Tora
et al, 1988; Vegeto et al, 1993; Meyer et al, 1990; Kastner et al, 1990).

PR-A and PR-B isoforms can have been isolated in both homodimer and heterodimer
forms, the heterodimer form may have transcriptional activation properties that differ
h m those of PR-A or PR-B homodimers (Meyer et al, 1990; Mohamed et al, 1994).
PR-A has been identified as a cell and promoter specific functional repressor of PR-B.
PR-A has been seen to act as a potent trans-dominant repressor of PR-B mediated
transcription. Additional PR-A was also capable of inhibiting glucocorticoid, androgen
and minemlocorticoid receptor-mediated genetranscription. This suggests a specific
role for the hPR-A isoform in thisregulatory process. This trans-dominant activity of
PR-A originates fiom the extreme N-terminal140aa region.
The different biological effects of PR-A and PR-B may function to generate tissue
specific regulation of progesterone, whereby different cell types can provide a differing

response to progesterone depending on the balance of PR-A and PR-B present in the
cell.
Allan et a1 identified a hormone-specific confonnational change in the LBD of PR

which is required for events that follow PRE binding (such as transcriptional activity or
receptor recycling). The conformational change may trigger HSP dissociation as well

as DNA binding. However this confonnational change is similar to that seen in nuclear
receptors that bind to their response elements in DNA independently of a ligand (Allan
et al, 1992).

1.3.2.1. Physiological Roles of Progesterone Receptor

Progesterone receptor has a major role in the functioning and maintaining of the

menstrual cycle (Figure1.2.)as well as the functions mentioned below.

Mammary Glands

Progesterone has a major developmental role in the normal mammary tissue, and it is
hypothesised that it controls mammary gland proliferation and development

(in

partnership with oestrogen) via the secretion of paracrine growth factors (Anderson,

2002). It also is believed to be involved in the formation of lobular alveolar structures
during pregnancy (Topper and Freeman, 1980). The influence of progesterone is likely
to be proliferative in this process, mediated by progesterone regulation of cell cycle
genes, growth factors, and growth factor receptors.

Progesterone also exerts a

differentiating effect on the breast through its role in lactation (reviewed in Graham and
Clarke, 1997).

Brain
Oestrogen and progesterone control specific brain functions involved in reproductive
behaviour. Progesterone regulates signals in the brain involving sexually responsive
behaviour. The most well defined aspect of progesterone effects on this process are PR
mediated effects in the hypothalamus and pre-optic area (reviewed in Graham and

Clarke, 1997).

Bone
Expression of PR in normal human osteoblast like cells has been reported (Wei et al,
1993), and it may have a role in bone matrix regulation, via its effect on

metalloproteinases.

Anti-oestrogen Action of Progesterone

Many of the effects of progesterone are thought to be due to its ability to oppose the
action of oestrogen, particularly in the uterus.

Progesterone abolishes oestrogen

induction of many of the known hormone-responsive genes (reviewed in Clarke and
SutherIand, 1990, Green and Clarke, 1997).
Progesterone directly reduces ER concentration, and additionally opposes ER-mediated
gene-regulatory events, although the molecular mechanisms of this antagonism are not
clear. However, the repressive effects of progesterone appear to be promoter- and cellspecific, and there is considerable variability between reports (reviewed in Graham and
Clarke, 1997).
PR-A has been demonstrated to have similar repressive effects on other members of the
nuclear receptor family, including those for androgens, mineralocorticoids, and
g~ucowrticoids(McDomell et al, 1994a; 1994b; Wen et d 1994), although the
physiological significanceof this observation remains to be determined.

1.3.3. Additional Transcription Factors

The Paired box 4 (PAX4) gene was fust identified in mice, and was subsequently
cloned h m humans @ohman et al, 2000). PAX4 is a member of the PAX family of
transcription factors ( D o h a n et al, 2000; Chi and Epstein, 2002)

PAX4 contains a paired box domain (a highly conserved DNA binding domain), an
octapeptide and a paired-type homeodomain (homeodomain found only in PAX4 and
PAX6) (Dahl et al, 1997; Dohrman et al, 2000). Pax proteins are key regulators of
vertebrate organogenesis since they play major roles in embryonic pattern formation,
cell proliferation and cell differentiation (Chi and Epstein, 2002; Dahl et al, 1997;
Dohrman et al, 2000; Epstein et al, 1994).
PAX4 is a transcriptional repressor that binds to a common element in the glucagon,
insulin and somatostatin promoters and it has been found to bind to an 8 bp consensus
sequence: AA(T1A)AATTA (Smith et al, 1999)
Additionally, it is also involved in pancreatic islet cell development, specifically the
differentiation of insulin producing beta cells (Dohrman et al, 2000; Soso-Pineda,
2004).

1.3.3.2. S N A I L
SNAIL is a zinc finger protein transcription factor transcribed from the Snail gene and
is 264 amino acids in length. The Snail gene was first isolated from Drosophila
(Simpson, 1983) after which the protein was isolated from human cell lines (Okaru et

al, 2001). SNAIL belongs to the SNAIL C2H2-type zinc-finger protein family (which
includes Slug) and contains 4 C2H2-type zinc fingers. It is involved in DNA, metal and
zinc binding. SNAIL is expressed in a variety of tissues, including placenta and adult
heart, lung, brain, liver, and skeletal muscle, with the highest expression in kidney
(Paznekas et al, 1999).

Drosophila SNAIL is a transcriptional repressor (Hemavathy et al, 2000; Nieto, 2002)
that acts to maintain the proper germ layers by repressing the expression within the
mesoderm of regulatory genes involved in ectodermal development (Leptin, 1991).
Snail bas an NH2-terminal domain containing a seven-amino acid SNAG domain.
Okaru et al used s i t e k t e d mutagenesis experiments to confirm that this domain is
important for the repressor activity of SnaH (Okaru et al, 2001).
SNAIL zinc-finger protein was thought to be required zygotically for mesoderm
formation (Boulay et al, 1987; Sipson, 1983).
A SNAIL binding site was identified in the CREaroCF region of the human aromatase
gene (CTGATGAAGT) and, when SNAIL interacts with this site, was found to repress
the activity of this promoter (Okary et al, 2001) thereby repressing the production of
aromatase, one of the enzymes involved in the synthesis of oestrogen (Section 1.2.2.).
Quenching is a form of gene regulation whereby repressors occupy neighbouring sites

in a target promoter and prevents the ability of the activator to gain contact with the
DNA bound transcription complex (Gray et al, 1994). Gray et al reported that this is the

mechanism used by Snail.
Normal breast epithelial cells and fibroblasts express SNAIL at relatively high levels,
however these levels drop significantly in breast cancer tissue (Okaru et al, 2001).
Okaru et al suggest that high expression of SNAIL in normal breast epithelial cells and
fibroblasts prevents proteins fiom biding to CREaro, the promoter element in the
mmatase gene. This prevents excessive synthesis of estradiol. However, low levels of
SNAIL expression in breast cancer tissue results in low levels of SNAIL binding to the

CREaro site in the aromatase promoter, enabling tramxiption factors to build up and
expression of mmatase which leads to synthesis of estradiol.

Additionally SNAIL has been implicated in the repression of Vitamin D receptor
expression in human colon cancers (Palmer et al, 2004).

1.3.3.3. RORa

Retinoid-related Orphan Receptor-a, or RORa, is an orphan nuclear receptor encoded
by the RORA (chromosome 15 q22.2) gene which encodes a protein between 468 and
548 aa in length depending on the isofonn.

The RORa gene generates four isoforms that share common DBDs and putative LBDs

but are distinguished by different N-tenninal domains (Gigue're et al, 1994) (Figure
1.13.).
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The RORa isoforms bind to monomeric RORE (RORa responsive element) found in the

regulatory region of target genes. These ROREs are generally composed of a 5' 6 base
pair A/T-rich sequence that precedes a 3' AGGTCA core half-site motif (Gigue're et al,
1994). It is thought that RORa binds DNA as a monomer, however it remains a
possibility that it could form heterodirneric complexes with an unidentified partner in
vivo (Gigue're et al, 1995).

Most RORa isoforms are tissue-specific and are involved in the regulation of different
physiological processes and have different target genes. Human RORa3 is only found in
human testis (Steinmayr et al, 1998). RORa is found ubiquitously expressed in mouse
tissue with highest levels of expression have been observed in the Purkinje cells of the
cerebellum, retina, lens, spleen, skeletal muscle, and testis (Retnakaran et al, 1994;
Matsui et al, 1995; Hamilton et al, 1996; Sashihara et al, 1996; Nakagawa et al, 1997;
Koibuchi et al, 1998; Koibuchi et al, 1998).
The structure of RORs is typical of nuclear receptors. They consist of four major
functional domains: an N-terminal domain in the Ail3 region followed by a highly
conserved DBD, a hinge region and a C-terminal ligand binding domain (Figure 1.13.).
The A/B region has been demonstrated to play a critical role in conferring DNA binding
specificity on the various isoforms (Gigue're et al, 1994; Gigue're et al, 1995). The
promoter context, in conjunction with the RORE sequence and the amino terminus, may
be responsible for which of the isoforms is recruited.
RORa has been implicated in a number of physiological roles (Figure 1.14.).
Cholesterol (7 dehydrocholesterol and cholesterol sulphate) have been identified as
RORa agonists (Kallen et al, 2004; Kallen at al, 2002), and have been found to regulate
the expression of genes involved in lipid metabolism (Kallen et al, 2002). These factors
suggest that RORa has a role in the regulation of lipid metaholism.High levels of RORa
has been seen in cerebellar Purkinje cells (Matsui et al, 1995), and knockout studies
have demonstrated that RORa deficient mice have display severe cerebellar atrophy,
characterized by a signifigant reduction in Purkinje cells and a loss of cerebellar granule
cells (Hamilton et al, 1996). Additionally, RORa has been implicated in spinocerebellar
ataxia type 1 (SCAI), an autosomal dominant inherited neurodegenerative disorder

characterized by progressive loss of motor coordination, speech impairment, and
problems swallowing (reviewed in Jetten, 2009).
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Figwe 2.14. PhysioIogitdfunctions of ROR (Jetten, 2009)

1.3.3.4. COUP TF I and I1

Chick Ovalbumin Upstream Promoter-Transcription Factor (COUP-TF) is one of the
best chrnacterized orphan nuclear receptors. It was first identified as a h o m d i e r ,
found to b i d to a direct repeat regulatory element, containing an imperfect direct repeat
of AGGTCA, in the chicken ovalbumin promoter (Pastorcic et al, 1986; Sagami et al,
1986; Wang et al, 1989). Each factor has the ability to generate its own distinct

expression profile during mammalian development (Qiu et al, 1994). COUP TF I is
identical to EAR? (Miyajima

et al, 1988)

while COUP TF I1 has been found to be

identical to ARP-1(Ladias and Karathanasis, 1991).

Both COUP TF I and I1 are expressed in many human tissues, being involved in many
biological regulation processes such as neurogenesis, organogenesis, determination of
cell fate and metabolic homeostasis (Tsai et al, 1994; Ladias and Karathanasis, 1991;
Wang et al, 1991; Mangeldorf et al, 1995; Ritchie et al, 1990; Qui et al, 1994).
COUP TF contains a 66-amino cis region which contains two conserved Zinc finger
motifs, this is the DBD region.
COUP TF I and I1 are identical but for one amino acid difference in within the DBD
which is a conservative change from Ser to Thr (Miyajima et al, 1988; Wang et al, 1989).

1.4. Coregulators: Coactivators a n d Corepressors
As stated previously in Section 1.3., nuclear receptors comprise of ligand-regulated (e.g.
estrogen receptors and progesterone receptors) and orphan transcription factors (a total
48 receptors in humans). These proteins play a central role in the bodys' ability to
transduce steroid, retinoid and other lipophilic endocrine hormone signals to the
genome (Tsai and O'Malley, 2004; Mangelsdorf et al, 1995). Nuclear Receptors have
the ability to recognise specific sequence motifs within the promoter, or enhancer,
regions of their target genes, generally associating with the ligand binding domain and
with the AF-1 and AF-2 domains of certain nuclear receptors. However, the ability of
the NR receptor to bind to the specific sequence motifs is dependant on, firstly, the
ability of the NR to access the motif through chromatin and, secondly, the relationship
of the NRs with the RNA Polymerase I1 holocomplex. (Roeder, 2005).

These

difficulties are overcome, or exacerbated, by coregulators. Coregulators are molecules

that are directly recruited by nuclear receptors and either activate (coactivator) or
repress (corepressor) the transcription of specific genes (Lonard and O'Malley, 2005).
Coactivator recruitment is generally ligand dependant while corepressors repress gene
expression primarily via interaction with NRs not bound to ligand to repress
transcription (Glass and Rosenfeld, 2000). Corepressor associated proteins such as
histone deacetylases, prevents transcription by creating a local chromatin environment
which hinders association of transcriptional machinery, this opposes the transcriptional
promoting activities of coactivators (such as acetyltransferases). The opposing actions
between pro-transcription and anti-transcription creates an equilibrium which can be
tipped either way according to the signals received (Reviewed in Lonard and O'Malley,
2007; 2006).
Core coregulators, those that interact directly with nuclear receptors, exist in large
steady-state complexes with multiple secondary co-coregulator partners.

Each

component may possess multiple enzymatic capabilities such as acetyltransf&ase,
methyltransferase, phosphokinase, ubiquitin ligase, and ATPase activities, ultimately
making these complexes versatile enzymatic 'machines' for regulating gene expression
(Lonard and O'Malley, 2006) (Figure 1.15.).
Currently, approximately 300 coactivators and corepressors have been reported
(http://www.NURSA.org), some examples are listed in Figure 1.15..
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1.4.1. Nuclear Receptor Coactivators

Coactivators associate with ligand bound activated NRs (or other DNA biidiig
transcription factors) and are required both for the transcriptional activation process to

occur (Drapkin et al, 1993; Tijan and Maniatis, 1994; Guarente, 1995; Verrijzer and

Tijan, 1996), and for enhanced gene expression.
Coactivators are diverse, both structurally and through their biochemical processes.
Coactivators function via numberous enzymatic means, including acetylation,
methylation, ubiquitination and phosphorylation. These enzymatic properties of the
coactivators enable them to function as chromatin remodelers (reviewed by Lonard and
O'Malley, 2006).
A family of coactivators, known as the pl60/SRC family, currently consists of 3

members, described below. The common domains of this family of coactivators can be

seen in Figure 1.16..
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Figure 1.16. Schematic diagram of the common structural andjimctional domains of SRC
family of coactivators. The lines above the bar identi% the regions containing conserved
strwtwal and functional feuhues among SRCs.
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helir/Per/ARNT/Sim (bHLWPAAS); the sermelthreonine-rich regions ( i ; the LXkZL motii
responsible for interaction with nucIear receptors (RID); the intrinsic transcription activation
domains of SRCs (ADI cad AD2); the glutamme-rich regions (e); and the HAT domain
idem$& in SRC-I and SRC-3.
The lines under the bar indicate regiom that are responsible for interaction with transcription

fmtars or other coreguIators. W ,k@ocyte enhancer factor-2C; TEF, lrbonriptiond
enhancerfactor; RID, receptor-interacting domain (Wu et al, 2005).

There are 3 members of the pl60lSRC family of coactivators, namely; SRC-I, SRC-2
and SRC-3 (Figure 1.17.)

CBP intaacIian

-

Aatylation

Basic helix-Imphelix domaim
PAS (PerlAmtlSim) domains
NR boxes (eoasensus W[U motifs)
GluIamine-rich regions

Figure 1.17. Multiple members of the SRC family. The proteins have been aligned according to

major structural similarities and to emphasize both the structural divergence of the carboxy
termini and the conservation of the amino-terminal dornains of SRC family members. Regions to
which specific functions of individual coactivators have been assigned are it~dicated.Only SRCI contains a consensus LXXLWNR box motif in this region. (McKenna et al, 1999b)

1.4.1.1. SRC-I
SRC-I was the first NR coactivator to be successfully cloned (Onate et al, 1995). This
coactivator exhibits a broad range of specificity in the coactivation of ligand dependant
transactivation of nuclear receptors, including PR, GR, ER, TR and RXR (Onate et al,
1995). The interaction of hSRC-1 with the LBD of the progesterone receptor is ligand

dependent (Onate et al, 1995) and is abolished in the presence of the antiprogestin
RU486.

In addition, a hSRC-1 mutant, containing only the C-terminal receptor-

interacting domain, suppresses PR coactivation by hSRC-1 in a dominant-negative
fashion, both in transient transfection and by in viho transcription assay Onate et al,
1995; McKenna et al, 1999b) indicating that the C-terminal domain is not involved in
the coactivation capabilities of the molecule.
Previous studies indicate that hSRC-I has the ability to mediate functional interactions
between the N-tenninal AF-1 (not conserved in sequence in nuclear receptors) and Cterminal AF-2 (located within the hormone-biding domain, highly conserved among
the nuclear receptors) domains of nuclear receptors. Individual hSRC-I domains are

required for 111 functional cooperation between AF-I and AF-2 of the progesterone
receptor (Onate et al, 1998), as well as the oestrogen receptor (McInemey et al, 1996).
This suggests that that the efficient assembly of the preinitiation complex by steroid
receptors is dependant on an SRC-1 assisted interaction between their individual AF
domains (McKenna et al, 1999b).
Additionally, research conducted by Xu et al suggested that peripheral steroid target
organs of mice containing a targeted disruption of the SRC-1 gene have a decreased

response to steroid hormones (Xu et al, 1998). Therefore, SRC-1 is responsibe for
causing an effective steroid hormone response.

In addition to the full-length SRC-1 (termed SRC-IA), several splice variants have been
described. SRC-lA, SRC-lC, SRC-1D and SRC-IE (Kamei et al, 1996; Yao et al,
1996; Takeshita et al, 1996). SRC-IA and SRC-IE are most studied.
SRC-le is a more potent coactivator for oestrogen receptor than SRC-1A (Robyr et al,
2000). For instance, the oestrogen-regulated rat oxytocin promoter is coactivated by

SRC-LE but not by SRC-IA, whereas both SRC-1 isoforms stimulate oestrogen
receptor-mediated transcription from an artificial ERE-containing promoter. Therefore,
SRC-1A coactivation appears to rely on the promoter context of the receptor target gene
(Robyr et al, 2000).
Both isoforms contain three nuclear receptor interacting motifs (LXXLL) found in
many co-factors (Heery et al, 1997). SRC-1A however possesses a fourth LXXLL
motif at its C terminus (Kalkhoven et al, 1998). Mutation of the fourth LXXLL in
SRC-1A does not affect transcription and its function is currently unknown (Robyr et al,
2000).
Additionally, SRC-I has histone acetyltransferase activity (HAT) (Spencer et al, 1997).
HATS are enzymes that acetylate conserved lysine amino acids on histone proteins by
transferring an acetyl group from acetyl CoA to form E-N-acetyl lysine. Acetylation of
histone molecule in DNA is generally linked to transcriptional activation.

SRC-2, also known as GRIP1 (glucocorticoid receptor-interacting protein l), TIF2
(transcription intermediary factor 2) and NCoA-2, are 160-kDa nuclear receptorinteracting proteins with considerable sequence and functional similarity to SRC-1
(Voegal et al, 1996; Hong et al, 1996, 1997; Torchia et al, 1997).
GRIPl(mSRC-2) and TIF2 (hSRC-2) associate in a ligand-dependent manner in vitro
with several receptor LBDs (Voegal et al, 1996) and, in vivo, with RARa, oestrogen
receptor and progesterone receptor in the presence of hormone, but not hormonal
antagonists (Voegal et al, 1996; Hong et al, 1996, 1997).

The identification of a third member of the SRClpl60 family was a highly polymorphic
protein isolated as pICIP @300/CBP cointegrator-associated protein) (Torchia et al,
1997), ACTR (activator of thyroid receptor) (Chen et al, 1997), RAC-3 (receptorassociated coactivator 3) (Li et al, 1997), AIB-1 (amplified in breast cancer-1) (Anzick
et al, 1997), TRAM-1 (thyroid receptor activator molecule 1) (Takeshita et al, 1997) and
SRC-3 (Suen et al, 1998), illustrates complex nomenclature in the SRC family
(McKenna et al, 1999b).
hSRC-3 interacts with and coactivates a wide variety of nuclear receptors in a liganddependent manner, including RAR, thyroid receptor, RXR, glucocorticoid receptor
(Chen et al, 1997), progesterone receptor (Li et al, 1997) and oestrogen receptor
(Anzick et al, 1997).
mSRC-3 exhibits greater promiscuity than other SRC family members by enhancing the
transcriptional activity of a number of different activators, including interferon-a and
CAMP regulatory element binding protein (CREB) (Torchia et al, 1997), which were
previously shown to be dependant primarily on CREB-binding protein (CBP) for
efficient activation.
Additionally, SRC-3 selectively enhances the transcriptional activity of ERa over that
of ERP, possibly reflecting a 60% difference in homology between the LBDs of these
isoforms (Suen et al, 1998).
SRC-3 is both regulated by phosphorlyation and distinct phosporylation patterns on the
SRC-3 molecule determine its specificity for different transcription factors (Wu et al,
2004).

Phosphorylation is required for SRC-3 activity, and the specificity of SRC-3 for
different transcription factors further depends on where phosphorylation is induced on
SRC-3 by a respective stimulus (Wu et al, 2004). It is proposed that a specific

phosphorylation-dependent code allows SRC-3 to activate gene expression specifically
and accurately (Wu et al, 2005).

1.4.3. Mechanism of Coactivator Action

Figure 1.18. demonstrates the various signalling pathways the SRC family are activated
by and their preferential targets.
The pl60lSRC family of caoctivators have multiple methods of activating genomic
transcription. Their two main mechanisms of action is to manipulate chromatin to
enable access to the transcription machinery and also to activate the nuclear receptor via

AF-I and AF-2 domains in the nuclear receptor.
SRC-1 and SRC-3 has been identified as possessing HAT activity (Spencer et al, 1997;
Lemon and Freedman, 1999; McKenna et al, 1999b).
C A M - 1 (Coactivator-associated arginine methyltransferase 1) functions as a
secondary coactivator through its associationwith the carboxyl-terminal region
of pl60 coactivators. C A M - 1 can methylate histone H3 in vitro, and though mutation
analysis was deemed necessary for the full coactivation activity of the p160 family.
Thus, coactivator-mediated methylation of proteins in the transcription machinery may
contribute to transcriptional regulation (Chen et al, 1999).

Figure l.1& Signaling to SRCs. Kinase-mediated signalingpathways activated by a variety of
stimuli (including steroid hormones, cytokines, andgrowthfactors) that can communicate with
SRCs, m e displqyed o h .Although seven olqior phmphorylation sites (serines372, 395. 517,
569, 1033, 1185 and threoninell79) were identrBed on SRC-I, it is m l e a r whether
phosphorylation is fleeted by steroid hormones (as indicated by ?; same is mfo*SRC-2),
and only phosphorylaiion at threoninell79 and soinell85 induced by CAMP were shown.

SRC-3 was wed as a model molecule as there is a deeper understanding of SRC-3
phosphmyIation. However, it is hypohesized thal this same mode of operation from SRC-3
could also apply to SRC-I and SRC-2. Although each SRC is able to coactivate with the
various recepfors in lransienl transfeetion assays, the preferred SRC parfner for diferent
receptor signaling is connected by an amw. (Wu et al, 2005)
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1.5.1. Breast Cancer

Breast cancer is the most common malignancy of women residing in, industrialized
countries and it is the most common cause of cancer associated morbidity and mortality
(Giacinti et al, 2006). Sixty five percent of primary breast cancers are ER positive
(Giacinti et al, 2006).
Oestrogen is involved in the growth and differentiation of epithelial cells in normal

mammary tissue. The mitogenic effects of oestrogens on breast epithelial cells are due
to, at least in part, increased expression of genes involved in the regulation of the cell
cycle (Vendrell et al, 2004). However, very little is known about the actual mechanism
of oestrogen mediated proliferation.
Target genes have been identified, through studies on oestrogen regulated gene
expression in breast cancer cells, which may be involved in mammary cell proliferation.
NOV, a gene that encodes for a negative regulator of cell proliferation, is down
regulated by oestrogen in breast cancer cells (Vendrell et al, 2004). WNT2 is a gene
whose expression is associated with abnormal proliferation in human breast tissue
(Huguet et al, 1994). WNT2 expression has been seen to increase following oestrogen
exposure (Vendrell et al, 2004). Oestrogen has also been shown to induce the down
regulation of the TACC gene family members, TACCI, EFNAI and ZNF217 (Vendrell
et al, 2004). The TACC gene family contain a TACC domain, which forms a coiledcoiled region in their carboxy terminus (Lappin et al, 2002). The TACC gene family

has been reported to contribute to the development of cancer (Raff, 2002), and a down
regulation in TACCl mRNA has been observed in breast tumors (Conte, 2002).
Prolonged stimulation of oestrogen receptor on breast ductal epithelium contributes to
the development and progression of breast cancer. Reducing oestrogen receptor levels
or altering its activity has been found to induce tumour regression. In these cases
treatment that are. designed to block the effects of oestrogens are important in halting
cancer progression (Osbome et al, 2000). (Discussed further in Section 1.5.2.)
While sixty five percent of primary breast cancers are ER positive, the remaining thirty
five are ER negative. ER negative breast tumours are associated with more malignant
and more drug resistant tumours.
Additionally, breast tumours that are initially identified as ER positive can loose their
ER expression during tumour progression (Yang et al, 2001). This can indicate that the
tumour is becoming more malignant.
Some ER positive breast cancers also contain progesterone receptors, whose presence
may indicate that the ER remains responsive to oestrogen and can still control specific
protein synthesis (Honvitz and McGuire, 1978).

1.5.2.

Selective Oestrogen Receptor Modulators - A treatment and

preventative agent for Breast Cancers

Treatments designed to block the effects of oestrogens are important in halting cancer
progression in ER positive breast cancers (Osbome et al, 2000).

Selective oestrogen receptor modulators (SERMs) perform this function and are
designed to be effective in breast cancer prevention and treatment as they inhibit the
proliferative effects of oestrogen that are mediated through the oestrogen receptor.
SERMs bind to the oestrogen receptor, alter its conformation, and thereby facilitate the
binding of coregulatory proteins that can activate or repress the transcriptional
activation of oestrogen target genes (Osbome et al, 2000).

1.5.2.1. Subdivisions of SERMs

SERMs can be divided into three major categories: Triphenylethylene derivatives, other
nonsteroidal compounds and steroidal compounds that have more complete
antioestrogenic activity. Tamoxifen and Raloxifene are the two major SERMs currently
used as a treatment for hormone responsive breast cancer.

Tamoxifen (Figure 1.19.), a member of the Triphenylethylenes group of SERMs, was
first synthesized in the 1960s, demonstrated to have antiproliferative effects in breast
tissue (Jordan, 1994) and shown to be an effective therapy in patients with ER positive
metastatic breast cancer (Osbome, 1998). The major metabolites of tamoxifen are Ndesmethyltarnoxifen and trans-4-hydroxytamoxifen, which has an affinity for ER
similar to that of 17-P oestradiol (Buckley et al, 1989).

Figure 1.19. Chemical Structure of Tamoxifen (www.pharmacology2000.com)

Tamoxifen has both oestrogenic and anti-estrogenic effects. It has agonist effects on
bone (Love et al, 1992), blood lipids and also the endometrium (Osbome, 1998) while
having antioestrogenic effects on the CNS and vaginal mucosa. The mixed oestrogenic
and antioestrogenic effects of Tamoxifen are species, tissue and cell dependent.
,

Tamoxifen has also been shown to have both oestrogenic and antioestrogenic effects on
specific subsets of genes within a singe cell type (Osbome et al, 2000).
Tamoxifen binds to the ER in breast cancer cells and antagonizes the effect of oestrogen
on a variety of growth-regulatory genes (Dhingra, 1999). The predominant effect it has
is cytostatic with the induction of a GI cell cycle block thereby slowing cell proliferation
and inhibiting cancer growth (Osborne, 1998). Tamoxifens dual activities provide some
advantages for patients receiving Tamoxifen treatment. Not only is there a beneficial
effect through inhibition of proliferation of breast ductal epithelium and breast cancer,
but due to Tamoxifens oestrogenic effects in certain tissues, women may also benefit
from maintenance of bone density and a reduction in cholesterol.

The associated

reduction in cholesterol is due to its oestrogenic activity in the liver, as serum
concentrations of total cholesterol and low-density lipoprotein are reduced by
tamoxifen, while the preservation of bone density is due to tamoxifens oestrogenic
effect in bone.

However, due to its varying activity in different tissues there are side effects associated
with Tamoxifen.

The most serious of these side effects are associated with its

oestrogenic activity in the endometrium, which can result in endometrium hyperplasia
and also low-grade endometrial cancers (Wilking et al, 1997). Additionally, due to its
antioestrogenic effects on the vaginal mucosa, treatment may result in menopausal
symptoms (Love et al, 1991).

Raloxifene
Raloxifene (Figure 1.20.) is in the group of nonsteroidal compounds.

It is a

b t h i o p h e n e derivative and it b i d s to the ER with an equal sanity to that of

oestradiol (Black et al, 1983). Raloxifene is an inhibitor of cultured breast cancer cells
and possesses antitumor activity in rat mammary tumour models similar to that of
Tamoxifen (Poulin et ai, 1989).

1.5.3. Nuclear Receptor Coregulators and Human Disease
Nuclear receptor coregulators are central to the regulation of NR-mediated transcription
and in the coordination of intercompartmental metabolic processes (Lonard et al, 2007).

Knockout studies have demonstrated the importance of SRC-1, SRC-2 and SRC-3 in a
wide variety of biological functions (Table 1.1.)
Consequently, disruptions in the SRC family of coactivators can lead to a wide variety
pathological states. The following is an overview of the pathological states which occur
as a result of these disruptions.
Knockout Phenotype
moderate motor dysfunction

SRC-1

delayed development of purkinje cells

I
I
I
SRC-2

I

control of energy balance
loss of skeletal response to oestrogen
altered hypothalamic-pituitary-adrenal axis function
altered hepaticfunction

control of energy balance in white and brown adipose tissue
essentialfor the progesterone-dependant uterine and mammary morphogenesis
testicular dysfunction
spermatogenesis defect and placental hypoplasia

animals of smaller size

SRC-3

I

delayedpuberty
reduced mammary gland development

I reduced adipogenesis and inhibition of neointimaformation by oestrogen

I

decreased response a IGF-1

Table 1.1. Consequences of SRC knockout studies (Adaptedfrom Lonard et al, 2007)

1.5.3.1. Cancer
Coactivators have been found to be over- and underexpressed in a number of cancers.
This is the largest group of coactivator related disease.

Coactivator overexpression may invoke carcinogenesis, enhance its progression or alter
the biological activities of therapeutic NR ligands (Shang and Brown, 2002).
Coactivator misexpression can be thought of as a pervasive agent in the progression, or
etiology, of human cancers.
SRC-1 has been found to be overexpressed in prostate, breast and gastric cancers. A
MOZ-SRC-2 fusion protein has been identified in acute myeloid leukaemia. Also, there
is a brain and breast cancer correlation with oestrogen and progesterone receptor and
SRC-2 expression.
SRC-3 has been associated with numerous carcinomas, including breast, pancreatic,
ovarian, endometrial, oesophageal squamous call and colorectal. Overexpression of
SRC-3 has been demonstrated in oral squamous cell carcinomas and a smaller isoform
of the protein has been identified in certain breast and gastric cancers. Additioanlly,
some polymophisms can protect against breast cancer and influence calcaneal bone
density. (All reviewed by Lonard et al, 2007)

1.5.3.2. Metabolic Syn'dromes

Knockout studies have found SRC-1 and SRC-2 to play opposing roles in energy
metabolism (Feige and Auwerx, 2007). SRC-l-b knockout mice are prone to obesity
due to decreased energy expenditure while SRC-2.'- knockouts are leaner due to the
reduced transcription of PPARy2 (a protein essential for the differentiation of
adipocytes).

SRC-2.'- knockout mice also display a subsequent increase in PGC-

la/SRC-I interaction which enhances the thermogenic actions of PCG-la in brown
adipose tissue. SRC-3's role in metabolism has been identified in the promotion of the

formation of white adipose tissue. SRC-3.'- knockout mice have a decreased adipose
tissue mass (Louet et al, 2006; reviewed in Lonard et al, 2007)

1.5.3.2. Coactivator Fusion Proteins
Genetic disruptions leading to coregulator fusions with other proteins exist in certain
cancers (Lonard et al, 2007). A MOZ-SRC-2 fusion protein predisposes an individual
to acute myeloid leukaemia (Troke et al, 2006).

1 . 5 . 3 . 3 . Coregulator Gene Polymorphisms
Coregulators function to control the extent of gene expression from nuclear receptors so
that fluctuations in their expression or small changes in their biological activity will lead
to significant differences in target tissue responses to hormone ligands. Individual
variations in secondary sex traits, obesity and susceptibility to cancer may be attributed
to alterations in the primary protein amino acid sequence and the cellular concentration
of coregulators (Lonard et al, 2007).
Generally, coregulator SNPs (small nuclear polymorphisms) are located in the
coregulator gene promotors or intronic or synonymous non-coding variants, however,
SNPs can, if infrequently, occur and affect the coregulator amino acid sequence (Lonard
et al, 2007).
There are 10 SNPs found in SRC-3 that affect its coding sequence and hence the
translated protein (Sheny et al, 1999; Lonard et al, 2007). A Q586H variant allele, one

of the 10 SNPs that affects the coding sequence of the SRC-3 protein, confers a
protective effect against breast cancer (Burwinkel et al, 2005)

1.64. Relationship of SERMs and SRCS
According to Lonard et al, SERMs have the ability to upregulate the expression of SRC1 and SRC-3 in cells and, additionally stimulate the transcription of other nuclear
receptors. They hypothesize that the differential agonist or antagonist action of SERMs
is dependant on the coactivator expression in oestrogen target tissues (Lonard et al,
2004). Shang and Brown have demonstrated that elevated expression of SRC-1 in the
uterus-derived Ishikawa cell line contributes to the increased agonist action of
Tamoxifen in the uterus, while lower levels of SRC-1 in the breast derived MCF-7 cell
line allow for Tamoxifen to function as an antagonist (Shang and Brown, 2002).

1.6. Identification of Transcription Factor Binding Sites
Current techniques available to enable the isolation of transcription factor binding sites
include chromatin immunoprecipitation combined with microarray detection (ChlP-onchip) and DamID.
principles.

These two techniques are based on fundamentally different

ChIP-on-chip analysis utilizes antibodies to identify genomic transcription factor
binding sites. An overview of the methodology can be viewed in Figure 1.21..
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Cells are isolated from tissue and fixed using 1% Formaldehyde which functions to
cross link and preserve transcription factor DNA binding. Cells are then lysed and the
nuclei isolated, following isolation the nuclei are lysed and the resultant lysate is
sonicated or enzyme treated to fragment the DNA into 300 to 1000 bp fragments.

An antibody directed against the transcription factor of interest is then added to the
sonicated lysate followed by cross linking reversal to release the antibody bound
proteins, proteins are removed by Proteinase K treatment, DNA is purified, amplified
using LM-PCR and labelled. They are then hybridized to a microarray after which
image and data analysis is performed.
The microarray used contains fragments of the 111 human genome and the locations of
the labelled sequences can be further malysed using a variety of techniques, including
bioinformatics.

1.6.2. DamID

The DamID technique relies upon the low level in vivo expression of a fusion protein
consisting of a protein of interested fused to Dam (DNA adenine methylation) isolated
from Escherichia coli. Dam methylates adenines in the sequence GATC, a trait unique

to this prokaryotic protein. When the Dam h i o n protein is bound to DNA the Dam

will methylate nearby GATC sequences (Figure 1.22.).
Once Dam methylation has occurred the transcription factor biding sites can be
isolated. Genomic DNA is isolated and methylated GATC sequences are cut between
GAmeand TC nucleotides using the methylation-sensitive restriction enzyme DpnI.
This digestion step creates a pool of blunt-ended DNA fragments that have 5' TC and

3'GAm sequences. A double stranded adapter oligonucleotide with a 32 bp 5' overhang
(dsAdR; formed using oligos AdRt and AdRb) is ligated to the blunt ends 5' overhang
ensuring directional ligation. Double strand adapter is used as double stranded DNA is
ligated more efficiently than single stranded oligonucleotides. This is followed by

DpnII digestion, a methylation sensitive enzyme that only cuts unmethylated GATCs.
A PCR primer identical to the 15 most 3' nucleotides of the AdRt nucleotide sequence
and the 5'TC nucleotides of the gDNA fragment is used to amplify adaptor-ligated
sequences (Vogel et al, 2007).

Ttanscription
Factor Binding
Sb

Figure 1.22. % methylation of GATC sequences of gDNA adjacent to Dam fusion protein
binding sites,

1.6.3. Bioinformatics
Bioinformatics encompasses a wide range of techniques that utilise statistics,
mathematics and IT to analyse biological information, such as genetic sequences. The

internel is the backbone to a variety of bioinformatical tools and following the

completion of the HGP (human genome project) a range of information can be obtained
from just one DNA sequence.

1.6.3.1 MotifViz
MotifViz is an interactive web server which serves to identify overrepresented known
transcription factor binding motifs (Fu et al, 2004). The identification of short sequence
motifs, such as transcription factor binding sites, in a set of given sequences may aid in
the understanding of transcriptional regulation. Overrepresented regulatory motifs in
promoter elements of genes often reflect the factors to which the promoter is responsive
to. The MotifViz programme uses algorithims to identify these overrepresented motifs.
MotifViz offers four algorithms to analyse genomic sequences; Rover, Clover, Motifish
and Possum (Fu et al, 2004). These four algorithms use different methods to find the
overrepresented motifs.
According to Fu et al, Clover uses a thermodynamic model with permutation or
background input for statistical evaluation of cis-element over-representation. Clover
screens a set of DNA sequences against a precompiled library of motifs and assesses
statistical over- or under-representation in the sequences (Frith et al, 2004). One of the
precompiled libraries that can be used is called JASPAR, which is a database of
eukaryotic transcription factor binding sites (Sandelin et al, 2004). The JASPAR
profiles contain non-reduntant transcription factor binding sites derived from published
collections of experimentally defined sites (Sandelin et al, 2004). JASPAR profiles
cover a variety of transcription factor classes; including the nuclear receptors. The
MotitViz algorithms, including Clover, have the option of using the JASPER profiles

when searching for over-represented sequences. Therefore, searches can be performed
to isolate any one of the JASPAR profiles, for example Nuclear Receptors. Utilizing
the Clover algorithm with the JASPER nuclear receptor profile enables identification of
overrepresented nuclear receptor biidiig sites in the genome sequences of interest.

The MEME Suite comprises of a set of Motif-based sequence analysis tools, which
includes MEME, TOMTOM and GOMO. The MEME Suite enables elucidation of
over-represented sequence motifs in a set of given sequences using MEME (Bailey and

Elkan, 2004). MEME analyses a set of given sequences and using a defined algorithm.
The algorithm discovers one or more motifs applying a technique known as
"expectation maximkation to fit a two-component finite mixture model" to the set of
sequences (Bailey and Elkan, 2004). The motifs discovered by MEME (an example
displayed below) can then be analysed further using other MEME Suite programmes,

such as TOMTOM.
TOMTOM uses the MEME motifs to search for transcription factor binding motifs

within them (Figure 1.23.).

Figure 1.23. A: MEME mots B: TOMTOM Oestrogen Receptor binding mots C: TOMTOM
Oestrogen Receptor binding mofiffoundinMEAB motg(A)

Critical cellular processes rely upon protein DNA interactions. Protein DNA binding
may trigger transcription initiation or repression, DNA repair or may alter the structural
conformation of chromatin an enable, or hinder, the binding of other proteins to the
DNA. Elucidation of the regions of DNA where specific proteins bind to could enable
us to gain a mgreater understanding of the proteins being investigated and also of the
genes they may regulate.
Oestrogen mediates its effects through the activation of its respective nuclear receptor.
The activated receptor then has the ability to translocate to the nucleus and regulate the
expression of genes controlled by oestrogen. The genes regulated by oestrogen are
determined by the cell type and the conformation of the chromatin.
Initially, the aim of this project was to investigate a reporter library of oestrogen
responsive elements (EREs) (Jennings, 2009). This library was constructed by Jemings
(Jemings, 2009) using DamID technology. Investigations on this library were to focus
on the identification of SERM responders and perform further tests to analyse the
isolated reporters.

This would provide a deeper understanding into the role of

Tamoxifen as an oestrogen antagonist. An overview of the aims are listed below:

.

To isolate SERM responsive reporter plasmids from an ERE reporter library

.

To assess the ability of the isolated sequences to mediate transcription in
conjunction with other nuclear receptors and coactivators to establish potential
novel interactions

To investigate the mechanism by which SERMs have the ability to activate certain
genes via the oestrogen receptor using mutant oestrogen receptor expression
plasmids.
The extent of gene activation by oestrogen is also controlled by coactivators and
corepressors. Coactivaors, such as the SRC family of coactivators, bind to DNA bound
nuclear receptor ligand complexes and fuaher increase the rate of gene transcription.
Due to interesting results obtained during initial investigations into the SERM
responders, it was decided to perform novel investigations into the SRC family of
coactivators. The aims of the investigation into the SRC family of coactivators is
described below.
To isolate sequences from the genome that associate with SRC-1A:Dam and SRC3 in association with either ligand bound oestrogen or progesterone receptors
To use bioinfonnatics to identify DNA cis elements, repetitive sequences and
overrepresented transcription factor binding sites in these isolated sequences
To assess the ability of the isolated sequences to mediate transcription in
conjunction with other nuclear receptors and coactivators to establish potential
novel interactions
Performing these investigations would enable a greater understanding in the relationship
between the effect of the coactivator molecules SRC-1A and SRC-3 and oestrogen and
progesterone receptor mediated transcription.

An additional aim, encompassing reporter plasmids from both the ERE, SRC-IA and
SRC-3 libraries, was to attempt to identify the location of transcription start sites in

selected isolated reporter plasmid sequences. The ability to obtain this information
would enable a deeper understanding of the binding sites that a variety of transcription
factors of transcriptional coregulators associate with.

3.0. MATERIALS
AND METHODS

3.1. Investigation of ERE (oestrogen responsive element)

Reporter Library
Construction of the ERE library was performed previously using DamID (Jennings,
2009). A hERa:Dam expression plasmid was constructed to enable the expression of an
ERa:Dam fusion protein when transfected into a cell line.

EREs were isolated under three conditions; those that interact with ERa:Dam and EtOH
(so to isolate EREs that associate with ERa not bound to ligand), those that interact with
ERa:Dam and Oestrogen (to isolate EREs that associate with oestrogen bound ERa) and
those that interact with ERa:Dam and Tamoxifen (to isolate EREs that associate with
tamoxifen bound ERa).

Transfection of pCR3.1 ERa:Dam to HeLa cells was

performed and cells were treated with above mentioned treatments (EtOH, oestrogen or
tamoxifen) to generate three separate libraries of sequences. The Dam portion of
ERa:Dam, when DNA bound, methylated GATC sites adjacent to the binding sites.
This was followed by DpnI and DpnII digestion to isolate the methylated GATC
sequences, adapters were ligated to these isolated sequences and LM-PCR was
performed. This was followed by insertion of the amplified sequences to a TOPO
library where analysis was performed including sequencing of the inserts. Further

analysis was enabled by transferring the TOPO library insert to a pGL3 Basic library.
Upon the transfer trans-activation assays were performed to gain information of the
promoter activity of the sequences.

Detailed information on the materials and methods used to generate these ERE reporter
libraries can be found in Jennings, 2009.

3.1.1. Transactivation Assays
Transactivation assays were used to further analyse the ERE reportcr library. The
methods for transactivation assays are described below, the example provided is for the
investigation of ERa and oestrogen on the ERE reporter library using HeLa Cells.

3.1.1 . l . HeLa Cell Preparation for Transfection
HeLa Cells (Baylor College of Medicine, Houston, Texas) were plated in 24 well plates
(xlO), with 50,000 cells/well in DMEM (with 4.5g/L D-Glucose and L-Glutamine,
without Sodium Pyruvate or Phenol Red) with 5% Charcoal Stripped Serum (Gibco)
and grown overnight at 37'C in 5% COz. All initial cell cultures were prepared by the
BCM cell culture core.

Prior to transfection cells were checked, using Inverted

Microscope, to assess cell health, growth and distribution.

3.1.1.2. Plasmid Preparation for Oestrogen Transfection
Plasmid premixes were prepared as follows. Ependorfs were labelled appropriately with
24 tubes for test (with reporter plasmid, hormone receptor and hormone) and 24 for
controls (reporter plasmid only). Reporter plasmid was added to each of the control
tubes at a concentration of 200ng/well while 200ng/well reporter plasmid was added to

the test ependorfs as well as 5ng/well hERa. These were left to incubate at 4'C
overnight.

A 1:50 lipofectamine dilution was prepared using DMEM (with 4.5g/L D-Glucose and
L-Glutamine, without Sodium Pyruvate or Phenol Red) without 5% Charcoal Stripped
serum (Gibco). To the test samples 2 0 0 ~ 1was added and 50p1 to the control. These
were then left to incubate at RT "C for 30 mins.

3.1.1.3.

Hela Cell Transfection

Hela Cell cultures were removed from the incubator and placed in a Laminar Flow
Hood where the medium was aspirated and replaced with 2 0 0 ~ 1DMEM (same as used
in premixes). Each well also received 5 0 ~ of
1 either test or control reporter plasmid

premix (Figure3.1. and Figure 3.2.).

Reporter Plasmid 1
Reporter Plasmid 2
Reporter Plasmid 3
Rsparter Plasmid 4

- - - -00

Reporter Plasmid 5

a

Reporter Plasmid 6

Total Volume in each well 2 5 0 ~ 1
Each weU contains:
HeLa cells grown overnight
2 0 0 ~ 1DMEM
Sop1 reporter plasmid Lipofectamine DMEM mix

Figure 3.1. Transfeetionprotocol: Plate organisation - Testplate

Plates were placed on a plate rocker for 10 mins and then moved into a 37OC incubator

with 5% COz for 4 hrs. During the incubation hormone/EtOH premixes were made
using DMEM (with 4.5& D-Glucose and without L-Glutamine, Sodium Pyruvate or
Phenol Red) with 5% Charcoal Stripped serum. EtOH was made to a final concentration
of 1 0 - ' ~in 12mls while 24mls E2 was prepared at a concentration of 1 0 ' ~control
~
wells were given only DMEM with 5% Charcoal Stripped Serum.

Figure 3.2. Transfectionprotocol: Plate organisation Control plate

When the incubation was complete plates were removed fiom the incubator, medium
aspirated and 500pl of the required hormoneEt0H premix (pre-warmed to 37'C) was
added to each well (Figrrre 3.3.). Plates were incubated for 24 hrs at 37OC with 5%

coz.
500pl EtOH Dilution
500pl Oestrogen Dilution
(Control plate had only DMEM)

Figure 3.3. Hormone and EtOH Dilutions

3.1.1.4. Luciferase Assay
If the plasmid contains a sequence with a promoter element and the relevant
transcription activators, oxyluciferin will be produced. The amount of oxyluciferin
produced is proportional to the strength of the promoter elements (See Section 4.1.1.1.
for further details).

Procedure
Following 24 hr incubation with hormonelEtOH, luciferase assay was used to assess
transcriptional activity in the HeLa cell line.
Medium was removed following the incubation and HeLa cells were lysed using 1 0 0 ~ 1
Luciferase Lysis Buffer (Appendix I) per well. The plates were- rocked on a plate
rocker for 10 mins. Cell lysate (25~1)from each well was pipetted into 96 well plates.
One-Glo Luciferase Assay System (Promega) was used to assess the luciferase activity
in each of the wells. The firefly luciferase enzyme (stored away from light at -20°C)
was brought to RT°C in darkness. The plates were read using a Luciferase Microplate
Lurninometer and the results analyzed.

3.2. Construction and Investigation o f Library of sequences
which interact indirectly to SRC-1A and SRC-3
A library of sequences that interacts with SRC-1A and SRC-3 via ligand bound ERa or
PR-B was constructed and investigated as follows.

3.2.1. Generation of pCR3.1 SRC-1A:Dam and pCR3.1 SRC-3:Dam.
pCR3.1 SRC-1A:Dam and pCR3.1 SRC-3:Dam fusion plasmids were constructed to
enable production of the SRC-1A:Dam or SRC-3:Dam fusion protein upon transfection
to cell cultures.

3.2.1.1. Generation of Dam PCR product
Genomic template DNA was obtained from Escherichia Coli bacteria (gDNA
previously isolated); long was added to 1pl 10X Accuprime Buffer I (Invitrogen), 2p1
lpM 50:50 primer mix (Figure 3.4.) (Invitrogen), 5 . 5 ~ 1dH20 and 0.25~1Taq DNA

Polymerase (Invitrogen). Primers were designed to amplify the full length Dam gene
generating a PCR product of 800bps.

Forward orimer
SaU:

5' ATC GCA

r'
E.Coli Dam 5' end
AAG AAA AAT CGC GCT m TTG AAG

"T"rCLe":
SalI restriction site

Reverse orimer
ApaI:

5'

3 3

Stop codon E.Coli Dam gene

ATC GCA GGG cccr'
GAA TTA m m CGC GGG TGA AAC GAC 3'

I
.
.

ApaI restnmon slte

Figure 3.4. Forward ondReverse Primersfor Dam PCR

PCR was performed (Table 3.1.) for 30 cycles. PCR products were stored at 4OC until

required.

Step

Temperature

Time

Initialization

94°C

2 min

Denaturation

94OC

15 sec

Annealing

56OC

15 sec

Elongation

68°C

I min

Hold

4°C

infinity

Table 3.1. PCR Programme Details for amplification of Dam from E. coli gDNA.

3.2.1.2.

Purification of PCR Product

QIAquick PCR Purification Kit (Qiagen) was used to purify the PCR product.
QIAquick Kits contain a silica membrane assembly for binding of DNA in high-salt
buffer and elution with low-salt buffer or water. The purification procedure removes
primers, nucleotides, enzymes, mineral oil, salts, agarose, ethidium bromide, and other
impurities from DNA samples.

Silica-membrane technology eliminates the problems

and inconvenience associated with loose resins and slurries.

Specialized binding

buffers are optimized for specific applications and promote selective adsorption of DNA
molecules within particular size ranges.
The QIAquick system uses a simple bind-wash-elute procedure. Binding buffer (PBI) is
added directly to the PCR sample or other enzymatic reaction, after which the mixture is
applied to the QIAquick spin column. The binding buffer contains a pH indicator,
enabling easy determination of the optimal pH for DNA binding. Nucleic acids adsorb
to the silica-gel membrane in the high-salt conditions provided by the buffer while
impurities are washed away. Pure DNA is eluted with a small volume of low-salt buffer
(EB Buffer).

Procedure
The Microcentrifuge protocol was followed and all reagents were from the Qiagen Kit.

PBI Buffer (100~1)was added to lop1 PCR product. This was applied to a 2ml
QIAquick spin column, inserted into a QIAquick collection tube, centrifuged at 13,000
rpm for 45 secs and the flow through discarded. PE Buffer (75pl) was applied to the
column and centrifuged as before. Flow through was discarded and sample centrifuged

as before. The column was then placed in a clean eppendorf tube and DNA eluted by
adding 5 0 ~ EB
1 (Elution Buffer) to the column, incubating for 1 min and centrifuging as
before.

3.2.1.3.

Restriction Digestion of pCR3.1 SRC-1 A:Luc, pCR3.1 SRC-

3:Luc and amplified Dam PCR product
Construction of pCR3.1 SRC-1A.Luc and pCR3.1 SRC-3:Luc plasmids have been
previously described (Lonard et al, 2004). A vector map can be viewed in Figure 3.5..
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Figure 3.5. Vector map of pCR3.l. (Invitrogen). Isolated genes for SRC-IA or SRC-3 were
inserted upstream of an isolated Luc gene in the highlighted 'PCR Product' region of the
polylinker sequence (Lonard et al, 2004).

ApaI digestions of pCR3.1 SRC-1A:Luc and pCR3.1 SRC-3:Luc were set up as
follows: lpl pCR3.1 SRC-1A:Luc or pCR3.1 SRC-3:Luc (from stock with a
concentration of 0.2pg/ml) was added to 1p1 NEB Buffer 4 (New England BioLabs),
7p1 dH20 and 1p1 ApaI (10U/p1) (Invitrogen).

The Dam PCR product digestion

consisted of 30p1 purified Dam PCR product, 3 . 4 ~ 1NEB Buffer 4 (New England
BioLabs) and 1p1 ApaI (10UIpI) (Invitrogen). These were mixed, briefly spun in a

centrifuge to ensure all liquid was in the base and incubated for 1 hr at 25OC. Both
samples were frozen at -30°C until required.
QIAquick PCR Purification Kit (Qiagen) was used to purify the digested plasmid.
Microcentrifuge protocol was followed as described in Section 3.2.1.2. DNA was
1
eluted using 3 0 ~ EB.
Sall digestions were set up as follows. DNA (previously ApaI digested and purified
pCR3.1 SRC-lA:Luc, pCR3.1 SRC-3:Luc or Dam PCR product) was added at a
quantity of 30pl to 3 . 5 ~ 1NEB Buffer 3 (New England BioLabs) and 1 . 5 ~ SalI
1 (10UIpl)
(Invitrogen). These were again mixed, centrifuged briefly to ensure all liquid was at the
base and incubated at 37°C for 1 hr.

3.2.1.4.

Excision of Luc fragment from pCR3.1 SRC-1A:Luc and

pCR3.1 SRC-3:Luc
Luc removal was performed to enable ligation of full length Dam to the plasmid in
place of Luc to generate a SRC-INSRC-3:Dam fusion construct. To each digestion
(Section 3.2.1.3.) 3 . 5 ~ 110X DNA loading dye was added. Agarose gel was made to a
concentration of 1% with 10% Ethidium Bromide (Sigma) and 1X TAE Buffer poured
over when set (detailed in Appendix I). Each sample was applied to the gel as well as
2pl 1 Kb Plus DNA Ladder (Invitrogen) to assess fragment size and the gel was run for
45 mins at 90V. A UV trans-iluminator (photographic) was used to detect the bands. A
UV trans-iluminator (non-photographic) was used to view bands and enable removal.
Required bands bCR3.1 SRC-IA, pCR3.1 SRC-3 and Dam PCR product) are excised

using a sharp blade and purified using QIAquick PCR Clean Up Kit (Qiagen). Bands
not required (-1600 bp Luc) are discarded.

3.2.1.5. Isolation and Purification o f gel-bound DNA
QIAquick PCR Clean Up Kit (Qiagen) was used to isolate and purify the gel-bound
DNA. Gel slices are dissolved in a buffer containing a pH indicator, allowing easy
determination of the optimal pH for DNA binding, and the mixture is applied to the
QIAquick spin column. Subsequent to this step the kit has the same principle as the
QIAquick PCR Purification Kit.

Procedure
Protocol was as follows; 450pl QC buffer was added to the agarose gel bound DNA and
heated to 37OC until the agar melted. The solution was then transferred to a QIAquick
spin column, inserted into a collection tube and centrifuged at 13,000 rprn for 1 rnin.
QIAquick PCR Purification Kit (Qiagen) was used to purify the isolated DNA.
Microcentrihge protocol was followed as described in Section 3.2.1.2.

DNA was

eluted using 30p1 EB.

3.2.1.6. Ligation of isolated Dam P C R product with Plasmid DNA
The following reactions were set up to ligate the Dam PCR product to pCR3.1 SRC-1A
and pCR3.1 SRC-3. Digested pCR3.1 SRC-1A or pCR3.1 SRC-3 plasrnid to a volume
of 11.11was mixed with 3p1 Dam PCR product, 3p1 dH20, 2p1 T4 DNA Ligase Buffer

(Invitrogen) and 1p1 T4 DNA Ligase (Invitrogen).

A control rcaction was also

performed which involved replacing 3pl PCR Dam insert with an additional 3p1 dH2O.
These were both incubated at RT°C for 1 hr. Following incubation the four samples
were heated to 70°C to inactivate enzyme activity.

3.2.1.7. Transformation of Plasmid DNA
Each ligation reaction, from Section 3.2.1.6., was added to 20p1 One Shot@ TOP10
chemically competent E.Coli (Invitrogen), flicked gently, put back on ice immediately
and left for 30 min. The cells were then placed in a 42°C H20 bath for 45 secs and
returned to ice. After 1 min on ice 500p1 SOC Medium (Invitrogen) was added to each
transformation reaction and incubated at 37OC for 1 hr. The samples were centrifuged at
7500 rpm for 1 min, 450pl prewarmed SOC Medium was removed and cell pellets
resuspended in the remaining SOC Medium. Each cell suspension was plated Agar
plates with 50pg/pl Ampicillin (Appendix I), prewarmed to 37OC and grown overnight
at 37OC.
Individual colonies were picked from the pCR3.1 SRC-IA:Dam, the pCR3.1 SRC3:Dam and grown overnight in 3ml LB Broth with 100pg/pl Ampicillin (Appendix I)
on a shaking incubator at 37°C.

3.2.1.8.

Isolation of Plasmid DNA

Plasmid DNA was isolated from the cultures using Chargeswitch Pro Plasmid Mini
Prep Kit (Invitrogen).

Chargeswitch@ Technology employs a novel mechanism that combines the strengths of
current plasmid prep methods while overcoming the inherent limitations. The use of
harsh reagents such as chaotropic salts, ethanol, or organic reagents, and isopropanol
precipitation, are replaced with a simple ion exchange procedure.

In this method,

plasmid is bound to a surface ligand that is positively charged at low pH, and eluted
when the pH is raised to 8.5 (Figure3.6.).

Procedure
The LB Broth culture was centrifuged for 10 mins at 7500 rpm, supernatant discarded
and pellet resuspended in 250p1 chilled Resuspension Buffer premixed with RNase A.
This was followed by the addition of 250p1 Lysis Buffer and samples were mixed by
inversion until the solution became viscous (3 min). Precipitation Buffer (250~1)was
added and samples were mixed by inversion until a white precipitate formed. Samples
were centrifuged for 1 min at 15000 rpm to pellet cellular debris. Supernatant was
transferred onto a Chargeswitch Protein Mini Prep Column inserted into a collection
tube and centrifuged at 15000 rpm for 1 min. The flow though was discarded and 7 5 0 ~ 1
Wash Buffer I added and centrifuged at 15000 rpm for 1 min. Wash Buffer I1 (250~1)
was added to the column followed by the same centrifugation procedure. The column
was placed into a clean, labelled Eppendorf tube where 50pl Elution Buffer was added
to elute the purified plasmid DNA. This was centrifuged at 15000 rpm and the column
was discarded.

1!

DNA Elution

I
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pH is raised topH 8.5. Pw$ed DNA
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elutes direct& into the solution
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Figure 3.6 Descriprion of the steps involved in the ChargeSwitchPro Plasmid Miii Prep Kit.

3.2.1.9. Plasmid Analysis
The plasmid DNA was digested with BamHI and EcoRI to determine if the plasmid had
the correct insert.
Restriciton digestions were set up as follows; 7pl purified plasmid DNA, was added to

1 pl NEB 4 Buffer (New England BioLabs), 1p1 BarnHI (IOUlfi) (Invitrogen) and 1p1
EcoRI (10UIpl) (Invitrogen). This was incubated at RTC for 1 hr, after which it was
run on 1% Agarose gel (section 3.2.1.4.).

3.2.1.1 0. Amplification o f pCR3.1 SRC-IAISRC-3:Dam Plasmids
E.Coli cells transformed with pCR3.1 SRC-1A:Darn and pCR3.1 SRC-3:Dam plasmid
DNA grown in Section 3.2.1.7. were used for further analysis.
100p1 of the original culture of E.Coli cells containing pCR3.1 SRC-1A:Dam or pCR3.1
SRC-3:Dam plasmids was transferred to 3ml pre-warmed LB broth with 100pg/pI
Ampicillin (Appendix I). These were swirled gently and incubated overnight at 37°C
on a shaking incubator.

3.2.1.1 1. Purification of Plasmid DNA
Highspeed Plasmid Midi Kit (Qiagen) was used to purify the plasmid DNA. Midi-preps
are used to obtain what is effectively a permanent supply of a certain plasmid, either for
transformation, or for later modification. Additionally, midi-preps remove endotoxins;
toxins found in bacteria which may lead to cell cytotoxicity during transfection.
Endotoxin-free DNA will improve transfection into sensitive eukaryotic cells and is
essential for gene therapy research.
QIAGEN Plasmid Kits clear bacterial lysates by centrifugation. The cleared lysate is
then loaded onto the anion-exchange tip where plasmid DNA selectively binds under
appropriate low-salt and pH conditions. RNA, proteins, metabolites, and other lowmolecular-weight impurities are removed by a medium-salt wash, and ultrapure plasmid
DNA is eluted in high-salt buffer.

The DNA is concentrated and desalted by

isopropanol precipitation and collected by centrifugation.

Procedure
The LB culture containing pCR3.1 SRC-1A:Dam and pCR3.1 SRC-3:Dam plasmids in
E.Coli cells was centrihged at 10,000 rpm for 5 mins after which the supernatant was
removed and the cell pellet resuspended in 4mls of Resuspension Buffer PI. P2 Lysis
Buffer (4mls) was added, mixed gently and left incubate for 5mins. P3 (4mls) was
adaed to the sample which was immediately poured into the barrel of the QIAfilter
cartridge, and left for l0mins. Buffer QC (4mls) was placed into HiSpeed Tip
(qualibration column) and left to flow through to calibrate it. After the incubation the
plunger was used to push the cell lysate into the previously calibrated HiSpeed Tip.
This was washed twice with lOmls Wash Buffer. DNA was eluted from the column
using 5mls Buffer QF and collected in a lOml tube. DNA was precipitated by adding
5.5mls Isopropanol (Fisher Scientific) to the eluate and this was incubated for 15 mins
at RT°C. This was centrifuged for 20 mins at 3500 rpm at 4°C. The supernatant was
discarded, lml70% ethanol (Pharmco-Aaper) added, sample was centrifuged for 2 mins
at same speed and temperature as previously described, 70% ethanol was aspirated and
the pellet was left to dry carefully. The cell pellet was dissolved in 5 0 0 ~ 1TE buffer

(Appendix I).

3.2.1.12. Determination of DNA Concentration
The concentration of DNA was then analyzed in a spectrophotometer using a
programme for double stranded DNA.

A 1 in 50 dilution of all DNA solutions was prepared by adding 2 p1 of DNA to 98 pl of
HzO. The spectrophotometer was blanked using 100 p1 of HzO. The dilution entered
87

into the machine and the absorbance set at 260 nm (A260). The

A260

I

A280

ratio was

also measured to determine the purity of the DNA contained in the samples.

3.2.1.13. Comparing pCR3.1-SRCl A-Dam and pCR3.1-SRCl A-Luc
Two digests were set up to compare pCR3.1-SRCIA-Dam and pCR3.1-SRClA-Luc.
7pl pCR3.1-SRC 1A-Dam was added to I p1 NEB Buffer 4 (New England BioLabs), 1p1
ApaI (10UIpI) (Invitrogen) and 1p1 SphI (10Ulpl) (Invitrogen). The other digestion
contained 1pl pCR3.1 -SRCl A-Luc, 7p1 dH20, 1p1 NEB 4 (New England BioLabs) and
l p l SphI (10UIpI) (10Ulpl) (Invitrogen). These were both incubated for 1 hr at 37'C
and run, along with 1 Kb Plus DNA Ladder (Invitrogen), on a 1% Agarose gel with
10% Ethidium Bromide (Sigma) for 30 mins at 90V (Section 2.2.1.4.).

3.2.1.14. Concentration of DNA for Sequencing
Sequencing was used to confirm the presence of Dam in the plasmid and to confirm that
it was inserted in the correct direction. A minimum DNA concentration of O.lpg/pl was
required for sequencing. DNA (500~1)was added to lml 100% EtOH (Pharmco-Aaper)
and 30p1 3M Sodium Acetate pH5.5 (Ambion) and incubated at -2OoC for 30 mins. The
sample was centrifuged at 15000 rpm for 5 mins and the supernatant aspirated. 200p1
70% EtOH was added and centrifuged at 15000 rpm for 30 secs and the supernatant
aspirated. The pellet was left until dry after which it was dissolved in a sufficient
volume of TE Buffer pH8.0 (Appendix I) to make approximately 0.2pg/pl DNA
concentration. A sample of this along with the reverse Dam primer (Figure 3.4.) was
sent to the BCM sequencing core for analysis.

3.2.2. Construction of Library of genomic sequences which interact
indirectly with SRC-1A:Dam

This process utilizes the SRC-1A:Dam expression vector (pCR3.1 SRC-1A:Dam)
constructed according to protocol described in the Section 2.2.1. to make a genomic
library of sequences which interact (mdirectly) to SRC-1A:Dam via, either, Oestrogen
Receptor a (ERa) or Progesterone Receptor-B (PR-B).
HeLa cell transfections, using the SRC-1A:Dam expression vector co-transfected with
ERa or PR-B expression vectors, with subsequent treatment of the corresponding
hormone were used to cause in vivo methylation of GATC sequences in genomic DNA.
Only GATC sequences next to where the SRC-1A:Dam fusion protein bound would be
methylated and could subsequently be isolated and amplified using PCR

3.2.2.1. Hela Cell Preparation for Transfection
HeLa Cells (Baylor College of Medicine, Houston, Texas) were plated in 6 well plates
(x2), with 200,000 celldwell in DMEM (with 4.5&

D-Glucose and LGlutamine,

without Sodium Pyruvate or Phenol Red) with 5% Charcoal Stripped Serum (Gibco)
and grown overnight at 37T in 5% (2%. All initial cell cultures were prepared by the
BCM cell culture core. Prior to transfection cells were checked, using Inverted
Microscope, to assess cell health, growth and distribution.

3.2.2.2. HeLa Cell Transfection
Transfections were canied out in duplicate.

Premixes were prepared prior to

transfection.
Each pCR3.1 SRC-1A:Dam plasmid and hormone receptor plasmid premix was

prepared with enough in each for 4 wells. They were made by adding the appropriate
volume of plasmids to separate Eppendorf tubes and 400pl DMEM (with 4.5&

D-

Glucose and L-Glutatnine, without Sodium Pyruvate or Phenol Red) without 5%
Charcoal Stripped Senun (Gibco) (Table 3.2.).

Well

TotalVol

Plasmid - SRC 1A

Hormone Receptor

1& 4

400pl

1OOOng pCR3.1 SRC-1A:Dam

1OOng pCR3.1 hERa

1 OOng pCR3.1 hPRB

TabIe 3.2. Plasmid Premix Preparation. Column number I represents the wells the premix is

required for (all in duplicate). Column number 2 represents the total volume of the premix.
Column 3 represents thefd
concenhation ofplasmidrequiredin the total volume (Column 2).
Column 4 represents the h a 1 concenhation of Hormone Receptor, or the absence of it in the
negative controlfor each well.

Lipofectamine premix was made by adding 12pl Lipofectamine (Invitrogen) to 1,200p1

DMEM without 5% Charcoal Stripped Serum (Gibco).
Rior to trausfection 400pl Lipofectamine premix was added to each pCR3.1 SRC1A:Dam plasmid and Hormone Receptor plasmid premix giving a total volume of

800~1.All ependorfs were centrifuged at 7,500 rpm for 10 sees to get the liquid to the
bottom and incubated at RTC for 30 mins.
Cells were removed from incubator and under Laminar Flow Hood medium was
aspirated from each well. This was replaced with 200pl of each appropriate premix

(Figure 3.7.). Plates were rocked for 30mins and then incubated for 4 hrs at 37'C in 5%

cQ2Total Volume in each well is 400 p1.
250ng pCR3.1 SRC-1A:Dam & 25ng pCR3.1 hERa
250ng pCR3.1 SRC-1A:Dam & 25ng pCR3.1 hPRB
250ngpCW.I SRC-1A:Dam

F i g m 3.7. HeLa Cell Transfection Layout. Figure demonstrates the jnaI trrmsfection
concentrotion of all expressionplasmids wed.

3.2.2.3.

Hormone Treatment of Transfected Cells

During the incubation hormone/EtOH premixes were prepared in DMEM (with 4.5 g&
D-Glucose and L-Glutamine, without Sodium Pyruvate or Phenol Red) with 5%
Charwal Stripped Serum (Gibco) to a final volume of lOmls for Oestrodiol and
Progesterone and 20mls for EtOH at the following concentrations: EtOH ~W'M, E2 10'

M and Progesterone ~W'M.

Following incubation the media was aspirated from each well in a Laminar Fume Hood
and 5mls of the appropriate hormone premix was added to the appropriate wells (Table

3.3.). The plates were then incubated at 37°C with 5% COz overnight.

Well

Plasmid - SRC 1A

Hormone Receptor

HormoneBlank

1

250ng pCR3.1 SRC IA Dam

25ng pCR3.1 hERa

EtOH

4

250ng pCR3.I SRC 1A Dam

25ng pCR3.1 hERa

E2

2

250ng pCR3.1 SRC 1A Dam

25ng pCR3.1 hPRB

EtOH

5

250ng pCR3.1 SRC 1A Dam

25ng pCR3.1 hPRB

Progesterone

3

250ng pCR3.1 SRC 1A Dam

EtOH

6

250ng pCR3. I SRC 1A Dam

EtOH

Table 3.3. Addition of Hormones to the transfected HeLa cells.

3 . 2 . 2 . 4 . Isolation of genomic DNA
The gDNA of the Hela cells should be methylated following the previously described
transfections. In principle SRC-1A:Da.m fusion protein will have bound indirectly to
specific genomic sequences and methylated the nearby GATC sequences. Genomic

DNA isolation was performed using an alcohol based precipitation technique.

Procedure
HeLa cells were harvested with HeLa Cell Lysis Buffer (Appendix I). To each well
5 0 0 ~ of
1 the Lysis Buffer was added. Duplicate wells were combined to give a total of
5 groups. The lysate from each group was transferred to individual ependorf tubes,

mixed and incubated at 55°C for 2 hrs after which 2 0 4 5M NaCl (Ambion) was added
to each tube.

Phenol:chloroform:isoamyl

alcohol

extraction

was

performed,

500~1

Phenol:chloroform:isoamyl alcohol (25:24:1) (Invitrogen) was added to each tube,
agitated gently for 5 min and centrifiged for 10 min at 10000 rpm. The top phase was
removed and placed in a clean ependorf tube. This step was repeated; the top phase was
separated and 2 0 0 4 chloroform (Fisher-Scientific) was added to each tube.

The

samples were placed in 55°C heating block for lhr to evaporate all chloroform and the
samples refrigerated.
When all chloroform had evaporated 10pg RNase A (Invitrogen) was added to the tubes
and they were incubated at 37OC for 1 hr. Phenol:chloroform:isoarnyl alcohol extraction
was performed again using 2 0 0 ~ 1 Phenol:chloroform:isoamyl alcohol (25:24:1)
(Invitrogen), agitating gently for 5 mins and centrifuging for 10 mins at 10000 rpm.
The top phases were removed and placed in clean ependorf tubes.

DNA was

precipitated by adding iml 100% EtOH (Pharmco-Aaper) and 'spooling' the fine
threads of DNA that formed with a pipette tip. The tips were then washed in 70% EtOH
(Pharmco-Aaper) for 5 mins and transferred to 100pl TE Buffer (Appendix I). The tips
were left in the Buffer overnight at RTOC to enable the DNA to dissolve fully.
Following incubation the samples were put in a 55°C water bath to ensure all DNA was
dissolved before the tips were removed.

3.2.2.5. Analysis of DNA Concentration
Samples were analysed for DNA concentration using a spectrophotometer (Section
3.2.1.12).

3.2.2.6. DpnI Digestion
The methylated GATC sequences in the isolated gDNA are digested by DpnI, which
specifically recognizes methylated GATC sequences, thus generating a pool of bluntended DNA fragments with 5'TC and 3'GAme', allowing their subsequent amplification
by ligation mediated methylation specific PCR

Procedure
DpnI digestion was performed by adding 0 . 5 ~ 1DNA from each of the samples into 2p1
NEB Buffer 4 (New England BioLabs), 2p1 DpnI (New England BioLabs) and the
appropriate amount of dH20 to make the total reaction volume to 20p1. These were
incubated at 37'C for 2 hrs followed by 80°C for 20 mins to inactivated DpnI.

3.2.2.7. Adapter Ligation
The purpose of the adapter ligation step was to ligate double stranded linkers to the
DpnI digested DNA. To allow PCR amplification of the DpnI digested sequences, a
double stranded adaptor nucleotide needs to be ligated to the blunt ends. The double
stranded adaptor is generated from the ligation of two separate single strand
oligonucleotides, with one strand having a S'overhang. The S'overhang of the.double

strand adaptor ensures directional ligation to the blunt end of the DNA sequences. A
double stranded adaptor was used in this step as the ligation of double stranded DNA is
more efficient than that of single stranded DNA (Figure 3.8.).

I . Formation of Adaptor
AdRT S'CTAATACGACTCACTATAGGGCAGCGTGGTCGCGGCCGAGGA3'
AdRb 3'GCCGGCTCTC 5'

DpnI Digested
Methylated gDNA

2. Adaptor Li~ation

Sequence

1

5'CTAATACGACTCACTATAGGGCAGCGTGGTCGCGGCCGAGGATChWNN
3'GCCGGCTCTC GNNNN
I'Me

Figure 3.8. Formation of double strunded adapter and its ligation

DpnI digested DNA (204) was added to 4pl 5X T4 DNA Ligase Buffer (Invitrogen),
2p1 ds adaptor AdR (comprising of Oligonucleotide AdR and AdRb, Figure 3.9., details
of procedure to construct in Appendix I) (50pM) (Sigma) and 2 . 9 ~ 1T4 DNA Ligase
(Invitrogen), giving a total reaction volume of 29p1. A control reaction was also set up
using 20p1 Undigested DNA from one of the samples rather than the DpnI digested
DNA. These were left to incubate for 2 hrs at RTDC and then heated to 80°C for 20
mins.
Right Adaptor (Top strand)
AdRT S'CTAATACGACTCACTATAGGGCAGCGTGGTCGCGGCCGAGGA 3'

Right Adaptor (Bonom Strand)
AdRb S'TCCTCGGCCG 3'

Figure 3.9. Double stranded adapters sequences
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3.2.2.8. PCR Amplification of Methylated Sequences
PCR amplification of the methylated sequences with ligated double stranded adaptors is
performed using an individual PCR primer (Figure 3.IO.) that is identical to the 15
most 3' nucleotides of the AdRt oligonucleotide sequence and the 5' TC nucleotides.
-

PCR Primer
AdR-PCRS'GGTCGCGGCCGAGGATC 3'
3. Primer Annealme and Extension
S'CTAATACGACTCACTATAGGGCAGCOTGGTCGCGGCCGAGGA
PCR Primer

\r

AdR-PCR S'GGTCGCGGCCGAGGATC -+
3'GCCGGCTCTCAGNNNN

I

Me

Figure 3.10. Sequence of PCR Primer and Annealing andExtension Step

This primer design prevents the amplification of non specific DNA products which may
be derived from random DNA breaks, as the PCR primer overlaps with the GA di-

nucleotide located at the ends of the DpnI digested fhgments. This ensures that only
these fragments are amplified in the PCR thus suppressing amplification of non-specific
ligation products, which generally will not have a GA di-nucleotide at their ends.

PCR (Table 3.4.) was used to amplify isolated sequences, and was set up as follows; 4p1

Linkered DNA, 2pl Accuprime Buffer I (Invitrogen), 0.5pl Primer AdR PCR
(Invitrogen), 13p1dH20 and 0.5pl Taq DNA Polymerase (Invitmgen).

Step

Temperature

Time

Initialization

94OC

3 min

Denaturation

94°C

30 sec

Annealing

58°C

15 sec

Elongation

72°C

Hold

4°C

I min
(5 min last cycle)

infinity

Table 3.4. PCR Programme for ampli$cation of melhylated sequences

3.2.2.9. Analysis of PCR products o n Agarose Gel
The products were run on 1% agarose gel with 10% Ethidium Bromide (Sigma) at 90V
for 45 mins (Section 3.2.1.4.).

3.2.2.10. Purification of PCR Products
PCR products were purified as per protocol described in Section 3.2.1.2. DNA was
eluted using 50p1 EB Buffer.

3.2.3. Cloning of PCR Products using pCRSlGWlTOP0 TA Cloning

Kit
The pCR8lGWlTOPO TA Cloning Kit (Invitrogen) was used due to its gateway cloning
compatibility. This combines TOP0 cloning and gateway technology to facilitate a 5
min, one step cloning of Taq Polymerase amplified PCR products into a plasmid vector

with greater than 95% efficiency. The resultant clones can then be sequenced and
chamcterid without difficulty.

Also, the clones can be transferred from the

pCR8/GW/TOPO entry vector to a Gateway destination vector of choice to enable
expression of the gene of interest in a number of systems. Figure 3.11. describes the
process flow.
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Figure 3.11. &hematic of Topoisomerase Method. Topoisomerase I recognition sites are
prepared on the Gateway Cloning Vector which ligates to the Tag amplified PCR products in a
5 min incubation at R E .

The resultant ligatohohonthen c m e s the release of the

TopoisomeraseI.

The pCR8/GW/TOPO vector (Figure 3.12.) is supplied with single 3'-thymidine

0

overhangs for TA Cloning and also with Topoisomerase I covalently bound to the
vector. Taq polymerase has a non-template-dependent tenninal transferase activity that
adds a single deoxadenosine (A) to the 3'ends of PCR products. The linearized vector
supplied in this kit has single, overhanging deoxythymidine (T) residues. This allows
PCR inserts to ligate efficiently with the vector.
Topoisomerase I from Vaccinia virus binds to duplex DNA at specific sites (CCCTT)
and cleaves the phosphodiester backbone in one strand (Shuman, 1991). The energy
from the broken phosphodiester backbone is converted by formation of a covalent bond

between the 3' phosphate of the cleaved strand and a tyrosyl residue (Tyr-274) of
topoisomerase I.

The phospho-tyrosol bond between the DNA and enzyme can

subsequently be attacked by the S'hydroxyl of the original cleaved strand, reversing the
reaction and releasing topoisomerase.

TOPO Cloning exploits this reaction to

efficiently clone PCR products

Figure 3.12. Vector map of pCR8/GWnOPO

3.2.3.1. Cloning reaction using pCR8IGWlTopo Vector

Dpnl digested DNA (lpl) were mixed with lpl Salt Soultion (Invitrogen), 3pl a 2 0 and
lpl TOPO Vector (Invitrogen). This was mixed and incubated for 15 mins at RTOC and
then placed on ice.

3.2.3.2. Transformation of Cloning Reactions
1
cloning reaction and adding it to 2 0 ~ 1
Transformation was performed using 2 ~ TOP0
Chemically Competent E. Coli (Invitrogen) and incubating on ice for 30 mins. This
was followed by a 30 sec heat shock at 42'C and then the samples were placed back on
ice. SOC medium (250~1)was added and the samples were incubated at 37OC for 1 hr.
The bacteria were then spread on labelled Agar plates with 100pg/ml Spectinomycin
(Appendix I) pre-warmed to 37'C and incubated at 37°C overnight.

Following

incubation, one of two steps took place.
Either individual colonies were picked (for analysis) and grown in 3mls LB Broth with
100pg/ml Spectinomycin followed by overnight incubation on agitating incubator at
37OC.

Alternatively plates were washed with 5mls LB Broth with 100pg/ml

Spectinomycin (Appendix I).

3.2.3.3. Purification of Cloned Plasmids
Charge Switch-Pro Plasmid MiniPrep Kit (Invitrogen) was then used to purify the
plasmid DNA (Protocol described in Section 3.2.1.8.).

3.2.3.4. Concentration analysis
The purified plasmids were analysed using the spectrophotometer (Section 3.2.1.12.) to
assess the DNA concentration and purity.

3.2.3.5. P l a s m i d Analysis
The plasmids were analyzed for the presence of an insert by enzyme digestion using the
restriction enzyme. The digest was set up as follows; 8pl purified DNA was added to
1p1 EcoRI (IOUIpl) (Invitrogen) and I p1 NEB Buffer 4 (New England BioLabs).

3 . 2 . 3 . 6 . Visualization of Digested Plasmid Products
The reactions containing the digested vectors were run on a 1% Agarose gel with 10%
Ethidium Bromide (Sigma) at 90V for 45 mins (Section 3.2.1.4.).

3.2.4. Creation of Expression Vector Containing Isolated Sequences

3.2.4.1. Generation of Destination Vector
In order to functionally test the isolated genomic sequences they had to be transferred
from the pCR8IGWITOPO cloning vector to an adapted destination vector with reporter
capabilities. This is achieved by ligating a blunt ended cassette containing attR sites
flanking the ccdB gene and the chloramphenicol resistance gene into the multiple
cloning site of the chosen destination vector (Figure 3.13.).

Figure 3.13. Newly construcledpGL3-Basic Vector

The destination vector of choice is the pGL3-Basic vector, a vector 41 18bp in length
which also contains a luciferase gene and lacks a promoter element. The isolated
sequences are shuttled from the entry vector to the multiple cloning site of the pGL3Basic vector which is located upstream of the Luc gene. If the sequence of interest
contains a promoter element it will enable Luc expression when transfected to HeLa
cells. It is this feature, plus its Gateway compatibility, that makes this a desirable
destination vector.

.

Initially, the vector linearized by digestion with the restriction enzymes NheI and Hind
111, followed by an alkaline phosphatase treatment to remove 5'phosphates, thus
decreasing the chance of vector religation. The reading frame shown below is then
ligated to the vector following a ligation reaction using fast link ligase.

Procedure
(This procedure was performed by Dr. David Lonard and Cormac Jennings)

To enable ligation of the cassettes the pGI3-Basic vector was digested with restriction
enzymes NheI and HindIII as follows: 1p1 pG13-Basic, 1p1 HindIII (10UIpI)
(Invitrogen), 1pI NheI (10UIpl) (Invitrogen) and 7pl NEB Buffer 4 (New England
BioLabs).
The digested vector was then treated with APex Heat-Labile Alkaline Phosphatase, a
novel Phosphatase that dephosphorylates 5'-phosphates. To the completed restriction
digest, 1p1 of Apex Heat-Labile Phosphatase was added. This was incubated at 37OC
for 10 mins followed by heat inactivation of the Phosphatase at 70°C for 5 mins.

3.2.4.2. Cassette Ligation

(This procedure was performed by Dr. David Lonard and Cormac Jennings)
The reading cassette was ligated to the digested pGL3-Basic Vector using Fast Link
ligase. The following ligation reaction was set up: 1pl Dephosphorylated pGL3-Basic,
2pl Gateway Reading Cassette, lpl Fast Link Ligation Buffer, 0 . 7 5 ~ 1lOmM ATP, lpl
Fast-Link Ligase and 10.25~1H20. The ligation reaction was incubated for 1 hr at
RPC.

3.2.4.3. Transformation of One Shot c c d B Survival Competent Cells

(This procedure was performed by Dr. David Lonard and Cormac Jennings)
Following the previous steps, the ligation reaction was transformed into One Shot ccdB
Survival Competent Cells. 1p1 of the ligation reaction was added to 1 vial of the One

Shot ccdB Competent Cells and then mixed gently. The vials were incubated on ice for
30 mins followed by heat shock for 30 secs at 4 2 C . The vials were then placed back
into the ice for another 2 mins. 2 5 0 ~ 1of SOC medium was added to the vial that was
then incubated for 1 hr at 37'C.

25p1 of the transformation reaction was spread on an

ampicillin plate and incubated ovemight at 37'C.

Resulting colonies were picked and

grown ovemight in LB medium containing 30pgIml chloramphenicol.

3.2.4.4. Plasmid DNA Isolation

(This procedure was performed by Dr. David Lonard and Cormac Jennings)
The plasmid DNA was isolated using the Qiagen Chargeswitch-Pro Plasmid MiniPrep
Kit, protocol according to Section 3.2.1.8. 1.5ml of the overnight bacterial culture was
processed.

3.2.5. Transferring the isolated cloned sequences to the adapted
Destination Vector
Once the destination vector is prepared, the gene of interested can be easily moved from
the entry vector to the destination vector. The gateway system takes advantage of the
site-specific recombination reactions enabling the bacteriophage

to intergrate and

excise itself out of a bacterial chromosome. This reaction is mediated by the LR
Clonase mix, consisting of integrase, integration host factor, and the phage excisionase
which catalyses the LR recombination reaction. The end result is the excision of the
gene of interest from the entry clone, pCR8IGWITOPO entry vector, and integration of

it into the pd-

destination vector, pGL3 Basic Vector, which then becomes the

expression clone (Figure 3.14.).

PCR~IGWITOPO
Entry Vector
(Containing isolated
sequences)

Adapted fiu
Destination
Vector

PGL3 Basic Vector,
now an expression clone PCRIIIGW~OPO
containing the isolated
sequences
(now empty)

F i g m 3.14. Transfewingthe isolated sequencesfrom the entry clone to the destination vector

In this case the LR clonase mix transfers the isolated sequence which is flanked by
attLl and attL2 sites in the pCRS/GW/TOPO entry vector into the newly generated
pGL3 Basic destination vector with ligated cassette containing two attR sites.
Following recombition of the matching attR and the attL sites the DNA hgment of
interest is flanked by attB sites. LR recombition reactions were set up for all
pCR8/GW/TOPO vectors.

3.2.5.1. LR Recombination Reaction
The pCRS/GW/TOPO Libraries (Song) were mixed with 50ng adapted pGL3-Basic
Dest (Promega), added to 4pI dH2O and lpl 5X LR Clonase Reaction Buffer
(Invitrogen) and incubated at RTOC for 2 hrs. Following the incubation 0.5d Proteinase

K

(2gpJpI) (Roche) was added and incubated at 37OC for a further 10 mins. The

Clonase reaction (1p1) was transformed to 2 0 ~ 1Chemically Competent E. Coli
(Invitrogen) and incubated on ice for 30 mins followed by 30 sec heat shock at 42 OC
and then placed back on ice. SOC medium (250~1)(Invitrogen) was added and the
samples were incubated at 37'C for 1 hr. This was then spread on LB plates with
100pglml Ampicillin prewarmed to 37'C and grown overnight in a 37°C incubator.

3.2.5.2. Growth of Library Plasmids
Each individual colony growing on the LB agar plates (Appendix I) was picked (using
a pipette tip) and placed in a lOml Falcon Tube with 5mls LB Broth (100pglml
Ampicillin) (Appendix I).

These were grown overnight at 37'C on an agitating

incubator.

3.2.5.3. Plasmid Purification
The Zuppy Plasmid Miniprep Kit (Zymo Research) was used to extract plasmid DNA
from 3mls of each culture, the remaining culture was stored, in an air-tight tube, at 4OC
until required. The 3ml culture was centrifuged at 7500 rpm for 5 mins, supernatant
aspirated and the bacterial cell pellet re-suspended in 600pl of TE buffer (Appendix I).
Cells were lysed by the addition of loop1 7X lysis buffer and mixed by gentle inversion
for 2 mins. Neutralization Buffer was chilled to 4'C and 3 5 0 ~ of
1 was added and mixed
by inversion until the entire sample turned yellow, this was then centrifuged at 15000

rprn for 4 mins. The supernatant was transferred into a zymo-spinTMI1 column which
was placed into a collection tube and centrifuged at 15000 rpm for 15 secs. The
supernatant was discarded, 2 0 0 ~ 1of Endo-Wash Buffer added and the samples were

centrifuged at 15,000 rprn for 30secs. Zuppy Wash Buffer (400~1)was added and
centrifuged at 15,000 rpm for 30secs.

The column was then removed fiom the

collection tube and placed in a clean, labelled ependorf tube after which 30p1 of Zuppy
Elution Buffer was added directly to the column matrix, left to stand for 1 min at RTaC
and centrifuged at 15,000 rpm for 15 secs.

3.2.5.4. Concentration analysis
The purified plasmids were analysed using the spectrophotometer (Section 3.2.1.12.) to
assess the DNA concentration and purity.

3.2.5.5. Sequencing
A selection of the library constructs were sent for sequencing at BCM sequencing
facility.

3.2.6. Functional

Analysis

of

newly

constructed

SRC-1A:Dam

Libraries

Libraries were analysed using Luciferase Assays. Details of the methodology used can
be found in Materials and Methods Section 3.1.1. Additional infonuation of plasmid

concentrations in the luciferase assays performed can be found in Appendix U.
Expression plasmids used were constructed previously by David Lonard and are as
follows:

pCR3.1 hERa - encodes full length human ERa
pCR3.1 hPR-B - encodes full length human PR-B
pCR3.1 COUP-TFI -encodes full length human COUP TFI
pCR3.1 COUP-TFII -encodes full length human COUP TFII
pCR3.1 RORa - encodes full length human RORa

pCMV5 SNAIL - encodes full length human SNAIL
pCR3.1 PAX4 -encodes full length human PAX4

3.3. Locating Transcription Start Sites
Reporter plasmids were analysed to assess where the transcription start site is located.
A modified GeneRacer Kit (Invitrogen) protocol was followed.

3.3.1. Modified Gene Racer Protocol

GeneRacer uses an advanced RACE (rapid amplification of cDNA ends) technique and
super~criptaI11 RT to improve the efficienct of amplifying full-length 5' and 3' cDNA
ends. GeneRacer ensures that only transcripts containing full-length cDNA ends are
amplified. The advanced protocol begins at the RNA level by specifically targeting
only 5' capped mRNA, subsequent steps result in the removal of the cap which is then
replaced with the GeneRacerTMRNA Oligo. During reverse transcription this RNA
oligo sequence is incorporated into the cDNA and only cDNA that is completely reverse

transcribed will contain this known sequence. 5' RACE PCR is then performed using
the homologous GeneRacerTM primer that is specific to the RNA oligo sequence and a
gene-specific primer. The result is amplified DNA that contains the full-length 5'
cDNA sequence. In addition to capturing the full-length 5' end of genes with known
transcriptional start sites GeneRacerTMcaptures additional 5' end sequence of genes
with unknown start sites

3.3.1.1. Transfection Protocol
An experiment was performed to locate the position of transcription start sites in the
COUP-TF responsive plasmid sequences (PI 1, P26, P27, P33) as well as 10 reporter
plasmids from the hERa library (-2p, -17, T29, T32, E30, T22, T31, T14, -30, E12) and
also pERE-Elb-LUC as a control. A modified GeneRacer (Invitrogen) protocol was
used to accomplish this.
HeLa Cells (Baylor College of Medicine, Houston, Texas) were plated in 5 x 6 well
plates at a density of 200,000 cells per well in DMEM (with 4.5g/L D-Glucose and LGlutamine, without Sodium Pyruvate or Phenol Red) (Gibco) with 5% Charcoal
Stripped Serum and grown overnight at 37'C with 5% C02. All initial cell cultures
were prepared by the BCM cell culture core. Prior to transfection cells were checked,
using Inverted Microscope, to assess cell health, growth and distribution.
Each reporter plasmid was prepared in duplicate; 8p1 lipofectamine was added to
1,500ng reporter plasmid and 1.6ml DMEM (with 4.5g/L D-Glucose and L-Glutamine,
without Sodium Pymvate or Phenol Red) (Gibco) without 5% Charcoal Stripped Serum.
COUP TFII (20ng) was also added to each COUP TFII responsive reporter plasmid and

20ng pCR3.1 hERa was added to the other 11 reporter plasmid samples. These were
incubated at R P C for 30 mins. Following incubation plates were removed from the
incubator and remainder of the protocol was carried out in a Laminar Flow Hood.
Medium was aspirated from each of the wells and replaced with 800pl of each reporter
plasmid premix (duplicate). The plates were returned to the 37°C with 5% C 0 2
incubator and left for 4 hrs. Medium was removed, again in a Laminar Flow Hood, and
2 ml 'DMEM (with 4.5gIL D-Glucose and without L-Glutamine, Sodium Pyruvate or
Phenol Red) (Gibco) with 5% Charcoal Stripped serum was added to each well. The
plates were returned to the incubator and left overnight.

3.3.1.2. RNA Isolation
The following day RNA was isolated as follows. HeLa cells were harvested using
7 5 0 ~ 1TEN Buffer (Appendix I) per well (TEN Buffer added, plates were checked
using a microscope to ensure all cells had dislodged from the base of the wells),
duplicate wells were combined into a single ependorf tube. Tubes were spun at 7,500
rpm for 20 sec to form a cell pellet. Liquid was aspirated and 250pl Trizol (Invitrogen)
was added to 2 tubes at a time and immediately vortexed to resuspend the pellet.
Chloroform (50~1)(Fisher Scientific) was added to each tube and vortexed for 30 secs.
Tubes were centrifuged at 15,000 rpm for 10 mins. The top phase was removed,
avoiding interface or lower layer, and transferred to a clean, labelled ependorf. 1 2 5 ~ 1
Isopropyl alcohol (Fisher Scientific) was added to each tube, vortexed and centrifuged
at 12,000 rpm for 5 mins. Liquid was aspirated and pellet was rinsed with 250pl 70%
EtOH (Pharmco-Aaper), vortexed and centrifuged at 12,000 rpm for 20 secs. EtOH was

removed and pellet was air dried at RTOC. RNase-free Hz0 (50p1) was added to each
tube, incubated for 30 mins and vortexed.

3.3.1.3. Concentration analysis
RNA concentration was quantified using a Spectrohotopmeter (Section 3.2.1.12.).
Sample T14 had no RNA and so was removed from the remainder of the GeneRacer
protocol.

3.3.1.4. Dephosphorylating RNA
This step involves RNA treatment with calf intestinal phosphatise (CIP) to
dephosphorylate non-mRNA or truncated mRNA.

Procedure
The RNA samples were combined, using 0 . 4 3 ~ 1from each of the 14 RNA samples
(total 6 ~ 1 ) .To this 1p1 10X CIP buffer, lpl RNaseOut, lpl CIP and 1p1 DEPC
(diethylpyrocarbonate) water (all Invitrogen) were added to give a total reaction volume
of 1 0 ~ 1 .This was mixed gently by pipetting, briefly vortexed and centrifuged for 2 secs
to collect the fluid. This was incubated at 50°C for 1 hr. Following incubation it was
vortexed briefly and placed on ice.

3.3.1.5. RNA Precipitation
When chilled, 50p1 Trizol was added and vortexed, then lop1 chloroform was added and
the sample was again vortexed. The upper phase was removed and transferred to a
clean, labelled ependorf and 25pl Isopropyl Alcohol (Fisher Scientific) was added,
sample vortexed and placed at -20°C for 30 mins. The sample was then centrifuged at
15,000 rpm for 5 mins and the supernatant aspirated. The pellet was rinsed with 50p1
70% EtOH (Pharmco-Aaper), votexed and EtOH aspirated. The pellet was dried at

RT°C and resuspended in 7p1 RNAse free H20.

3.3.1.6. Decapping Reaction
A lop1 decapping reaction was set up using 7p1 of the dephosphorylated RNA, 1p1 IOX

TAP Buffer, Ipl RNaseOut and lyl TAP (all Invitrogen). This reaction was mixed
gently by pipetting, briefly vortexed, centrifuged to collect the fluid and incubated for 1

hr. Following incubation the sample was placed on ice. RNA precipitation protocol was
repeated.

3.3.1.7. Ligation Reaction
Dephosphorylated, decapped RNA (7p1) was added to the tube (from the GeneRacer
Kit) containing pre-aliquoted, lyophilized GeneRacer Oligo (0.25pg) (Invitrogen). This
was mixed gently by pippetting up and down to resuspend the RNA Oligo and
centrifuged briefly to collect the fluid. A 5 min incubation at 65'C was performed to
relax the RNA secondary structure, this was then placed on ice to chill for 2 min and

centrifuged to collect the fluid. When chilled 1p1 10X Ligase Buffer, 1p1 lOmM ATP,
1pl RNaseOut (40Ulpl) and lpl T4 RNA ligase (5UIpI) (all Invitrogen) were added to
the tube (total volume of 10p1) and mixed together gently by pipetting. This was
incubated at 37'C for 1 hr, centrifuged gently and placed on ice. RNA precipitation
protocol was repeated.

3.3.1.8. Reverse Transcription
The ligated RNA (1Op1) was added to lpl Luc Reverse primer (50pM) (Figure 3.15.)
(Invitrogen), 1p1 dNTP mix and 1p1 RNase free Hz0 (all Invitrogen) and incubated at
65°C for 5 mins. Then, 4p1 5X First Strand Buffer, 1pl DTT 0.1M, 1pI RNaseOut and
1pI Superscript I11 RT°C was added (total reaction volume 10p1) (all Invitrogen),
centrifuged briefly and incubated at 55OC for 45 mins.

5' CGTATCTCTTCATAGCCTTATGCA3'

Figure 3.15. Luc Reverse primer sequence

To inactivate the enzymes the sample was then placed at 70°C for 15 mins, placed on
ice for 2 mins and centrifuged briefly to collect the fluid. To the reaction 1p1 RNase H

(2 U) (Invitrogen) was added and incubated at 37'C for 20 mins. This was stored at 20°C until ready for PCR.

3.3.1.9. PCR Amplification o f c D N A

PCR was performed using 1p1 cDNA, 0 . 5 ~ 1Luc Reverse Primer (detailed previously)
(1OmM) (Invitrogen), 0 . 5 ~ 15' GeneRacer Primer (Figure 3.16.), 2 . 5 ~ 110X Accuprime
Buffer I, 0 . 2 5 ~ 1Accuprime Taq HIFI and 20.25~1dHzO (total volume 2 5 ~ 1 )(all
Invitrogen). The PCR programme details are outlined in Table 3.5..

Figure 3.16. GeneRacerTM5'primer

Temperature

Time

Initialization

94°C

2 min

Denaturation

94°C

15 sec

62°C

15 sec

Elongation

68OC

15 sec

Denaturation

94°C

Annealing

56°C

15 sec

Elongation

68°C

15 sec

Hold

4°C

_"'"1.
Annealing

1

,

15 sec

I]

x5

infinity

Table 3.5. PCR Programme for AmpliJcafion of cDNA

3.3.1.10. Analysis of PCR Products
PCR products and I Kb Plus Ladder (Invitrogen) were run on 3% Metaphor Agarose
Gel (Appendix I) at 90V for 45 mins (Section 3.2.1.4.).

3.3.1.1 1 . Purification of PCR Products
PCR products were purified using QIAquick PCR Purification Kit (Qiagen) following
protocol described previously (Section 3.2.1.2). DNA was eluted from the column
using 30p1 EB.

3.3.1.12. Amplification of Plasmid
Purified DNA ( 2 ~ 1 )was added to 20p1 One Shot@ TOP10 Chemically Competent
E.Coli (Invitrogen), flicked gently, put back on ice immediately and left for 30 min.
The cells were then placed in a 42°C H20 bath for 45 secs and returned to ice. After 1
min on ice 500pl SOC Medium (Invitrogen) was added to each transformation reaction
and incubated at 37OC for 1 hr. The samples were centrifuged at 7500 rpm for 1 min,
450p1 SOC Medium was removed and cell pellets resuspended in the remaining SOC
Medium. Each cell suspension was plated on Agar plates with 50 pg/pl Ampicillin
(Appendix I), prewarmed to 37'C, and grown overnight at 37OC. Following incubation
the plates were observed. Colonies growing were picked, using a pipette tip, and the tip
placed in 5mls LB Broth with 50pglpl Ampicillin (Appendix I). This culture was
grown on an agitating incubator at 37°C overnight.

3.3.1.13. Plasmid Purification
Following incubation 3mls of the culture was purified using Zuppy Plasmid MiniPrep
Kit following protocol described in Section 3.2.5.3.

3.3.1.14. Analysis of DNA
The eluate was analysed for DNA concentration using a spectrophotometer and diluted
to give a concentration of 200ng/pl.

3.3.1.15. Sequencing
The diluted DNA was sent to the BCM sequencing core for sequencing analysis.

3.4 Statistical Analysis
Analysis was conducted using Microsoft Excel. Student's t-test was used for analysis of
transfection data in cell lines.

This study aimed to examine an oestrogen responsive element (ERE) reporter library
generated by DamID to identify and investigate SERM responders. Subsequent to this,

DamID was employed to create a library of human genomic regions where SRC-1A
associates with ligand bound ERa or PR-B.

4.1. ERE Reporter Library Investigation
The oestrogen receptor binds to EREs to mediate gene expression. An ERE reporter
library was generated using the DamID technique described in the Materials and
Methods Section, using a ERa:Dam fusion protein (Jennings, 2009). The ERa:Dam
fusion protein was used in conjunction wit.hormone treatment with EtOH (V Libmy),
Oestrogen (E Library) or Tamoxifen (T Library) to generate three separate reporter
libraries.

The function of this was to address questions such as; what adjacent transcription factor
binding motifs are found co-associated with EREs, and also whether the level of gene
expression varied between ERa and ER$ biding.
Initial screening investigatio~~s
were performed on these Libraries (20 reporter plasmids
h m each library were investigated) to assess the differential response of reporter
plasmids in this library to Oestrogen, Tamoxifen and Raloxifene. Tamoxifen and
Raloxifene are selective oestrogen responsive elements (SERMs) which are used in the
treatment of Oestrogen responsive tumours such as breast.
investigations are described below.

The results of these

4.1.1.

Identification

a n d I n v e s t i g a t i o n of S E R M R e s p o n d e r s f r o m

E R E reporter Libraries
Initial ERE Library construction was previously performed using transfection protocol
to transfect an ERa:Dam plasmid to HeLa Cells as described by Jennings (Jennings,

2009). This was followed by cell treatment with Oestradiol, Tamoxifen or Ethanol.
The cells were incubated and during this time the ERa:Dam protein formed a nuclear
receptor complex with either oestradiol or tamoxifen, this enabled in vivo targeted
methylation of GATC sequences close to ERa binding sites. Selective amplification of
isolated sequences was perfomed using LM-PCR, cloned using a TOP0 entry vector
(pCRSIGWITOP0) and the sequences sub-cloned to an adapted gateway compatible
reporter vector @GL3-Basic) via LR recombination reaction (Figure 4.1.).
pGL3-Basic was the reporter vector of choice, which contains no promoter element, and
the isolated DNA sequence is inserted into a multiple cloning site, upstream from a Luc
gene (Figure 4.2.). The absence of a promoter site and the presence of a Luc gene
upstream from the insert enables the use of assays to examine the functional activity of
the insert.
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Figun 4.1. Overview ofthe construction ofthe ERE reporter libraries (Jennings, 2009)
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Figure 4.2. pGL3-Basic Vector displaying Ampicillin gene for selectivity, the location ofwhere
the genomic insert ir ligated to rhe vector and the location ojrhe Lucifrme gene, upstream of
the genomic insert.

The result of these steps is three separate ERE reporter libraries. Each is obtained from
transfecting ERa:Dam to HeLa cells and treating these cells with EtOH, Oestradiol (E2)
or Tarnoxifen (4HT). These served as the starting point for further investigations
described below.

4.1.1.1. Initial Screening of ERE Reporter Plasmid Libraries

'

Initial screening trans-activation assays were performed on 20 plasmids from each of
the three ERE Reporter Libraries (Ethanol, Oestrogen and Tamoxifen), described
previously. These assays were used to identify reporter plasmids whose promoter
responded more favourably to Tamoxifen (4HT) or Raloxifene (Ral) (SERMs) than to
Oestrogen. This response may indicate the presence of a SERM responsive sequence,
where Tamoxifen or Raloxifene has the ability to induce gene expression when it
associates with the particular region of DNA that is isolated in the reporter plasmid.
The luciferase assay was then used to quantify functional activity for each plasmid. As
stated previously, the pGL3 Basic reporter vector does not contain a promoter site and
contains a luciferase gene upstream of the insert. Therefore, if the isolated sequence
that was inserted into the pGL3 Basic vector contains a functional promoter sequence it
will drive the expression of luciferin in the HeLa cells, the amount of oxyluciferin
expressed will be proportional to the strength of the promoter (Figure 4.3.).
Luciferase Assay was performed as per Materials and Methods Section 3.1.1.4.

The

Figure 13. Theory of the Dunsactivation Lucifeme Assay

The luciferase assay is based on the fact that luciferin (or flouroluciferin), when mixed

with oxygen and firefly luciferase, produces oxyluciferin (or oxyflouroluciferin)
(Figure 3.4.), levels of which can be quantified using a luminometer.

Figure 4.4. Chemical reaction thar occurs during the Luciferme Assay @romega.com)

Figure 4.5. displays the results from initial luciferase assays.
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Figure 4.5.

Luciferase assay results following co-transfection of pGL3-Basic reporter

constructs withpCR3.I hERafollowed by 24hr hormone treatment: 10-7M EtOH (Ethanol), 109ME2 (Oesh.odiol), 10-7M4HT (Tatnarifen) or 10-7MRal (Raloxifne).

Nine reporter plasmids were found to display this SERM response (E5p, E2, E73, E78,
E82, T4p, T8, T77, T100). All nine were sent to sequencing to confirm they are of
genomic origin. However, upon sequencing only two were found to be of genomic
origin, E5p and T4p (highlighted in purple boxes in Figure 4.5.b. and Figure 4.5.c).
The plasmids of non-genomic origin did not undergo further investigations.

Figure 4.6. displays more detailed results of the transactivation assay of the two

genomic SERM responsive plasmids (highlighted in purple boxes in Figure 4.5.: T4p
and E5p).

Figure 4.6. Lucifrase assay results following co-transfection of pGL3-Basic reporter T4p or
E5p with pCR3.1 hERa followed by 24hr hormone treatment. (Same assay as in Figure 4.5.close up of results)

Oestrogen responsive reporter plasmids were used as a comparison (highlighted in blue
boxes in Figure 4.5.: El2 and V17). Figure 4.7. displays more detailed results of two
E2 responsive reporter plasmids, of genomic origin, which were to be used as a
comparison.

Figure 4.7. Lucifease assay results following co-transfiction ofpGL3-Basic reporter El2 or
V17 withpCR3.1 ERafollowed by hormone treatment. (Close up of results from Figure 4.5.)

f i e oestrogen responsive reporter constructs, El2 and V17 (Figure 4.7.), were used as
a comparison to the SERM responsive reporter constructs T4p and E5p (Fkure 4.6.).
The difference in the two responses can be seen from obmation of Figure 4.6. and
Figure 4.7.. In the SERM responsive plasmids Tamoxifen and Raloxifme response is

much greater than that of the Oestrogm response. This is the opposite of the Oestrogen
responders. The response observed in the Oestrogen responders is one that would be
expected due to the antagonistic activity of Tamoxifen and Raloxifene. Locating these
SERM responsive sequences could be important in identifying the factors that result in
Tamoxifen resistance during the treatment of breast cancers and also could be used to
identify which genes are activated following Tamoxifen biding and in which tissues
these SERM responsive sequences are active in.
The two SERM reporter plasmids, T4p and E5p, were investigated further to observe
the effects of other transcription factors and ERa mutations on their transcriptional
activity.

4.1.1.3. Investigation of Mutant ERa on SERM Responders
Mutant ERa reporter plasmids were employed to assess which sites are required for the
S E W responsive plasmids to continue to cause transcription. C205H is a DBD (DNA
Binding Domain) mutant, L539A is an AF-2 defective mutant and S118A is an AF-1
defective mutant.
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Lucifrare assay results following co-iransfection of pGL3-Basic reporter

constructs (T4p in Panel A; ESP in Panel B) with pCR3.I hERa or hERa expression mutants
W R 3 . 1 C205H, pCR3.1 LS39A or pCR3. I SlI8A). This war followed by 24hr hormone
treatment with ~ ( T ' M E ~ o H @thatroo, IU'M ~2 (Oeshadioo, IU'M ~ H (Tamoxifn)
T
or IU'M
Ral (Raloxifene):p<O.OS,

.*p<0.01 mutant ERa compared to w i l d - ERa
~

A significant reducation in transcriptional activity was observed when mutant ERa was
compared to wild-type ERa following corresponding hormone/drug treatment w0.05,

p<0.01) (i.e.: wild type ERa transfection followed by Raloxifene treatment is compared
to C250H transfection followed by Raloxifene). Furthermore, analysis of the wild-type

ERa result itself indicated the significance of the SERM responsive plasmids response

to Raloxifene (p<0.05) and Tamoxifen @<0.01), in the case of T4p, and of Raloxifene
( ~ 1 0 . 0 5alone
)
in the case of E5p compared to E2 treatment.

The results (Figure 4.8.) demonstrate that all ERa mutant domains tested are required
for promoter activity in the SERM responsive reporter plasmids indicating a fully
functional ERa molecule is required for this SERM response to occur.

4.1.1.4. Investigation of Transcription Factors and Co-Factors on SERM
Responders
SNAIL and PAX4 are nuclear receptors, while SRC-3 is a nuclear receptor co-activator.
These nuclear receptors and nuclear receptor co-activators were used due to information
obtained from bioinformatic studies (Lonard, 2009; unpublished observations). PAX4
binding sites were found in a number of the isolated ERE reporter plasmids, as was
SNAIL. SRC-3 was investigated due to its proven co-activation of ERa (Anzick et al,
1997).
Figure 4.9. shows the results of the two SERM responsive reporter plamsids
transfected to HeLa cells with pCR3.1 (control; blank plasmid), pCR3.1 hERa, pCR3.1
hERa with pCMV5 SNAIL, pCR3.1 hERa with pCR3.1 PAX4 and pCR3.1 hERa with
pCR3.1 SRC-3. Each transfected group of cells were incubated for 4 hrs and then
underwent a 24 hr treatment with either EtOH, Oestrogen, Tamoxifen or Raloxifene.
Statistical analysis on this data was investigated as was Figure 4.8.. The results in this
case indicate that E5p and T4p both result in a significant response to Raloxifene and
Tamoxifen when compared to E2 treatment @<0.05, p<O.01).
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Luciferase assay results following co-transfection of pGL3-Basic reporter

constructs with pCR3.1 (empty vector), pCR3.1 hERa, pCR3.1 hERa and pCMV5 SNAIL,
pCR3.1 hERa andpCR3.1 PAX4 or pCR3.1 hERa andpCR3.1 SRC-3. This was followed by
24hr hormone treatment: 10-7M EtOH (Ethanol), 10-9M E2 (Oesiradiol), 10-7M 4HT
(Tamoxifen) or 10-7M Ral (Raloxifene).*p<0.05, **p<O.01 hERa alone compared to hERa cotransfected with respective nuclear receptor/co-activator

It is apparent from Figure 4.9. that the isolated SERM responsive sequences are
activated by the transfection of pCR3.1 hERa alone followed by hormone/drug
treatment. pCR3.1 PAX4 and pCMV5 SNAIL exert a significant co-repressive effect
on the sequences (p<0.05, p<0.01) and pCR3.1 SRC-3, interestingly, does not coactivate transcription in these sequences, in fact SRC-3 appears to significantly corepress these SERM responsive reporter plasmids (p<0.05, p<O.01).
The effect of SNAIL and SRC-3 on oestrogen responsive reporter constructs (El2 and
V17) was also investigated and results can be seen in Figure 4.10. The repressive
SNAIL response seen in SERM responsive reporter plasmids (Figure 4.9.) is mimicked

in the oestrogen responsive reporter plasmids (Figure 4.10.) with a significant
reduction in transcriptional activity observed in both constructs (p<O.OS, p<0.01)
The effect of SRC-3 on the oestrogen responders was investigated to identify whether

there is differential regulation of SRC-3 on the two groups of reporter constructs. It can
be seen (Figure 4.10.) that SRC-3s transcriptional coactivator ability is restored in
these plasmids, cooperating only with E2 treated cells co-transfected with ERa and
SRC-3, not with Raloxifene. These results correlate to previous findings that SRC-3 is
a coactivator of ligand bound ERa (Anzick et al, 1997).
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Figure 4.10. Lucifrase assay results following co-transfection of pGL3-Basic oestrogen
responsive reporter consfructs, VI 7 and EI2, withpCR3.1 hERa andpCR3.1 (empty expression
vector) orpCR3.1 hERa rmdpCR3.1 SRC-3fbllowed by 24hr hormone treatment: 10-7MEtOH
(EthanoI), 10-9M E2 (Oestradio~,10-7M or 10-7M Ral (Raloxvme).*p<0.05, **p<O.Ol hERa
alone compared to hERa co-transfectedwith SNAn

Two SERM responsive plasmids were identified from the ERE reporter library
constructed by Jennings (Jennings, 2009). Transactivation assays were performed to
assess the mechanism by which these SERMs (Tamoxifen and Raloxifene) function to
activate, rather than repress, ERa. The initial investigative assay used mutant ERa
expression plasmids to determine is transcription could still be activated by a mutant
ERa. The results indicated that the DNA-Binding, AF-1 and AF-2 domains were all
necessary in order to activate transcription, indicating that the SERMs are interacting
with ERa in a similar mechanism to Oestrogen.
Transcription factors and transcriptional coactivators were investigated next to assess if
there was any differential response found to SERMs as compared to the oestrogen
responsive constructs. A differential SRC-3 response was observed. SRC-3 has been
previously reported to be an ERa co-activator. The results obtained indicated that, for
the SERM responsive reporter constructs, SRC-3 has the ability to co-represses
activities of ERa.
It was decided to investigate the SRC family of 'co-activators' further.

4.2. S R C - 1 A and SRC-3IERa and PR-B Reporter Library

Generation and Investigation
Due to the interesting results obtained from the investigation of SRC-3s effect on
SERM responsive ERE reporter constructs it was decided to investigate the SRC family
of coactivators in further depth, generating a library of reporter plasmids that bind

indirectly to SRC-1A or SRC-3 via ligand bound ERa or PR-B. SRCs bind to promoter
elements in DNA via ligand bound nuclear receptors (Onate et al, 1995). More
information on this family of molecules, and coregulators in general, can be found in
Section 1.4. Investigations focused on SRC-1A and SRC-3, chosen due to their ability
to bind to a range of nuclear receptors, including ERa and PR-B.

The purpose of this study was to generate a reporter plasmid library of genomic
sequences which associate, via steroid hormone receptors (ERa or PR-B), with SRC-1A
or SRC-3 and further to this, evaluate the sequences ability to regulate transcription.

This should enable a greater understanding of the involvement of these two SRC
molecules in the regulation and transcription of SRC regulated genes. An overview of
the steps involved in this process can be viewed in Figure 4.11..
Step 1: Generation ofSRC-IA :Dam andSRC-3:Dom exuression vectors

cation

of methylated genomic sequences using LM-PCR

I

Top0 Cloning of the Generated PCR Products
Plasmid Isolation
&p&

Generationof Reporter Vectorscontaining DamID isolatedsequences
Sequencing of reporter plasmid inserts

StreB; Bioitformatid Amtysis
Functional Analysis of the newly generatedSRC-IA:Dam Reporter Vectors

StcD Locoting TranscriptionStart Sites using GeneRacer

Figure 4.11. Overview of the D a d D mediated SRC-IA gDNA interacting sequence isolation
process.

4.2.1. Generation of pCR3.1 SRC-1A:Dam and pCR3.1 SRC-3:Dam.

Reporter plasmid library construction fustly began with the generation of an SRC-1A
(or SRC-3) Dam fusion protein. A pCR3.1 SRC-1A Luc Vector underwent SalI and
ApaI digestion (Materials and Methods Section 3.2.1.3), effectively cutting out the Luc
The Dam gene was amplified from genomic Escherichia coli by PCR,

gene.

purification of PCR product and subsequent complimentary restriction digestions (ApaI
and SalI) (Materials and Methods Section 3.2.1.l. to 3.2.1.3.). This left corresponding
digested ends which during a ligation reaction c o m b i i g the isolated Dam gene and the
SRC-1A vector minus the Luc gene resulted in a vector which was composed of the
SRC-1A gene located upstream and next to the Dam gene (Figure 4.12.).
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Figure 4.12. Theprocess of conshuctingpCR3.1 SRC-1A Dam plasmid
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4.2.1.1. Generation of Dam PCR product, pCR3.1 SRC-1A and pCR3.1
SRC-3
The Dam gene was amplified from E. coli by PCR. The Dam forward primer contained
a SalI restriction recognition site at the 5' end and the Dam reverse primer contained a
ApaI restriction recognition site at the 5' end (Materials and Methods Section 3.2.1.1.).
Following PCR amplification and DNA purification (Materials and Methods Section
3.2.1.2.) the PCR products were digested with SalI and ApaI, as were plasmids pCR3.1
SRC-1A:Luc and pCR3.1 SRC-3:Luc (Materials and Methods Section 3.2.1.3.).

Figure 4.13. presents a 1% agarose gel which displays the bands of the isolated Dam
PCR products (Lanes 2 and 3) along with digested pCR3.1 SRC-1A:Luc (Lanes 4 and
5) and pCR3.1 SRC-3:Luc (Lanes 6 and 7).

- .-,7500 hp

--I600

bp

Dam I'CK
Products .-800 bp

Figure 4.13. 1% Agarose Gel. Lane 1 is molecular weight marker. Lane 2 and 3 are Dam PCR
Products. Lane 4 and 5 are the restriction digestedpCR3.1 SRC-1A:Luc plasmids and lane 6
and 7 are digestedpCR3. I SRC-3:Zucplasmids.

The gel demonstrates that both the PCR amplification of Dam and the digestion of
pCR3.1 SRC-1A Luc were successful as the Dam PCR product (Lane 2 and 3) was
present at the expected size (800 bp) and the SRC-1A:Luc (Lane 4 and 5) vector

backbone is present at 7500 bp with the excised Lec insert at 1600 bp. The gel also
shows the unsuccessful digestion of pCR3.1 SRC-3 Luc (Lane 6 and 7) as there is no
band at the expected 1600 bp site, which would be indicative of successful restriction
digestion and release of Luc fragment.

4.2.1.2. Removal o f the Luc fragment
The Luc fragment (1600 bp) was removed from the gel and discarded (Materials and
Methods Section 3.2.1.4. and 3.2.1.5.).

4.2.1.3.

Ligation of Amplified Dam PCR Product and pCR3.1 SRC-

I AJSRC-3
The pCR3.1 SRC-IA plasmid minus the Luc fragment was ligated to the Dam PCR
product (Materials and Methods Section 3.2.1.6.).

A control ligation was also

performed for each plasmid which involved performing a second ligation for each
plasmid, excluding the amplified PCR product.

E. coli cells transformed with ligated plasmids were plated on agar containing
ampicillin (Materials and Methods Section 3.2.1.7.) and incubated overnight.

The

results of growth can be seen in Table 4.1..
There was an absence of growth on the pCR3.1 SRC-IA Control plate which was
indicative of inefficient restriction digestion (which confirms the lack of a Luc band in
Figure 4.1 1.). A small number of colonies were present on the pCR3.1 SRC-IA Dam
plate.

The high number of colonies on the pCR3.1 SRC-3 Control plate was an

unexpected result, further analysis was required to confirm ligation was successful in
the case of pCR3.1 SRC-lA:Dam, and to confirm all steps were successful in the case
of pCR3.1 SRC-3:Luc ApaIISalI digestion (as there was no evidence of initial Luc
removal from the pCR3.1 SRC-3:Luc plasmid).

Plasmid

Colonies Observed on Agar Plate

pCR3.1 SRC-1A Dam

2

pCR3.1 SRC-1A Control

None

pCR3.1 SRC-3 Dam
pCR3.1 SRC-3 Control
Table 4.1.

:

/
/
/

17

Observation of Agar Plate Growth following ligation of ampliJied Dam fragment

and digestedpCR3. I SRC-la!SRC-3plasmid.

Colonies of interest (two from pCR3.1 SRC-1A:Dam plate and two from pCR3.l SRC3:Dam plate) were picked and cultured (Materials and Methods Section 3.2.1.7.).
Plasmid DNA was isolated as per Materials and Methods Section 3.2.1.8. and analysed.

4.2.1.4. Analysis of Constructed Plasmids
Plasmid DNA was assessed using EcoRI and BamHI enzyme digestions (Figure 4.14.)
to determine if the plasmid had the correct insert (Materials and Methods Section
3.1.9.).
It appears that the BamHI and EcoRI digestion did not successfully reveal a Dam insert
as no band at the expected 535 bp was observed.

Figure 4.14. 1% Agarose Gel with products of BamHI and EcoRI Digestion.' Lane I is the
molecular weight marker. Lane 2 and 3 are digestedpCR3.I SRC-1A:Dam. Lane 4 and 5 are
pCR3. I SRC-3:Dam. No Dam fiagment visible around the expected 535 bp size.

Digestion analysis was then repeated using BamHI and EcoRI (Materials and Methods
Section 3.2.1.9.). and only pCR3.1 SRC-1A Dam showed evidence of containing a Dam
fragment at the expected size of 535 bp (Figure 4.15.)

Figure 4.15. 1% Agarose Gel, with products following BamHl andApal Digestion. Lane I is
molecular weight marker. Lane 2 is pCR3.I SRC-1A:Dam. Lane 3 and 4 is pCR3.1 SRC3:Dam. Damj?agment faintly visible at 535 bp size in lane 2 only, no band visible for pCR3.1
SRC-3:Dam

4.2.1.5. Optimisation of Techniques to Construct pCR3.1 SRC-3:Dam
Due to unsuccessful construction of pCR3.1 SRC-3:Dam adjustments were made to the
methods used.
Protocol was repeated from the initial digestion with ApaI and SalI (Materials and
Methods Section 3.2.1.3.). Electrophoresis was performed on the digested pCR3.1
SRC-3:Luc plasmid ( ~ i g u r e4.16.).

There was no evidence of the

L U ~gene

at the

expected 1,600 bp site.
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Figure 4.16. 1% Agarose Gel, following restriction digestion with ApaI and Sall. Lane I is a
molecular weight marker. Lane 2, 3, 4 and 5 are restriction digestedpCR3.I SRC-3:Dam.

Adjustments were made to the original protocol to enable successful construction of
pCR3.1 SRC-3:Dam. The ApaI digestion step was adjusted as well as the ligation step.
The ApaI digestion was performed with 3p1 pCR3.1 SRC-3:Luc, 1p1 NEB Buffer 4
(New England BioLabs), 5p1 dHzO and 1p1 ApaI (Invitrogen) and the ligation time was
extended from 1 hr to 2 hrs.
The ApaI digestion was performed with 3 times the amount of pCR3.1 SRC-3 Luc to
provide more plasmid DNA and thus give a higher chance of obtaining sufficient
amounts of plasmids, also ligation time was extended from 1 hr to 2 hrs to provide more

time for the PCR DNA Dam to ligate to the plasmid. Results from the gel (Figure
4.1 7.) confirmed that the Luc gene was cut from the pCR3.1 SRC-3:Luc plasmid.

Figure 4.1 7. 1% Agarose Gel; following Luc excision. Lane I is molecular weight marker.
Lane 2 and 3 are pCR3. I SRC-3:Luc. The Lucjiagmenr has been excised.

However, following ligation and transformation to chemically competent E. coli cells
and overnight incubation on agar plates neither the test or control plates obtained any
growth. A 6 hr ligation at R Y C was performed on the digested pCR3.1 SRC-3 plasmid
(no Luc gene) in an attempt to successfully ligate the Dam PCR product to the pCR3.1
SRC-3 plasmid. This also yielded no growth following transfection to chemically
competent E. coli cells. Attempts to construct pCR3.1 SRC-3 Dam were suspended.

4.2.1.6. Further Analysis of pCR3.1 SRC-1A:Dam plasmid
The agar plates growing E. coli colonies with pCR3.1 SRC-1A:Dam plasmids were
purified and plasmid DNA isolated (Materials and Methods Section 3.2.1.10 and
3.2.1.1 1). The resulting purified plasmid DNA was assessed using restriction digestion
to compare pCR3.1 SRC-1A:Dam and pCR3.1 SRC-1A:Luc using the restriction

enzyme SphI (Materials and Methods Section 3.2.1.13). Figure 4.18. displays a 1%
agarose gel following electrophoresis of the restriction digestions (of pCR3.1 SRC1A:Luc and pCR3.1 SRC-1A:Dam) and confirms a difference in the banding pattern of
the pCR3.1 SRC-1A:Dam and the pCR3.1 SRC-1A:Luc plasmids.

Figure 4.18. 1% Agarose Gel containing SpI restriction digested plasmids. Lane I contains
molecular weight marker. Lane 2 contains the pCR3. I SRC-1A;Dam digestedplasmid. Lane 3
contains the pCR3. I SRC-1A;Luc digestedplasmid.

Sequencing was used to confirm the directionality of the gene and to confirm that the
full length gene for both SRC-IA and Dam are present (Materials and Methods Section
3.2.1.14.).
A minimum DNA concentration of O.lpg/pl was required

for sequencing.

Spectrophotometric analysis of the plasmid DNA revealed the concentration of DNA to
be 0.068pg/pl with a

260/2so

ratio of 1.75. DNA had to be concentrated to enable

sequencing to be performed (Materials and Methods Section 3.2.1.12.).

Following

concentration of the plasmid spectrophotometric analysis determined the DNA
concentration to be 0.177pg/pl with a 260/2go ratio of 1.44. DNA was more concentrated
but was not as pure.

Sequencing confiied presence of Dam downstream and adjacent to the SRC-1A gene

(Figure 4.1 9.).

Primar

SRC-1A

Dam Sequence

Unknown sequence

3'ACCGTGGGGmGTACAAAGCCAGCAAGTTCGTCCACCrmTACGTGTGCCGCCGTTGCTGCnATACTG
CGTCGAACmGACGACATGCAAmGCGCGCTGATACCACTCACGCGTTAACATCGTATCGTGAnGGAGA
TCAGCACTGGAATATGGCGCTCAACCAGACCTTCGGCGATCTCCGCCAGATGCGCTTGmGTTCAAGCGTAAA
ACTGmGTGTGATACGCCGTAAAGTTGGCGGTCGCAGACAGCGGTGCATAAGGCGGATCGCAATAGACGAC
GGATGCATCATCTGCGCGCGCCATGCTATC~GTMMCTCACAATAUGGCATTCTGCGCWCA
GCGAAGTGATACAACTCTGCTTCCGGGAAATAGGOrCrmGTAGCGGCCGAACGGCACGTTAAACTCACCGC
GCAGATTGTAACGACACAGGCCGTTGTAACCGTAGCGGmCAAATAT~CAGTACCGCCCGACGGAAcG
G A T C C T G G C l l l T G T T G A A C T C T T ' C G C G G A A C T G A T A G T A A
CTCGCGTGCGGCCTGTACGTACTCATCAGTACGCATC~CACAATG~ATAGAGACTGATCAGGTCGCTATTG
A T A T C G G C A A G G A T A T A A C G A G A A A A G T C G G T G A G A A C
AGACATTCGCCCTTGGGCAAATGCCGmAATATCATCAAGCAGGGGATACnGCCCCCTGCCCACUM
AAGCGCGA~CTTGTCGACTTCAGTCAGTAGCTGCTGACGGAGGCTCTTCTGCTGGGCCTGGGOGGTCT
GTGGTCCTGACGTGGGC~GAGTTCCCAGTGGACCAGGCTGGmCAGGTMGGGTCCCCGCCTACCAGAT
TCACTGTACACTGGACGTCAGWCACCTWCCTGTTGCACCTGCTGGGTTCCATCTGCTTCTG~MG
AAGGTCAGTGGATGAGAGCTGGTTGCAGTAGAGGCCTGTGTGTCTCAGTGCGGGATCAmATCTGCCTCA
GGGCCMCACAGTGmCAmCCTGGCCA~CTGCAAAGAAGCTTCATCTTGCAATCTGGGCATCAAmGG~
CATGGmC~GAACATCCGTAmCCACCTGCAATGGAACCCGGCGGGAAGTGCTCTCATCAAGAGTTS

Figure 4.19. Plasmid insert sequence displaying correct direction of SRC-1A and Dam genes.
Red nucleotides depict the SRC-IA gene, underlined red indicated the location of the primer
sequence used, blue indicates the Dam sequences and the black nucleotides me of unknown
origin,possibly originatingfrom the plamid.

Confinnation of the Dam gene insertion downstream of the SRC-1A gene in the
plasmid enabled the DamID procedure to begin. The newly created plasmid containing
the SRC-1A:Dam fusion gene (Figure 4.20.) was used in HeLa cell transfections,
which, upon transfection would express the SRC-1A:Dam fusion protein.

(Fusion Gene)

t

pCR"3.1
5060 bp

. Comments for pCR.J.1
5060 nucleohdes

Figure 4.20. Vector map of pCR3.1. (Invitrogen). Thisfigure details the insertion of the newly
formed SRC-1A:Damfision gene to the 'PCR Product' region of the polylinker sequence. SRC3:Dam fusion gene was inserted to the same site. The SalI digestion site is located in the end of
the SRC-1A and SRC-3 sequence which was already present in the plasmid lie Dam is then
linked to that SaN site in the SRC-IA or SRC-3 genes to the ApaI site located in the polylinker
sequence (highlighted in red).

4.2.2.

Construction of Library of genomic sequences which interact

indirectly with SRC-1A:Dam via hERa o r PR-B
The purpose of this section was to investigate the involvement of SRC-1A in hERa and

hPR-B mediated transcription. Figure 4.21. demonstrates the DamID process whereby
the SRC-1A:Dam fusion plasmid is transfected to HeLa cells along with an expression

plasmid for hERu or hPR-B. Following 4 hr incubation the cells were treated with
either oestradiol, progesterone or ethanol. In vivo binding of the steroid and its receptor
occur, followed by translocation to the nucleus where the complex associates with the
hormone response elements in the genome and SRC-1A:Da.m interacts indirectly with
the genome via the receptor ligand complex. When bound, the Dam can then methylate
the proximal GATC sequences. The DNA is then isolated and undergoes analysis. UV
spectrometry is used to analyse the concentration of the DNA' and its purity. The end
result of this step is isolated gDNA some of which contains methylated GATC
sequences marking where the SRC-1A:Dam associated with the genome via either
hERu and E2 or hPR-B and progesterone.
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4.2.2.1.

Transfection of HeLa Cells with SRC-1A:Dam Expression

Plasmid
The following steps were performed to enable SRC-1A:Dam expression in HeLa cells,
which via indirect binding of SRC-1A to the DNA will permit Dam methylation of
nearby GATC sequences.
250ng SRC-1A:Dam was transfected to Hela cells with co-transfection of 25ng hERa or
hPR-B expression vectors. The transfected HeLa cells were incubated for 4 hrs after
which hormone treatment was performed with Oestradiol or Progesterone for 24 hours.
A subset of the transfected cells were also treated with ethanol, which would enable the
isolation of SRC-1A:Dam that binds to DNA bound nuclear receptors that bind in the
absence of hormone treatment.
A transfection reaction was also performed transfecting SRC-1A:Dam without a nuclear
receptor expression vector and treating these transfected cells with EtOH which would
act as a control during LM-PCR mediated specific amplification of methylated GATC
sequences, as no GATC specific methylation should occur when cells are transfected
with SRC-1A:Dam alone. (As per Materials and Methods Section 3.2.2.1. to 3.2.2.3.)

4.2.2.2. Isolation of Genomic DNA
Genomic DNA was isolated from the transfected HeLa cells using an ethanol
precipitation technique as per Materials and Methods Section 3.2.2.4 and the DNA
concentration and purity analysed using a spectrophotometer as per Materials and
Methods Section 3.2.2.5. The results of this can be seen in Table 4.2..

Transfeetion

DNA Concentration

& Hormone Treatment

PUP1

ERa & EtOH

0.135

1.69

ERa & E2

0.093

1.64

PR-B & EtOH

0.047

1.63

PR-B & Prog

0.030

1.69

Control

0.008

1.73

DNA Purity
A ~ ~ ~ I ~ ~ .

Table 4.2. Spectrophotometric analysis of isolated genomic DNA from HeLa Cells transfected

with pCR3.I SRC-JA:Dam co-transfected with the noted nuclear receptor followed by 16 hr
treatment with the noted hormone/EtOH

4.2.2.3. Specific Amplification o f Methylated G A T C Sequences
Isolation of the methylated GATC sequences was achieved with the use of the DpnI
enzyme, which specifically recognizes methylated GATC sequences, thus generating a
pool of blunt-ended DNA fragments with 5'TC and ~'GA"''

(Materials and Methods

Section 3.2.2.6)
The DpnI digested partially methylated sequences were amplified using a methylation
specific LM-PCR method. The LM-PCR procedure (Materials and Methods Section
3.2.2.7) ensures only methylated DNA fragments are amplified. DpnII digestion, which
is typically part of the protocol, was not performed. DpnII destroys (via digestion) all
fragments containing unmethylated GATC sequences which excludes them from
amplification, however this DpnII digestion this step was omitted from protocol. The
activities of DpnI functions to digest only methylated GATC sequences therefore
unmethylated GATC are not cut, leaving short DNA sequences with digested ends

(Figure 4.22.).

The unmethylated GATC sequences should remain 'hidden' in long

DNA sequences and therefore 'ignored' during the adapter ligation step. Therefore the

unmethylated GATC sequences will not interfere with the LM-PCR. In this protocol
DpnII digestion was not performed.

CTAG
CH,

1

CH3

Dpnl
Digestion

Figure 4.22. DpnI digestion of methylated GATC sequences in isolated gDNA

Additionally, non specific DNA products which may be derived from random DNA
breaks are excluded from the PCR due to the specificity of Primer design. The PCR
primer overlaps with the GA dinucleotide located at the ends of the DpnI digested
fragments, ensuring only these fragments are amplified thus suppressing amplification
of non specific ligation products, which, generally, will not have a GA dinucleotide at
their ends.
The LM-PCR reaction (Figure 4.23.) also incudes a control for DpnI digestion. The
control is gDNA from one of the samples which did not undergo DpnI digestion,
therefore no adaptor mediated amplification of these methylated sequences should take
place as they were never digested and should remain 'hidden' in long strands of gDNA
(similar to the unmethylated GATC sequences).
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Figure 4.23. LM-PCRprocedure

Following LM-PCR (Materials and Methods Section 3.2.2.7 and 3.2.2.8) the samples
are run on a 1% agarose gel (Materials and Methods Section 3.2.2.9.) to enable
visualisation of LM-PCR products (Figure 4.24.).
The PCR products create a smear in the gel indicating that there is a variety of sequences
isolated from the transfected HeLa cells. PCR product sequences all appear to be
shorter than 500 bp. Transfections treated with EtOH appear to have a larger amount of

DNA as the bands appear brighter. Primer Dirners are visible in the gel.
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Figure 4.24. 1% Agarose Gel electrophoresis of (LA@-PCRproducts from LM PCR of DNA
isolatedfrom the HeLa cells transfected to SRC-1A:Dam with ERdPR-B transfectionfollowed
by treatment with E2/Prog for I6hrs. Genomic DNA was then digested with DpnI, Adapters
were ligated to the blunt ends of the isolated sequences and LMPCR was performed.

Lane 1 (Figure 4.24.) contains molecular weight marker. Lane 6 contains the control,
that is a control reaction set up during the adapter ligation stage, this a control run as per
the tests but with undigested (not DpnI digested) genomic DNA from one of the
samples of isolated genomic DNA from the transfected HeLa cells.
Lane 2 (Figure 4.24.) contains LM-PCR generated PCR products resulting from the
amplification of GATC methylated sequences following the transfection of HeLa cells
with the SRC-1A:Darn expression vector, co transfected with an expression vector for
ERa followed by treatment with ethanol. The lane shows LM-PCR products ranging in
size from approximately 100 bp to 500 bp. These LM-PCR products show that not only
is the fusion product able to indirectly bind to DNA but the Dam fusion protein of the

SRC-1A:Dam molecule is functioning and can cause GATC methylation. Even though
the SRC-1A:Dam and ERa transfected HeLa cells were treated with ethanol there are
still PCR products. It is known that ERa had the ability to bind DNA in the absence of
hormone.
Lane 3 (Figure 4.24.) contains LM-PCR generated products resulting from the
amplification of DNA containing methylated GATC sequences following the
transfection of HeLa cells with the SRC-I A:Dam expression plasmid and cotransfection
with ERa with subsequent treatment with oestradiol. PCR products in this lane range in
size, similarly to Lane 2, from 100 bp to 500 bp. However there is much less LM-PCR
product in this lane when compared to Lane 2. This could indicate that SRC-IA binds
preferentially to ERa in the absence of Estradiol, whereas the ERa agonist, Oestradiol,
enhances ERa genomic binding. Basically, there was less SRC-1A:Dam indirect DNA
association during the transfection conditions of Lane 3 when compared to Lane 2.
Lane 4 and 5 (Figure 4.24.) contains LM-PCR generated products resulting from the
amplification of DNA following the transfection of HeLa cells with the SRC-1A:Darn
expression plasmid with cotransfection of PR-B followed by treatment with ethanol
(Lane 4) or Progesterone (Lane 5). Both of these lanes contain less LM-PCR products
when compared to Lanes 2 and 3 respectively, indicating that the SRC-1A:Dam
transfections with cotransfection of ERa was more successful than that with SRC1A:Da'm and PR-B. Lane 5 contains the least amount of LM PCR product with LMPCR product size ranging from approximately 100 bp to 400 bp while lane 4 product
sizes range from 100 bp to 500 bp.
Lane 6 contains the DpnI undigested genomic DNA following LM-PCR protocol. The
absence of a banding pattern is due to the fact that the DNA template in this case is

gDNA from HeLa cells that have been transfected with the SRC-1A:Darn expression
plasmid, cotransfected with PR-B, and treated with progesterone but DpnI digestion was
not performed. As no DpnI digestion has taken place, the methylated GATC sequences
are not isolated and thus double stranded adapters can not ligate and LM-PCR cannot
occur. Additionally, the primer dimer band at IOObp is the brightest of all lanes
indicating no primers have been used in the LM-PCR procedure that was performed on
the contents of this lane.
A faint band is visable at approximately 100 bp in Lanes 2 through 6 (strongest in Lane
6). This is a primer dimer band, which result when primers annealing to each other
forming a dimer, due to the low concentration of target amplicons.

4.2.3. Cloning of PCR Products using pCR8IGWITOPO T A Cloning
The isolated, amplified SRC-1A:Dam sequences were then sub-cloned into a gateway
entry vector. pCR8lGWlTOPO was the vector of choice, chosen due to its function as a
gateway entry vector (vector map can be seen in Materials and Methods Figure 3.13.).
This vector contains a TOPO cloning site which can efficiently clone Taq amplified
PCR products.

Taq polymerase has non-template dependent terminal transferase

activity that adds a single deoxyadenosine (A) to 3' ends of PCR products. The
pCR8lGWlTOPO vector has overhanging deoxythymidine (T) residues which enables
efficient ligatation of the Taq amplified LM-PCR products into the TOPO vector

(Figure4.25.).
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Fkuw 4.25. Process involved in inserting the sequences to the TOPO gat-

vector and then

to the speciol~designed destination vector.

The TOPO cloning reactions were set up as per Materials and Methods Section 3.2.3.1.

Sequences iaohted from transformation:

No.

Denoted

Colonies

2

la and lb

None

-

SRC-1A:Dam cotransfected with PR-B, treated with EtOH

2

3a and 3b

SRC-1A:Dam cotransfected with PR-B, treated with progesterone

1

4a

SRC- I A:Dam cotransfected with ERa, treated with EiQH
SRC-1A:Dam cotransfected with ERa, treated with oestradiol

Tabk 4.3. Table displaying the number of coloniesfollowing overnight growth of Chemically
Competent E. coli cells hansformed with TOPO cloning reaction products.

The products of the cloning reactions were transformed into chemically competent E.
coli according to Materials and Methods Section 3.2.3.2 and plated onto spectinomycin
plates for overnight growth. The plates were examined for the presence of colonies
(Table 4.3.).
Colonies that grew were individually picked and grown (to increase plasmid containing
bacterial numbers) in LB Broth containing 100pg/ml Spectinomycin to select for the
TOPO Cloning Vector which contains a spectinomycin resistance gene. The cultures
were purified using a Mini-Prep system and the purified DNA was analysed using
spectrophotometry (Materials and Methods Section 3.2.3.3. and 3.2.3.4.). The results
can be seen in Table 4.4..
Isolated plasmids were then screened for the presence of inserts by restriction digestion.

Sample
la
lb

3a
3b

4a

DNA Concentration DNA Purity
& Hormone Treatment
A
~
~
lrgl~l
ERa & EtOH
1.81
0.079
ERa & EtOH
0.176
PR-B & EtOH
0.171
PR-B & EtOH
0.142
PR-B & Prog
0.107
Transfection

~

Table 4.4. Results of speclrophotometric analysis of TOPO Libraries.

EcoRI restriction digestion sites flank the TOPO cloning sites in the pCRS/GW/TOPO
cloning vector (Figure 4.26.). Restriction digestion of the plasmids using EcoRI
enables further assessments of the insert (Materials and Methods Section 3.2.3.5.).

I

~

L
7,'

ACGMTTCGCCCT

MGGGCGMRC

1 TTCCCGGTTMG

TGCTTAAGCGGGA~

Restriciton digestion
of TOPO plasmids
and electrophoresis
on 1%agarooe gel

Molecular wight
marksr

EcoRl restriction
sltsa flank (he
LMPCR

amplified inseri

I

-- -

Figure 4.26. EcoRI restriction digestion sites on either site of the M - P C R insert enable

analysis of the inserts.

The restriction digested plasmids were then run on a 1% agarose gel (Materials and
Methods Section 3.2.3.6.) to enable visualization of the presence of inserts (Figrrre
4.27.).

Due to the lack of colonies obtained using this protocol, the p d u r e was optimized.

To increase the number of TOPO inserts a reduced quantity of LM-PCR product was
added and the volume replaced with dH2O (lpl PCR Product and 3pl dH2O rather than
4pl PCR Product). As a result of this adjustment to the TOPO cloning procedure

approximately 2000 colonies were obtained on each of the 4 agar plates (ERa and
EtOH, ERa and E2, PR-B and EtOH or PR-B and Prog).
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Figure 4.27. 1% Agarose Gel containing a restriction digesfion of TOP0 vectors containing

ZM-PCR inserts with EcoRI. This step was to screen for colony inserts. Lane 1 contains
molecular weight marker. The remaining lane contents are described above the gel.

Each plate was washed with LB Bi.oth containing 100pg/ml Spectinomycin (Materials
and Methods 3.2.3.2.), plasmid DNA was purified, isolated, and concentration was
determined using a spectrophotometer (Materials and Methods Section 3.2.3.3 and

3.2.3.4).

4.2.4.

C r e a t i o n of Expression Vector C o n t a i n i n g I s o l a t e d Sequences

Sequences needed to be cloned into a reporter vector to enable functional investigation
of the promoter activity of the sequence that was isolated. As pCR8IGWlTOPO

(Figure 3.11.) is not a reporter vector, a LR recombination would have to take place
between the pCRIGWlTOP0 entry vector containing the cloned sequences and a
destination vector, which has reporter capabilities. In order to do this a gateway vector

conversion system with One-shot ccdB Survival competent was used to convert the
reporter vector of choice @GL3-Basic Vector) into a gateway vector (Figure 3.12.)
according to Materials and Methods Section 3.2.4.1. to 3.2.4.4.

Upon successful generation of the pGL3-Basic destination vector, a LR Clonase
reaction was performed on the TOPO Cloning reaction (Materials and Methods Section
3.2.5.1.).

The LR recombination reaction facilitates the transfer of the DNA inserts

contained in the pCR/GW/TOPO entry vector into the newly generated pGL3-Basic
reporter vector. The pGL3-Basic reporter vector was manipulated to enable its function
as gateway destination vector.
Following the LR recombination reaction the products were transformed into competent
bacteria and plated on LB Agar plates with 100pg/ml Ampicillin to select for the
presence of the pGL3-Basic Dest vector (Materials and Methods Section 3.2.5.2.). A
record of colony growth can be observed in Table 4.5..
plate

Initial Tra~~sfection

No.

Colonies

1

From HeLa ceUs transfected with SRC-IA:Dam,

/
2

4

cotransfected with expression plasmid for ERa
From HeLa cells trwfected with SRC-1A:Dam,

LM-PCR Generated

3

4

and treated with Ethanol

-

No. of

60

whansfected with expression plasmid for ERa

Products, following
and treated with E2
TOP0 Cloning and { From HeLa cells transfected with SRC-1A:Dam,
transfer to pGL3-Basic

cotransfected with expression plasmid for PR-B

Vector

and treated with Ethanol
From HeLa cells transfected with SRC-I A.Dam,

6

63

cohansfected with expression plasmid for PR-B
and treated with Progesterone
-

Tabh?4.5. Resultant colonies contahingpGL3-BmicpImmidsfoII~~ing
E. coli tranfection

Colonies were individually picked from plates 2 (El-E60) and 4 (PI-P60), grown
overnight in LB Broth containing 100pg/ml Ampicillin which was followed by mini
prep (Materials and Methods Section 3.2.5.3.) to isolate and purify the pGL3 Basic
reporter plasmids (Figure 4.28.).

Individual
colonies
picked

Mini prep
pefformed

on cultures
to purify
plasmid
DNA

-

1

-

1

1

1

1

1

1

Further Analysis

Figure 4.28. Isolation andpreparation ofpGL3 Basic Colonies

Spectophotometric analysis was performed to analyse DNA concentration and purity
(Materials and Methods Section 3.2.5.4.).

Once the concentration of each plasmid

solution was identified they were diluted with TE Buffer to give a final concentration of
0.2pgp1.

4.2.5.

F u n c t i o n a l Analysis of Newly C o n s t r u c t e d E x p r e s s i o n V e c t o r s

The isolated sequences are now contained in a newly generated pGL3-Basic vector
library. As the sequences are now in a reporter vector, it is possible to identify if the
isolated sequences are able to bind ERa or PR-B, and if the addition of WT SRC-IA
will result in increased or decreased transactivational activity.
To determine the functionality of the individual sequence contained in the pGL3-Basic
reporter vectors trans-activation assays were performed using HeLa cells transfected
with individual pGL3-Basic Luc reporter constructs and wild type hERa or hPR-B
expression vectors. Four hours post transfection cells were treated with Oestrogen (for
WT hERa transfected cells), Progesterone (for WT hPR-B transfected cells), EtOH or
no hormone treatment and cells were incubated for a further 24 hrs. (Materials and
Methods Section 3.1.1.4.). A luciferase assay (see Section 4.1.1.1. for more details of
Luciferase assay) was then used to measure the functional activity of each plasmid.

4.2.5.1. Initial Transactivation Assays
The initial aim of this procedure was to screen the pGL3-Basic Libraries for plasmids
for functional genomic inserts. Results obtained are displayed in Figure 4.29..
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Figure 4.29. Luciferase Assay results following HeLa cell transfection with 2OOng reporter
plasmid (El-E23; PI-P24) with cotransfection of Sng hERa expression vector for the reporter
plasmid library of sequences that associate with hERa and SRC-IA and long hPR-B expression
vector for the reporter plasmid librav of sequences thai associate with hPR-B. Following a 4
hr incubation the transfections were treated with either 1 0 ~~eslrogen
1~
or 1 0 ' ~ ~ r o ~ e s t e r o n e

for 24 hrs. A subset of reporter plasmids were treated with EtOH and another subset received
no hormone treatment (NHT) as controls. Graph A displays the results from the hERa
tramfiction, while Graph B isfrom hPR-B transfection.

The function of these initial assays was to separate those reporter plasmids that had
genomic sequences that indirectly bound to SRC-1A via hERa and Oestrogen or hPR-B
and Progesterone h m those that did not (ie: vector or bacterial sequences).
Theoretically the genomic sequences isolated should respond to hERa and Oestrogen
or hPR-B and Progesterone if a relevant corresponding transcription start site is present.

The graphs show no differential increase of transcriptional activity in any of the
plasmids, this can be seen in both of the graphs displayed above where expression with

EtOH and Hormone remain similar throughout all of the plasmids. If the reporter
plasmids had a sequence that had a promoter in it in which' SRC-lA, hERa and
Oestrogen bound to during the DamID assay then a selective activity would be seen.
Lack of activity could mean a number of things; that the sequences that are inserted in
the plasmid do not contain a promoter and therefore Luc could not be transcribed, that
the sequences have some other effect on transcription or that the sites isolated bind to
SRC-1A in association with other proteins and not specifically the nuclear receptor and
steroid that was added (endogenous transcription factors).
Sequencing was performed to differentiate genomic from non genomic sequences and to
enable further investigation into these sequences.

4.2.6. Sequencing of Reporter Library Inserts
Sequencing was initially performed on a select number of reporter plasmids from each
library. It was then determined that the PR-B reporter plasmid library worked at a
higher efficiency than the ERa reporter plasmid library (i.e. there were more genomic
sequences in the PR-B library) and so further sequencing analysis focused on the PR-B
library.
Sequences were analysed using NCBI BLAST (National Centre for Biotechnology
Information,

Basic

Local

Alignment

Search

Tool,

http://blast.ncbi.nlm.nih.gov/Blast.cgi). Sequences identified as containing genes that
encode for Progesterone Receptor, SRC-1A or Globin were excluded as they were

considered to be non-genomic (sequences not from sites that associated with SRC-1A
when the library was being constructed). Sequencing was performed on the PR-B
library until twenty one genomic sequences were obtained (PI, P2, P4, P10, PI 1, P15,
P19, P20, P21, P22, P23, P24, P26, P27, P32, P33, P36, P37, P38, P40, P45).
Sequences can be viewed in Appendir IZZ.

4.2.7.

F u r t h e r Analysis o f Genomic PR-B Library

A further trans-activation assay was performed on the twenty one selected PR-B
plasmids using HeLa cell transfections, co-transfecting 21 different hPR-B reporter
plasmid sequences and expression vectors for hERa, hPR-B, hGRa simultaneously with
and without SRC-1A. Four hrs post transfection the cells were treated with a
combination of Oestrogen, Progesterone and Dexamethasone. pGRE-Elb-Luc was
used as a positive control to confirm that the cells were able to withstand such a high
level of continued plasmid dNA and hormone treatment.

Figure 4.30. and Figure 4.31. display the results. The results show a similar pattern to
that seen in previous transactivation assays. The control, pGRE-Elb-Luc, displayed a
15 fold increase in luciferase activity following the addition of the hormone mix; none

of the reporter plasmids displayed the same, or even a similar result.

I

RLU

Figure 4.30. Lucifrase assay resulfs. HeLa cells were cotransfected with 5OngpCR3.1 (Emply
Vector), 2OOng S R C - 1 A : h PR-B reporter plasmidr and expression vectors for hER~(5ng)~
PR-B (long) and GR(l0ng). Four hrs post tranasfection cells were treated with a hormone mix
O ~ E ~ ~ Prog
U ~ (1U7iy)
W , and ~ e x ( l ~ ~and
I l Qincubatedfor 24 hrs.
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Figure 4.31. Lucifrase assay results. HeLa cells were cotransfected with 50ngpCR3.1 SRC-

IA, 200ng SRC-1A:Dam PR-B reporter plasmids and expression for hERa(5n&, PR-B (1Ong)
and GR(1Ongl. Four hrs post tranasfction cells were treated with a hormone mix of E2(1U
9A@,Prog (1U7i@andDex(lU711Qand incubatedfor 24 hrs.

The results of this trans-activation assay proved that the SRC-1A Dam protein did not
bind to the genome in association with either hERa and Oestrogen or hPR-B and
Progesterone during library construction. Results also c o n f i i that the methods used
were functional as pGRE Elb Luc (a reporter plasmid containing a sequence responsive

to GR). It was then necessary to go through other channels to decide which direction to
go to next.

4.2.8. Bioinformatics
Genomic sequences were analysed using Bioinformatic Tools to assess .the pattern of
transcription factor binding motifs in the genomic reporter plasmids.

4.2.8.1.

NCBI Blast

NCBI Blast (mentioned in Section 4.2.6.) was the initial tool used to identify genomic
sequences located in the reporter plasmids.

This programme matches sequences

provided with possible locations in the genome. It was also used to identify possible
genes that flanked the isolated sequences (Table 4.6.).

class 2A, member 1

member 8 isoform b

Table 4.6. Genes thatpant the 3' and5' ends of isolated sequences (PI-P45).

4.2.8.2. MotifViz: Clover
Clover (Frith et al, 2004) is an web based bioinformatical programme that searches for
known transcription factor binding sites within a given set of sequences.

This

programme was used to search for 'ALL JASPER' (all receptor sites) and 'ALL
Nuclear Receptors' (all nuclear receptor sites) and obtained the data displayed in Table
4.7. and Table 4.8. A threshold is a filter that is put in so it is possible to filter the
results so only those with the highest values are displayed. For example a threshold of
four would only display results that have a score of four or more. Motifs from the ALL
Jasper Clover search were scored according to the best base pair match; a high score
reflects a good motif match within the sequences. Scores can be seen in Table 4.9..
Analysis of Clover results revealed a number of transcription factor binding motifs that
could be investigated further.
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Motif

Score

Snail

5.89

Thingl-E47

4.46

NF-kappaB

2.91

Gklf

2.1
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2.08

c-REL

1.73

SPl
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1.42

HMGN

1.36

HFH-2

1.34

~ 6 5
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Pbx

0.831
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Tall beta-E47S

0.593

Pax-4

0.494
0.458

deltaEFl

0.352

llSF

0.306

DoD

0.231

SOX17

0.179

HFH-1

0.166

Hen-1

0.113

Table 4.9. Transcription Factor motifsfound in the sequences. The 'Score' indicates the extent
to which the mohyfound in the sequence matches the actual franscription factor binding motif:

5.89 being the best matched.

4.2.8.3. MEME Suite

MEME identifies overrepresented motifs in a set of given sequences. MEME found
three repetitive sequences throughout the genomic DNA library analysed. The one most
prevalent motif (Motif 1) can be seen in Figure 4.32.. Motif 1 was found in P2, P10,

PI 1, P23, P26, P37, P40 andP45.

Figure 4.32. MEME Motif1 found in P2, PIO, PII, P23, P26, P37, P40 and P45

4.2.8.4. TOMTOM
Each motif MEME finds overrepresented can then be analysed further using
TOMTOM. TOMTOM finds known transcription factor binding motifs within the
overrepresented MEME sequence. The best matched TOMTOM transcription factor
binding motif for MEME 1 Motif 1 can be seen in Figure 4.33..

Figure 4.33. TOMTOM Result from MEME Motif lis a [ranscription factor binding motif for

Other binding motifs found from TOMTOM are listed in Table 4.10..

Table 4.10. TF Binding Motifs in MEME Results found using TOMTOM

Bioinformatical data obtained from Clover and MEME was reviewed and further
investigation focused of transcription factors that appeared in both sets of analysis tools.
These included SNAIL, COUP-TF I and I1 and RORa.

4.2.9.

F u r t h e r Trans-Activation

Assays t o I n v e s t i g a t e u n k n o w n

T r a n s c r i p t i o n F a c t o r SRC-1A a s s o c i a t i o n
It was a possibility that SRC-1A Dam associated with nuclear receptors endogenously
present in the HeLa cells when the library sequences were being selected. It was then
necessary to identify which nuclear receptors were involved. Based on bioinfonnatical
data range of nuclear receptors were investigated to assess what SRC-1A associated
with on the genome. Bioinformatical data on the presence of transcription factor
binding motifs influenced the choice of transcription factor used in the transactivation
assays, the MotifViz programme Clover was the main programme used.
SNAIL was the first transcription factor to be analysed and was chosen due the presence
of a very high score (good match to transcription factor motifs and present in multiple
reporter plasmids) in the MotifViz results. The luciferase assay was performed to
assess the influence of SNAIL on the transactivation of reporter plasmids in the
presence or absence of SRC-1A (Figure 4.34.). It is apparent from the graph that some
of the plasmids are responsive, regardless of the transfection, and the reporter plasmids
that are cotransfected with SNAIL and SRC-1A simultaneously in the transactivation
assay seem to have a similar or lower response than when transfected with SRC-1A
alone. Levels of transcription induction are not strong enough to conclude that SNAIL
associates with, and affects transcription of, the sequences contained in the reporter
plasmids.
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Figwe 4.34. Lucifrase a s s q results following HeLu cells cotrmfection with 200ng isolated,
sequenced reporter plasmid (PI-P45) with either; 1: pCR3.1 (emptJ.'vector), 2: pCR3.1 and
pCMVs SNAIL, 3: pCR3.I andpCR3.1 SRC-ZA or 4: pCMV5 SNAIL andpCR3.1 SRC-IA.
pGL3 Basic (empty vector) was used as a control. The trmj2cted HeLa cells were then
incubatedfor 24hrs.

The next transcription factor to be analysed for its influence on the reporter plasmid
library was RORa. This is an orphan nuclear receptor whos motif was seen in four of
the reporter plasmid inserts (p10,p26, p38 and p45) using the MotifViz programme.

Figure 4.35. displays the results following transfection of the reporter plasmids (Pl-

P45) and demonstrated some interesting results. Increased transcriptional activity is
seen in P2,P20,P37 and P45. Out of these responders, only P45 was seen to have an

RORa binding site in MotiNiz. Neither bioinformatical programme (MotifViz or
h4Eh-E) identified the presence of a RORa binding motifs in P2,P20 or P37. Levels of
transcription in pGL3Basic is low indicating there is a high possibility of the presence
of motifs in the reporter plasmids that cause transcription induction. However, overall
levels of gene transcription are still relatively low.

Figure 4.35. Lucifrase assay results following HeLa cell cofransfection with 200ng reporter
plasmih (PI-P45) and eitherpCR3.1 orpCR3.1 RORa pGL3 Basic (empty vector) was used
as a negative control andpGRE-Elb-Luc was wed as apositive conhol.

Normalized results (or fold induction) can be viewed in Figure 4.36. This further
confirms the transcriptional activationof P2, P20, P37 and P45 by RORa.

RORa: Normalized Data
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Figure 4.36. Normalized resultsfor RORa transfection described in Figure 4.35.

COUP TF motifs were also seen in the bioinformatical results, from both MotifViz and
TOMTOM. Results obtained following transfection of COUP TFI or COUP TFII

expression plasmid (Figure 4.37.) demonstrated that both COUP TFI and I1 induced
transcription in all of the reporter plasmids to some degree while pGL3 Basic (empty
vector) transcriptional response remained relatively low.

Figure 4.37. Lucgerase assay results following cotrmfection of HeLa cells with reporter
plasmid (PI-P45) and either pCR3.I (empty vector), pCR3.1 COUP TFI or pCR3.1 COUP
TFII.pGL3 Basic was usedas a negarive control.

Reporter plasmids p26, p27, p33, p40 and p45 appeared to be the best responders
following COUP TFI and COUP TFII transfection and all had levels of transcription
higher than that seen in pG13 Basic. These reporter plasmids were focused on in M e r
tests.
Interestingly, p10 and p23 were the only two plasmid sequences seen in MotifViz to
have COUP TF binding motifs and neither of these displayed a higher level of
transcription induction with COUP.
To assess the concentration of COUP TFI and COUP TFII that were required for M e r
transfections titres were performed. Initial COUP TF transfections were performed

using 25ng (data not displayed) and long per well. Lower concentrations were used for
the tittes. The results can be seen in Figure 4.38..
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Figure 4.38. Lucifrase assay results jollowing HeLa cell cotransfection with 200ng reporter
plasmid and O.IngpCR3.l(empry vector) /pCR3.1 COUP TFI /pCR3.I COUP WII or 0.25ng
pCR3. I /pCR3.I COUP TFI / pCR3.1 COUP TF II or IngpCR3.1 /pCR3.1 COUP T%I /
pCR3. I COUP TFII. pGL3 Basic was used as a negative control.

Following observation of the results in Figure 4.38. and previous results in Figure 4.36.
its was decided to use 2ng COUP TFI and COUP TFII in further transfections, a
concentration not tested, however, lng appeared to provide good specific results and it

was suspected that 2ng would retain the specificity and provide additional activation
capabilities.
COUP TF is an orphan nuclear receptor trauscription factor. COUP TF has been seen
previously to bind to an intermediate and not directly to the genome. It is this capability
of COUP TF that led to investigations to determine if COUP

TF was binding to an

intermediate transcription factor. RORa in the presence and absence of SRC-1A was

investigated to see if it cooperated with COUP TFI or I1 to regulate transcription

(Figure 4.39.).
The results displayed are normalized fold inductions, obtained by dividing the reporter
plasmid result by that obtained using an empty pGL3 Basic vector which provides a
normalized result and then dividing the nornaked result by the normalized result
obtained from the empty pCR3.1 vector (expression plasmid blank).

PCW.l

•RORa

RORa (L SRCIA

Figure 4.39. Lucifeme arsay results following H e h cell cotransfection of reporter plosmidr

(P26,P27, P33, P40, P45) with pCR3.l / COUP TFI / COUP TFII followed by pCR3.1 /
pCR3.1 andpCR3.I RORa /pCR3.1 RORa andpCRf.1 SRC-IA. pGL3 Basic war wed ar a
negalive control, and to enable normalked values to be calculated. Statistical malysis wos
perfonneed by comparing HeLa cell trmfection withpCR3.1 to that with COUP TFI or COUP
TFII and RORa and SRC-IA. *p<0.05, **p<0.01 negative conaolpCR3.1 compared to RORa
& SRCIA co transfected with either COUP TFZ or COUP TFII

The results indicated that COUP TFI and 11, but particularly COUP TFI, were
displaying an interaction with RORa and SRC-1A to induce gene transcription. This
was particularly evident with reporter plasmid P45, where both COUP TFI and COUP
TFII interacted with RORa and SRC-1A to significantly induce gene transcription
(p<0.01) (Figure 4.39). There appears to be cooperational activity between COUP
TFIICOUP TFII, RORa and SRC-1A. Certain COUP TF responders (P26 and P45)
show greater transactivation. Additionally, the results confirm that RORa alone is
unable to induce gene transcription.
The final set of transactivation assays performed functioned to assess a variety of
concentrations of COUP TF I, COUP TF 11, RORa and SRC-1A. The results can be
seen in Figure 4.40., with normalized values in Figure 4.41.).
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Figure 4.40. Luciferare results following HeLa cell cotransfection with 200ng COUP
responsive reporter with transcriptionfhctorx as described above. pGL3 Basic war w e d as a
negative control.

The results demonstrate that, particularly in P27 and P45, these transcription factors
work co-operatively in a concentration dependant and site specific manner.

Figure 4.41. Normalized valuesfor Figure 4.40. (Colour Key crm be viewed in Figure 4.40.)

Figure 4.42. is a simplified version and can summarize the results obtained from this
transactivation assay. The pGL3-Basic reporter plasmid chosen to demonstrate the
results is P45.
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Figure 4.42. Simplified resultsfrom Graph E in Figure 4.40. using long COUP TFVII.

It can be seen from this graph that the empty vector provides no response, this is the
negative control. COUP TF I, COUP TF I1 and RORa did not cause a large increase in
transcription when transfected alone, while SRC-lA, when co-transfected with RORa,
displayed a slight increase in transcription. However, when COUP TF I was cotransfected with RORa it increased the transcriptional response, when compared to
COUP TF I alone, by greater than 10 fold.

Interestingly, when COUP TF I was co-transfected with both RORa and SRC-1A it
elicited the greatest response, indicating that there is some form of cooperativity
between the three molecules. This is in contrast to COUP TFII which demonstrated
only modest transcriptional activity when cotransfected with RORa and SRC-1A.

4.2.10. Bioinformatical Investigation of COUP TFI, RORa and SRC-

1A Responsive Sequences
Bioinformatical analysis was performed on sequences P26, P27, P33, P40 and P45 to
ascertain any commonality between these COUP TFI, RORa and SRC-1A responsive
sequences.

The analysis focused on the MEME suite, using both MEME and

TOMTOM. These are described in more detain in Section 4.2.8.
Meme analysis presented with three motifs found in the sequences. Motif 1 (Figure

4.43.) is a motif found in all five sequences.

Figure 4.43. MoafI

TOMTOM analysis of Motif 1 revealed just one transcription factor biding motif

(Figure 4.44.), Chop-cEBP.

Figure 4.44. Transcriptionfacor binding site for ChopcEBP

Figure 4.45. Motif2 found in P26, P27, P33, P40 and P45

TOMTOM found no transcription factor binding sites in Motif 2. Motif 3 was found in
sequences P26, P33, P40 and P45 (Figure4.46.).

Figwe 4.46 Mohy3, present in P26, P33, P4O and P4.5

TOM TOM isolated a transcription factor binding site for Broad Complex 1 in Motif 3
(Figure 4.47.).

Figure 4.47. TOMTOM results from Mohy 3 revealed transcription factor binding site for
Broad-complex I

Further analysis is required on the selected reporter plasmid sequences however they
provide interesting insight into possible cooperation between COUP TFI, RORa and
SRC-1A.

4.3. Locating Transcription Start Sites in Reporter Plasmids
GeneRacer technique (Materials and Methods 3.2.7.) was used to attempt to locate the
transcription start site in reporter plasmid sequences. This method proved unsuccessful
in locating the transcription start sites of the COUP TF responsive reporter plasmids or
reporter plasmids from the ERE library.

Sequences obtained can be viewed in

APPENDIXIV (TSSl to 6 from trial 1, TSS7 to 12 h r n trial 2). It appeared that the
LucRev primer was binding non-specifically to endogenous DNA and not to reporter
plasmid DNA. Attempted optimization of this method still proved unsuccessful. A
failure to produce PCR products can be seen in Figure 4.4&.

Primer Dimer

Figure 4.48. 1% Agarose Gel electrophoresis of Gene Racer transcrtiption start site PCR
products. Lane I contains molecular weighf marker. Lane 2 contains PCRproducts. No PCR
products seen, only primer dimers.

Initially, the aim of this project was to investigate a reporter library of oestrogen
responsive elements (EREs) which constructed by Jennings (Jennings, 2009) using
DamID technology. Investigations on this library were to focus on the identification of
SERM responders and perform further tests to analyse the isolated reporters, including
assessing the ability of the isolated sequences to mediate transcription,in conjunction
with other nuclear receptors and coactivators and to perform ERa mutation analysis.
The purpose of this was to gain a deeper understanding into the role of Tamoxifen as an
oestrogen antagonist.
SRC-3, a well documented coactivator and a member of the SRC family of coactivators,
appeared to repress SERM responsive reporter activity and it was decided to investigate
the influence of SRC family members further. This body of work aimed to isolate
sequences from the genome that associate with SRC-1A:Dam and SRC-3 in association
with either ligand bound oestrogen or progesterone receptors using DamID technology,

the same technology that was used to construct the ERE library. Following construction
of the library, further aims included the use of bioinformatics to identify DNA cis
elements, repetitive sequences and overrepresented transcription factor binding sites in
these isolated sequences and to assess the ability of the isolated sequences to mediate
transcription in conjunction with other nuclear receptors and coactivators to establish
potential novel interactions
An additional aim, encompassing reporter plasmids from both the ERE, SRC-1A and
SRC-3 libraries, was to attempt to identify the location of transcription start sites in
selected isolated reporter plasmid sequences. The ability to obtain this information

would enable a deeper understanding of the binding sites that a variety of transcription
factors of transcriptional coregulators associate with.

5.1. Oestrogen Responsive Element (ERE) Reporter Library
Investigation
This portion of the investigations focused on the investigation of SERM responsive
reporter plasmid sequences, comparing the responses of these sequences to that of
oestrogen responsive sequences.
Transfections were performed on the ERE library to identify SERM responsive and
oestrogen responsive reporter plasmids. Four were selected for further investigations
following sequencing to ensure the plasmid inserts were of genomic origin. E5p and
T4p were selected as SERM responsive plasmids, while V17 and E l 2 were selected as
oestrogen responsive reporter plasmids to use as a comparison during the investigations.
Transfections were performed on these reporter plasmids to assess the ERa binding site
requirements of the SERM responsive plamsids and the oestrogen responsive plasmids.
These transfections were performed to determine if the differential response of the
oestrogen and SERM responsive plarnsids was attributed to the SERMs interacting with
a different area of the ERa molecule perhaps causing ERa to bind in a different way to
the DNA.

It is known that when tamoxifen binds to ERa it causes a different

conformational change to those that occur when oestrogen binds. The conformational
change that occurs when Tamoxifen binds repositions Helix 12 of the ERa molecule
and prevents the binding of coactivators (Shiau et al, 1998), preventing AF-2 activation.

Therefore Tamoxifen functions as an ERa antagonist to genes which rely on the AF-2
region for ER-mediated transcription (Ring and Dowsett, 2004).
It is known that there are three major domains (DNA binding domain, AF-2 domain and
AF-I domain) required in order for effective ERa meditated transcription to occur. A

DNA Binding Domain mutant, an AF-2 defective mutant and an AF-1 defective mutant
were used during the transfections and cells were treated with EtOH, oestrogen,
tamoxifen and raloxifene. The results (Figure4.8.) revealed that all three domains were
required for effective ERa meditated transcription in both subsets of reporter plasmids.
This contradicts the theory that Tamoxifen does not require the AF-2 domain to activate
AF-2 independent genes and suggests that in these reporter plasmids there is an
alterative mechanism operating.
Following ERa mutant analysis of the SERM responsive plasmids, further investigation
was performed to assess their response to transfections with hERa alone and hERa with
either SNAIL, PAX4 or SRC-3. These transfections were then treated with EtOH,
oestrogen, tamoxifen or raloxifene.
The results revealed interesting results. The results obtained from transfections with
SNAIL and PAX4 were as expected and both have been previously demonstrated to act
as transcriptional repressors (Hemavathy et al, 2000; Nieto, 2002; Smith et al, 1999)
and the levels of transcription from both transfections were lower than that of the ERa
transfections (for all treatments, EtOH, oestrogen, tamoxifen and raloxifene). However,
the result obtained from transfection with SRC-3 revealed SRC-3 also acted as a
repressor when it associated with the sequences contained in the reporter plasmids E5p
and T4p. This result was surprising as SRC-3 has only previously been reported to act
as a transcriptional coactivator (Wu et al, 2002, 2004, 2007; Feng et al, 2006; Naeem et

al, 2007; Chen et al, 1999). Oestrogen responsive reporter plasmids E l 2 and V17 were
then used to assess their responsiveness to SRC-3. These transfections produced a
'typical' response of a coactivator, producing approximately a 3 fold increased
transcriptional response with the addition of SRC-3.
The interesting results obtained using SRC-3 led the project to further investigate the
family of SRC coactivators.

5.2.

SRC-1A

and

SRC-3

Library

Construction

and

Investigation
SRC-1A and SRC-3 are two of the members of the SRC family of coactivators that
were focused on in this section. The major aim of this section was to construct four
reporter plasmid libraries (using DamID technology), containing sequences that
interacted with SRC-1A or SRC-3 via either ERa and oestrogen or PR-B and
progesterone.

Construction of these libraries would enable further analysis of the

libraries to be performed to gain a greater understanding in the relationship between the
effect of the coactivator molecules SRC-1A and SRC-3 and oestrogen and progesterone
receptor mediated transcription. Additionally, if successful, it would enable a new
method for investigating a broad range of coactivators and reveal more about the
sequences that these molecules influence.
The primary step was to construct SRC-1A: and SRC-3:Dam fusion plasmids. This
process used a pCR3.1 SRC-1A:Luc plasmid or a pCR3.1 SRC-3:Luc plasmid, whereby
the Luc gene was excised from the plasmid and replaced with a Dam gene, which was

inserted directly downstream of the SRC-IA or SRC-3 gene, forming a fusion gene.
The Dam gene was isolated from E.Coli DNA and amplified using PCR.
Results of the Luc excision step revealed successful removal of the Luc fragment from
the pCR3.1 SRC-1 A:Luc plasmid, however, removal of the Luc fragment from pCR3.1
SRC-3 appeared to be unsuccessful.

Protocol was continued however for both

plasmids, the Luc fragment was removed and discarded and a ligation reaction was
performed to ligate the amplified Dam gene to the pCR3.1 SRC-1A and pCR3.1 SRC-3
plasmids and transformed to chemically competent E.Coli cells and ncubated on agar
containing ampicillin overnight.

Controls were also transfected which involved

transfecting the pCR3.1 SRC-1A or pCR3.1 SRC-3 plasmids without a Luc or Dam
gene. The results demonstrated successful excision of the Luc gene from the pCR3.1
SRC-1A:Luc plasmid as there was no growth on the control agar due the the pCR3.1
SRC-1A being in linear form and thus unable to express its ampicillin resistant gene.
pCR3.1 SRC-1A:Dam therefore was successfully constructed.
On the other hand, a high number of colonies observed on the pCR3.1 SRC-3 control
plate indicated that the Luc excision step was unsuccessful, as the control plasmid was
able to express the ampicillin resistant gene.
pCR3.1 SRC-1A:Dam and pCR3.1 SRC-3:Dam colonies were picked and purified for
further analysis.
Further analysis confirmed the successful construction of pCR3.1 SRC-1A:Dam and the
unsuccessful construction of pCR3.1 SRC-3:Dam. Sequence analysis confirmed the
directionality of the Dam gene in the pCR3.1 SRC-1A:Dam plasmid.

Due to difficulties in constructing the pCR3.1 SRC-3:Dam expression plasmid the
attempts to do so were suspended. However, as construction of the pCR3.1 SRC1A:Dam was successful, this SRC-1A:Dam fusion plasmid was used to construct a
genomic library containing sequences that the SRC-1A:Dam fusion protein interact
indirectly with via either hERa and oestrogen or hPR-B and progesterone.
Once the pCR3.1 SRC-1A:Dam plasmid was constructed and processed DamID
protocol could proceed.
The DamID protocol involved in vivo targeted methylation of GATC sequences
adjacent to the indirect binding sites of the SRC-1A:Dam fusion protein. This was
achieved by cotransfecting HeLa cells with the pCR3.1 SRC-1A:Dam plasmid along
with expression plasmids for either hERa or hPR-B, followed by treatment with the
respective hormones (either oestrogen, progesterone or EtOH).
Following the transfection protocol genomic DNA was isolated from the transfected
HeLa cells and DpnI digestion was performed to enable isolation and amplification of
methylated sequences.
LM-PCR amplification was performed and the resultant sequences were analysed to
ensure a variety of sequences were amplified (successful LM-PCR products will appear
as a smear on agarose gel). Smears were present for all four LM-PCR reactions,
however the sequences obtained using the receptors plus EtOH contained more DNA
than that obtained from receptors plus hormone. This could indicate that SRC-1A:Dam
preferentially binds indirectly to DNA via unbound receptor, however this has not been
previously reported and in fact the action of SRC-I has been found to be ligand
dependant (Onate et al, 1995). However, the appearance that there is more LM-PCR
product in the lanes that did not contain hormone does not indicate that SRC-1A has the

ability to activate promoter elements contained in these sequences, it merely suggests
that SRC-1A has the ability to bind to unligand bound ERa and PR-B.
Protocol was adjusted, using a reduced amount of LM-PCR product and as a result of
this optimization the TOPO cloning procedure obtained approximately 2000 colonies.
Rather than perform restriction digestions on this TOPO library, colonies containing
sequences obtained with ERa with oestrogen and PR-B and progesterone were directly
transferred to an expression vector library.
The expression vector used was pGL3-Basic, which was adapted to be gateway
compatible by Jennings (Jennings, 2009) and enables functional analysis of the isolated
sequences. This vector contains a Luc gene located downstream of the sequence insert
site. Additionally, it does not contain a promoter sequence, thereby the sequence insert
can be investigated to assess for promoter activity.
Isolated sequences were transferred from the TOPO vector to the pGL3-Basic vector
using gateway cloning technology.
The pGL3-Basic reporter library was fuctionally tested using HeLa cell transfections
followed by the luciferase assay.
This protocol was used initially to screen plasmids for genomic inserts. In theory, if the
plasmids contained sequences that bound, indirectly, to the SRC-1A:Dam fusion protein
via the receptor (ERa or PR-B) and hormone (oestrogen or progesterone) and contains a
promoter element, following HeLa cell transfections with the relevant receptor and
hormone, the luciferase assay will be able to detect the promoter activity.
The results from these transactivation assays were unsuccessful as all reporter plasmids
showed no response.

Lack of response could mean a number of things; that the

sequences that are inserted in the plasmid do not contain a promoter and therefore Luc
could not be transcribed, that the sequences have some other effect on gene expression
or that the sites isolated bind to SRC-1A in association with other proteins and not
specifically the nuclear receptor and hormone that was added (endogenous transcription
factors).
In total there were approximately 65 reporter plasmids in each library. Sequencing was
performed on 5 plasmids from each library to determine which sequence inserts are
from genomic origin (using NCBI Blast) and which are bacterial or vector sequences.
lnitial sequencing determined that the library obtained from pCR3.1 SRC- 1A:Dam
cotransfection with PR-B followed by treatment with progesterone contained a higher
percentage of sequences of genomic origin than the library obtained from pCR3.1 SRC1A:Dam cotransfection with ERa followed by treatment with oestrogen. As neither of
the library sequence inserts appeared to respond to the receptor and hormone (Figure
4.29.) it was constructed with further analysis was performed on the PR-B library as it
contained a higher amount of genomic inserts. The first 21 plasmids that contained
genomic inserts from the SRC-1A:Dam PR-B progesterone library were used for further
analysis.
Additionally, NCBI Blast revealed genes located upstream and downstream the isolated
sequences. Providing information about the genes possibly controlled by the isolated
sequences provides additional information regarding on the isolated sequences and their
function in the genome.
The initial .assays performed on these plasmids involved two transactivation assays.
The first was a cotransfection of HeLa cells with the said plasmids and expression
vectors for SRC-IA, ERa, PR-B and GR. The cells were then simultaneously treated

with oestrogen, progesterone and dexamethasone. The second transactivation was set
up the same except the SRC-IA expression vector was substituted with pCR3.1, the
empty expression vector. The theory behind this was to assess if any of these ligand
bound receptors interacted with the plasmid inserts and if SRC-1A had any affect on
their action on the sequences. pGRE/El bLuc, a reporter plasmid containing a sequence
responsive to GR was used as a control to ensure the procedure was working. The
control responded to the transactivation assay as expected, with the addition of SRC-1A
to the transfection the gene expression of the control increased by 13 fold. However the
test plasmids showed no significant response to either transactivation assay.

A

significant response would be that similar to the control, in that there is a response to the
addition of hormone and not to the addition of EtOH. The test plasmids showed
approximately equal response to hormone and to EtOH indicating the isolated
sequences do not interact with ERa, PR-B or GR.
It was a possibility that during DamID step whereby GATC methylation occurred SRC1A:Dam indirectly bound to the DNA via proteins endogenously present in the HeLa
cells. A bioinformatical approach was then taken to attempt to identify possible binding
sites within the isolated sequences. Two programmes were used; MotifViz and The
MEME Suite. Motifviz (Fu et al, 2004) identifies overrepresented regulatory motifs
(i.e.: transcription factor binding sites) in a given set of sequences while MEME does
not locate transcription factor binding sites but merely identifies over-represented
sequence motifs in a set of given sequences (Bailey and Elkan, 2004). A second part of
the MEME Suite is a programme, known as TOMTOM, which is used to then identify
transcription factor binding sites within the overrepresented sequence motifs identified
by the MEME programme.

Of the transcription factor binding motifs identified by the above mentioned
programmes, the transcription factors SNAIL, RORa and COUP TFI & I1 were the ones
most prevalent and these were focused on for further investigations.
Transactivation assays with SNAIL and SRC-IA and with RORa revealed no
significant results.
Transactivation assays with COUP T F I (chicken ovalbumin upstream promoter
transcription factor I) and COUP TFII did find 5 responsive plasmids. However,
plasmids that responded to COUP TFI and COUP TFII did not, according to
bioinformatical results, contain COUP binding motifs.
COUP TFI and COUP TFII belong to the steroid receptor superfamily (Wang et al,
1989). Currently, no specific ligands for these transcription factors have been identified
and thus they are classed as orphan nuclear receptors.
COUP-TF is one of the best characterized orphan nuclear receptors.

It was first

identified as a homodimer, found to bind to a direct repeat regulatory element,
containing an imperfect direct repeat of AGGTCA, in the chicken ovalbumin promoter
(Pastorcic et al, 1986; Sagarni et al, 1986; Wang et al, 1989). In mammals two genes
have now been identified: COUP TFIlEAR3 and COUP TFIIIARP-1 (Miyajima et al,
1988; Wang et al, 1991; Ladias et al, 1991). COUP TFI and COUP TFII are closely
related transcription factors however each factor has the ability to generate its own
distinct expression profile during mammalian development (Qiu et al, 1994).
Both COUP TF I and I1 are expressed in many human tissues, being involved in many
biological regulation processes such as neurogenesis, organogenesis, determination of
cell fate and metabolic homeostasis (Tsai et al, 1994; Ladias and Karathanasis; 1991;

Wang et al, 1991; Mangeldorf et al, 1995; Ritchie et al, 1990; Qui et al, 1994; Kastner
et al, 1995; Park et al, 2003)
COUP TF contains a 66-amino acis region which contains two conserved Zinc finger
motifs, this is the DBD region; COUP TF I and I1 are identical but for one amino acid
difference within the DBD which is a conservative change from Ser to Thr (Miyajima et
al, 1988; Wang et al,

1989).

COUP-TF has been seen to act as a transcriptional activator and repressor. It was
initially identified as a transcriptional activator (Sagami et al, 1986) and further to this
has been seen to demonstrate transrepression capabilities (Cooney et al, 1992; Tran et
al, 1992; Park et al, 2003; Achatz et al, 1997; Leng et al, 1996), via DNA-independent
heterodimerization of the ligand binding domain COUP TFs with other nuclear
receptors, for example thyroid hormone receptors, retinoic acid receptors and retinoid x
receptors (Leng et al, 1996; Kruse et al, 2008).
One possible mechanism of action hypothesised by Leng et al, suggests that the
heterodimerization of the COUP TFs with the nuclear receptor LBD results in either
suppression of the AF regions in these receptors or reduction of the nuclear receptors
ligand binding ability (Leng et al, 1996).
The ability of COUP TF to heterodimerize to other nuclear receptors raised a number of
questions relating to the results already found. The fact that none of the COUP TF
responsive plasmids contained a known COUP TF binding sites (results from clover
bioinformatical approach) lead to the question: perhaps COUP TF is interacting through
another nuclear receptor and is operating via a novel binding site?

Initially, transactivation assays were performed to reduce background (non specific
response from the empty vector) obtained in the plasmids response to COUP TFI and
COUP TF 11. It was then determined from these titre assays that 2ng was the optimal
amount of COUP TFI and COUP TFII to use in further investigations.
As the affects of RORa on the reporter plasmids was studied previous to COUP TF, and
COUP TF has been demonstrated to have RAR (retinoic acid receptor) interaction
capabilities (Kliewer et al, 1992), RORa was the first investigated.
HeLa cell transfections were performed, cotransfecting reporter plasmids with COUP
TFI or COUP TFII (or empty expression vector, pCR3.1) and then each of these groups
with either expression vectors for RORa alone or with expression vectors for RORa and
SRC-1A. pGL3 Basic was used as a control. The results demonstrated that the COUP
TF responsive plasmids did respond more favorably to COUP TF, RORa and SRC-IA.

Figure 4.43. demonstrates a summary of these results obtained, this response was seen
in P27 and P45 in particular. From this figure it can be seen that there is no response
with the empty vector transfection alone (pGL3 Basic; V). Results from transfections
with reporter plasmid with either COUP TFI, COUP TFII or RORa showed a slight
response, but when compared to further responses it was negligible. Cotransfection
reporter plasmid, RORa and SRC-1A showed a response approximately double to that
seen in RORa alone. Cotransfection of reporter plasmid, COUP TFI and RORa showed
a dramatic response, as did COUP TFI and RORa although this was not as significant.
When SRC-1A was added to these transfections the response increased further.
It is clear from these results that P27 and P45 contain binding sites that facilitate some
form of cooperational binding between COUP TFI and RORa, whose relationship with

DNA is enhanced with the addition of SRC-IA.

As, in this situation, the association of COUP TFI with RORa results in transcriptional
acitivaiton it suggests that COUP TF is not associating with the ligand binding domain
of RORa, as previous studies have found the binding of COUP TF to the ligand binding
domain of other nuclear receptors (thyroid hormone receptors, retinoic acid receptors
and retinoid x receptors) (Leng et al, 1996) to result in transcriptional repression.
Rather than forming a COUP TF1:RORa heterodimer, the two molecules could bind to a
novel binding motif within these sequences at separate times and cany out separate
fhctions. The action of each of these molecule alone may not be sufficient to induce
transcription, however when the actions of each of the molecules are combined
transcription is activated.

The role of SRC-IA may involve mediation of the

association of these molecules to the DNA, acting perhaps as a 'crane', moving one of
the receptors in, enabling it to cany out its actions, removing it and bringing in the
second.
However, these are only hypothesized models of how these factors are interacting and
fiuther work would have to be carried out to assess the exact mechanism of how these
nuclear receptors are functioning to activate transcription and what the role of SRC-IA
has in this mechanism.
Additionally, in order for this to have occurred during the construction of the library
RORa and COUP TF would have to be endogenously present in the HeLa cells used
during these steps, as the SRC-1A:Darn would have had to preferentially bind to the
COUP-TFs and RORa than to the ligand bind progesterone receptor.
RORa, COUP TFI and COUP TFII can be found in cancerous cervical cells, which is
the origin of HeLa cells (www.genecards.com). This confirms that cancerous cervical
cells have the ability to produce all three of the orphan nuclear receptors, therefore there

is the possibility that instead of SRC-IA Dam binding to the respective hormone
receptor which attached to its ligand (hERa and E2 or hPR-B and Progesterone), it
therefore seemed that SRC-1A Dam had a higher affinity for COUP TF or RORa in the
conditions provided than it had for ERa or PR-B.
The five COUP TF responsive plasmids were bioinformaticaly analyzed using the
MEME Suite.

TOMTOM revealed no COUP-TF or RORa binding sites in the

sequences.

5.3. Locating Transcrition Start Sites
It was attempted to locate the transcription start sites of a selection of reporter plasmids
from both the ERE reporter library and the SRC-IA reporter library.

This was.

unsuccessful despite optimisation of the techniques used.
The identification of transcription start sites within the reporter plasmid sequences
would have enabled further investigation into the effect of the transcription start site to
transcriptional activation.
Further optimisation would be required to enable this technique to be used to investigate
transcription start sites.

5.4. Future Work
Further work still needs to be performed on the activity of SRC-3 as a transcriptional
repressor in the SERM responsive plasmids identified.

The role of DamID to investigate this further was unsuccessful and once a SRC-3:Dam
fusion plasmid has been constructed this may be an option to identify where SRC-3
association sites on the genome. It would prove interesting to identify sites in the
genome where SRC-3 binds via Tamoxifen bound ERa, and to attempt to locate more

SERM responsive sequences.
The DamID technique did not work as expected but with alternative methods the
problems encountered could be avoided. Primarily the method did not produce a library
of sequences that bound to either of the ligand bound receptors that were being
investigated. However it did result in a selection of sequences that were isolated due to
SRC-1A:Darn binding via endogenous transcription factors in HeLa cells, of which it
was identified that COUP TF and RORa were just two that a selection of the reporter
plasmids responded to. Further investigations, and perhaps trial and error, would be
required to identify the endogenous transcription factors that the remaining sequences
were isolated by.
Additionally, an interesting study would involve deducing the mechanism of action of
the cooperation between COUP TFI, RORa and SRC-IA to activate gene transcription.
Co-IP (Co Immunoprecipitation) followed by western blots could be used to identify if
there is and heterodimerization occurring between COUP TFI and RORa or not and the
results from those investigation would influence further work performed.
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Buffer, dissolved in microwave) add 2.5 pg Ethidium Bromide

Ampicillin Agar (50 pg//rl)
16g LB Agar (Lennox L Agar, Invitrogen)
500mls dH2O
250 pl Ampicillin (from 100 mglml Stock Solution)

Spectinomycin Agar (50 pg/pl)
16g LB Agar (Lennox L Agar, Invitrogen)
500mls dHzO
250 p1 Spectinomycin (from 100 mgtml Stock Solution)

Ampicillin LB Broth (100 pUml)
12g LB Broth Base ( Lennox L Broth Base, Invitrogen)

600mls dH20

600 p1 Ampicillin (from 100 mgtml Stock Solution)

Spectinomycin LB Broth (100 pL/ml)
12g LB Broth Base (Lennox L Broth Base, Invitrogen)
600mls dHzO
600 p1 Spectinomycin (from 100 mg/ml Stock Solution)

Double Stranded AdR (drAdR) 5OmM
Dissolve IOOmM each of AdRt and AdRb in dH20. Combine equal volumes of AdRt
(100 mM) and AdRb (100 mM). Mix and place in a tightly closed tube in a beaker with
water of about 90°C. Let the beaker cool to room temperature (20°C), to enable the
adaptors to anneal slowly. Aliquots were stored at -20°C.

APPENDIXI1
Trans-Activation Assays

8

P26,27,33,40,45

9

P26,27,33,40,45

10

P26,27,33,40,45

long COUP-TF II
lOng RORa
2ng pCR3.1 or COUP TFI or COUP TF 11
And
SOngpCR3.1 or lOngRORaorSongpCR3.1 SRClA
~ n g p ~ ~~3~. C1 O U P T F ~ ~ C O U P T F ~
And
5Ong pCR3.1 or ZSng RORa with 25ng pCR3.1 or 25ng
RORa with 25ng pCR3.1 SRClA
O.lngpCR3.1 COUPTFI
COUP TF I1
0.25ng pCR3.1 COUP TF 1
COUP TF I1
Ing pCR3.1 COUP TF I
COUP TF I1

pG13 basic control

pGl3 basic control

pGU Basic

* Transfection Number 4.
Plate was divided into 3 groups

I
Group 1

1

Reporter

1

Yes
I

Yes

I

Additional

Hormone

Control

50 ng pCR3.1

Hormone Premix

Substitute Hormone for EtOH IO-'M

I

I
Yes

I

Group 3

Receptors
Yes

Yes

1

Group 2

1

I

I

I
50ng pCR3.1 SRC 1A

Substitute Hormone for EtOH 1 0 . ' ~

Hormone Premix
I

I

Reporter Libruy

Expression Plasmid

Hormone

Control

Treatment
1

ERa DAM (28)

2.5ng hERa

2

ERa - DAM
20 h m
EtOH, E2 and 4HT
SERM induction reporters
( h m E2 and 4HT Libraries)

5ng hERa

3

4

ESP, T4p, El0

5

ESP, T4p, El0

6

ESP, T4p, El0

7

ESP, T4p, El0

5ng hERa (in all transfections)
25ng pCR3.1
25ng SNAIL
25ng SRC-3
5 ng pCR3.1
5ng pCR3.1 hERa
5ngpCR3.1 hERa& long SNAIL
sng p c ~ 3 . 1~ E R U& long P A X ~
pCR3.1 hERa& SOngpCR3.1 SRC3
5ngpCR3.1
5ng pCR3.1 hERa
5ngpCR3.1 hERa& IOngSNAIL
5ngpCR3.1 hERa& lOngPAX4
pCR3.1 hERa & 50ngpCR3.1 SRC3
5ngpCR3.1
Sag hERa
5ng C205H
5ng L539A
5ng S118A
5ngpCR3.1
5ng hERa
5ng C205H
5ng L539A
5ng S118A

10-lM Ral
10% E2
IO-~M
~HT
10-'M ~ a l
10% E2
10-'M 4HT

~ o - ~E~OH
M
10% E2
10-M 4HT
l a - l ~~ a l
1W7MEtOH

~ o - ~~2
M
~o-'M 4HT
IO-~M
Ral
10-lM EtOH
10% E2
IO-~M
~ H T
1 0 . ' ~~ a l
IO-lM EtOH
10% E2
1 0 - l ~~ H T
10-'M Ral

Substitute Ral for lW7M EtOH for each hansfection
2OOng pGL3-Basic and pERE-E lb-LUC
Substitute Hormone for 10-'M EtOH for each eansfection
Substitute Hormone for lW7M EtOH for each transfection
pERE-El b-LUC as positive conhol.

P-Library reporter plasmid sequences

>SP1
GATCCTTGTTGGCRTATCACTTCCATACCCTCRRRTRTTRTTCRTCCTTGGATTCATTGTTGGCTCTTGTTTCTATGCATACTGTTTGGATTCCTTGGTGRRGT
TGCTCTGTRTGTGCCTGTTRTTCTTRGTCRTRCCCACRGCCCRGAGCRCTTCCTCGRRCTCTGTCTCATGRRTGTCTCTATTTGGTGTACAGCACGGGCTTGTC
AGTCTCCRRRRCTGRGTTCTGRTC
>SP2
GATCCTCTAGTCAGCCCTRTGTTCRTRRTTCCTRRGGGGAGRRCCC&CCTGCCCTGTGTAGAGGCCCCGACCCACTGTCCCTTTTCCAGGCRGAGCTTGGACCC
ATCRTRRRTGTCATGACT~GGCGTGGGAGGGTGGGGATCGTGTACTGTRRTATTWGAGRRTTAGGACATCTGTTTRRTTTAGTATTCRRRTGGGGATAC
TTTGGRTGTTWLTGRTC
>SP4
G
I

A
G

T C A T C C
G C A G C

R R G T R G
G A G G G

G
T

R G G G G G R R
C C A G T T ~

G
G

G T G R R T
G C T G G

G
A

G G T A G G
m C T G T

G
G

T
T

A

TGCTGGCTRTTTGGRRGGGTCCRGRRTCGCCTGGTRRGACRCRRCRGTGGGGCRRGGGATC
>SF10
TCTGRRRCTCCTGGCCTCMGCRRCAGCCTCCCRRGTCRCTGGGGTTRCAGGCRTGRGCCRCCGTGCCCRGCTCCTRRTATGATMTTCCRRTTCATATTTGAT
TGRTGGRRRCCTGCATRTMTCRRGACCRGCRTAGTTTRRRRAGGGTCRRCTGTRTTGTGTTCMGACRTTTTCTGGTGGGTATGACTGGATCCTG
>sell
GATCGR%GTTCCRGACCTRRCTTGGCRGTAGCACTGCTTTATTCAGATGGCCCATCCTATTCCGRRTGTTRRTTTGCTCTGTTCTTCRTATTCAtATTTTTAT
GCCGRRTTTCTAGCTCCTGCGTCTCTATTGCGGGCCCTMGTCGCTGTTTCACTWCTTTGGMCCTGACTCCGGWTCTCATTCTTTCGTCCCRRGAT
CTCAGCCAGRRRGAGAGTTCCGCGCGGCGGCGTCTTCRRGCGCGCGGGCTGGGAGCGCGGGTTCTGATC
SSP15

GRTCCRCRTGTGCRRGCTTGGGRRCGAGTCCARRRTTTATM-TTATTTGWTTGATTTCCTGAGTTTTCCTTTTTCTCCATRRCTTTCATACTTTCTGG
TTCCTTGGGGTCCTTCTATATCRRGGRRGCCRGGGTTTTAGTTATCCCRCTCTGAGGTGCRCTTCTGGTGTGCCCACRTCCAGGTCWCRRTGMGGAW
TCCRGRTGGACGACAGTGGTGGTCRGCCTCRCCRTCCRGGTCCRAACRRTGRRRGGACRRTCCRGRTGGRCGACAGTGGTGGTCAGCCTCRCTCTCTTGGRRCC
RRGGRTCCTC
.SP19
~TCCTCTGGTTTGCCTRRGCTTTCCWGRRTCRTCTGRWTTTTTCTCRTTGAGCTGTGCCAGCRTRTRGCRRRGTTTGTATTAGCTTGGTCCRRRTGGA
CTCRGTTAGRRGATI\GTATATCTGCRGCRGCAGRGCCRCCTCCTRGCCTCCCTCRCTCRCCRTCCTGAGCGRTRCCCTCCCTGTTGATC
>SPZO
GATCCAGGAGGCTCTAGGGTCCTGACTCCRGGCCTGRGRTCTTTCCRCMGTCCCTGTTGCCTGGCCTGTGTTTGCCRRTGRRRCCRGCTTGCTRRCCTGG

TCRCWTTAGRRTAGTGTTGATGTCCTAG~GGCCRCTRTGRRRGGTRGCCAGGAGGGGGCTGCCCGRRRCTGTATGTGGTGAGGRCACTCCACATCG
GATGGGAGGRRGGCAGCCCRTCAGAGCCTCCTTTTTGGGTRTATTGRGAGTRGATGGTTCRCCTGGCTTGGGGCTRRCCCTGAGTGATCC
>SP21
GRTCATGRRGTCGRRRRGAGTRRRGTCCCATTTWCCAGGCAGTCTRRGTCCAGACRCGTGGCATTTGGCCAGTCCTCTCCCTGCATCCRRCCTGCCCTCTCA
RRTCCTTGTCRCTCGGGCAGATGCCCCTGCTCACTGTGCCCTTCCCTTTGGGGGTTCCTGATAGACCRCAGCTAGCCCAGTGGGTGCCACATTCACTGTGTCRR
GTRTAGARRGGGCRGCCGAGRTC
>SP22
WLTCCRTTTGTGTTCRTGCCGCRGmTCTRCCRGRTCRTGCGCCRGTGCCGATGRCTTCTGRRCCCTTTCTCATGAGCTTCTGCTTTTGGGTCCTGAGcTTGGc
CTTCRCRRRTGCCCTTCCTGGGRGCRGCRTCTGTGACCRGCTGTRGTAGTCRGGGTTCTCCRGRGRRRRAGRRCCRRTTRTGTGTGTGTGTGTATTTGTATGTA
TIITTATGRTRRTTRCTRTTATRRRGRRTTGGCTCRTGTGRTTATGGRGGCRGTCRRGTCTCRR~ATC
>SF23
GATCCTWCAGGGACCCCCTCRGIUU\CTRRRCARCAGTGTGGTARRGRGGRRRGTCTGRTCGRCTTGRGTTMTCCCTRTTGCACAGCTGGGTGCGTTGG
CTCACGCCTATRRTCCCRGTAcTTTGGGAGGCCGAGCRRGGTGGRTCRCCTGAGGTCAGGAGTTCGAGACCAGCCTGGCC~GGTGGCMCACTGTCTCTAc

TRRRRRTRCRRRRATTAGCCRGACGTGGTCACGGACRCCTGTRRCCCCGGCTACTTGGGAGGCTGAGGCACRRGRRTCGCTTGRRCCCAGGAGGCAGAGGTTTC
AGTGAGCCRRGRTC

XP24
GATCTGTGRTGCTCTCTGTCRCCCRTTGGRGRRGCCCRRCGTCWGGGCTCAGCCTCTGCCRRRGGCTGCCCTCTGGTGGCTGCTTGGTTCTTGAGGGTCCAG
*G*GRRTAGCTTGCTGGTTCCTTCTTTCCRGRGmTCRGCTGGCRTTGCAGAGGGATc
'np26
GIITCATGTGTRRCRRTGTRCTGRTGGRRARTGCTTACCTCRRTRRRCTRRTGCTRGTGRCCGRRTTATTCRTTGGTGTGGATTCATAGATACTTRRCCAGTTGA
TGACRRGRRTGCTGRRGRRRTACCRRGRTCTTCRGCCCTTTT~TTCCGTCTAGRGGCCGGGCACGGTGGCTCRTGCCTGTRRTCCCRGCACTTTGGGAGG
CTGAGGCGGGCGGATC
>SP27
GRTCTACGCRTGCGTCTGTAGACGTGGTGGTACATGTATGCCCACACATTGCACACGCCCRCACGCGC
>SF32
G

R

T

C

A

T

C

C

R

R

G

T

A

G

G

A

G

G

G

G

G

R

R

G

G

T

G

A

R

T

G

G

G

T

R

G

G

G

T

T

TGGCRGCGAGGGTCCRGTTRRGGCTGGRRRCTGARTTTTACRGCAGmGCGTTCTGTCTAGTTGTGGGATTTTCCTCTAGGRRTACGGTTATAGWCWGA
TGCTGGCTRTTTGGRRGGGTCCAGRRTCGCCTGGTRRGACACRRCAGTGGGGCRRGGGATc
>SF33
GRTCTGTGTTTGTRRCCRCACGTGTTGTRGGTTRTRTGGTGTGCARTGGRRCCCRGCCRTGACTCCTRTACGTGGGTGTGRRRCRRCRCCCRTTTTTCTCTGAG
TACRGRRGGlilUjRRRGCRGRTTCCRCTRGCATCACTGTCACTTCCTGAGATCRTTTGTTWTGCACTATTGRRTTTTAGGATC
>SF36
G G A T C A C A G G G T C A G G
AGGTGCGAGRRTTGAGRRRGTCCTGRRCRRTRRTTGCCAGA

A

G

R

T

C

G

R

G

G

C

C

G

C

A

C

T

G

G

C

T

C

G

>SP37
GATCCTCTAGTCAGCCCTRTGTTCATRRTTCCTRRGGGGAGRRCCCRCCTGCCCTGTGTAGAGGCCCCaCCCACTGTCCCTTTTCCAGGCRGAGCTTGGACCC
ATCRTRRRTGTCATGRCTRRRRGGCGTGGGAGGTGGGGGATCGTGTACTGTRRTATTWGAGRRTTAGGACATCTGTTTRRTTTAGTATTCRRRTGGGGATAC
TTTGGATGTTGATGATC
>SP38
GATCRGTGCAWLGRTATGTGRCRRGACCCCATTWCAGAGTCTAGACRRTRGTTACGTRRCCTGRGTGRTCRRTGCRGRGATCTGTCACRRTGCCCTTTRGGC
AGRCCTTR~C~GAGTGACRRCACCTGGGTGATCRGTGCRGAGRTRTGTCRCRRTGCGCCCATRGGCRRRTCCMGA~GTCCGTCACCTGTGTGATCAG
TTCRGmTATGTGAGRRTGCCCCCRGTAGGCRGRGCCTRGRGRRCRGTCCCTTCACCTGGGTGRTCRGTGCRGRTRTRTTTCACRRTGCCCCTGCAGGCRGRG
TGTRRGC19RGAGTTACATCRCCTAGRTGRTC
>SP40
AGGRTCGRTGGTTCCRGRCCTRRCTTGGCRGTAGCRCTGCTTTATTCAGATGGCCCATCCTATTCCGRRTGTTRRTTTGCTCTGTTCTTCATATTCRGATTTTT
ATGCCGRRTTTCTAGCTCCTGCGTCTCTRTTGCGGGCCCTMGTCGCTGTTTCRCTRRGCTTTGGRRCCTGRCTCCGGGmTCTCATTCTTTCGTCCWG
ATCTCAGCCRGMGAGRGTTCCGCGCGGCGGCGTCTTCRRGCGCGCGGGCTGGGAGCGCGGGTTCTGATCCTCGGCCGC
>spa5
GATCCTCCCGCCTCGGCCTCCCRRRTTGCTGGGRTTACAGGCGTGRGCCRCTGCGCCTGGCCTRTTTRRRGTCTTTCRGCAGRRGTAGTRRTACGCRCAGAGAT
GCATTTTGGGRRGATGMTGTGCCRGTGTTRTGTTCTAGAGCIGRGTTGTCCAGTRTGGTAGCCACTGGCTRCATGTGGCTATTTMCTTMT~T
TCAGATCCTC

Gene-Racer sequences

-

TSSl
G G A

G G C T T A C G A T T C G C C C T T G G A C A C T G A C A T G G A C T G R G G T G G T T T T C
C C A G G G C G A G G C T T A T C C A T T G C A C T C C G G A T G T G C T G A C A C G
A A G G G C G A A T T C G C G G C C G C T A A A T T C A A T T C G C C C T A T A C C

CTGGCGTTACCCAACTTAATCGCCTTGCAGCACATCCCCCTTTCGCCAGCTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCCWCAGTT
GCGCAGCCTATACGTACGGCAGTTTAFiGGTTTACACCTATAAAAGAGAGAGCCGTTATCGTCTGTTTGTGGATGTACAGAGTGATATTATTGACACG
CCGGGGCGACGGATGGTGATCCCCCTGGCCAGTGCACGTCTGCTGTCAGATAAAGTCTCCCGTGAACTTTACCCGGTGGTGCATATCGGGGATW
GCTGGCGCATGATGACCACCGATATGGCCAGTGTGCCGGTCTCCGTTATCGGGWGAAGTGGCTGATCTCAGCCACCGC-TGACATC G C C R T T A A C C T G A T G T T C T G G G G A R T A T A R A T G T C A G G C T C C G

CAGAEACGGTGCTGACCCCGGATGAATGTCAGCTACTGGCTATCTGGACAAGGWCGWGCGWGA-GCAGGTAGCTTGCAGTGGGCT
TACATGCGATAGCTAGACTGGGCGGTTTATGGACAGCAGCGACGATGCAGCTGGGGCGCCCTCTGTAGTGGGAGCCTGWGTAACTGATGCTTTCT
GCGCAGATCTGATGGCGCAGGGATCAGCTCTGATWGAWCGATGAGATCGTCGCATGATGGAACAGATGAATGGCACGCAAGTCCCGACCTTGC
TGAAGCTATCGATAGACTGCCACAAAGACAAATCGGTCTTGAGCCAGTTCGGTTACCGAAG
TSS2
GTCGGGTAACGGAATTCGCCCTTCGTATCTCTTCATAGCCTTATGCAGTGTccTTTTCTAcTccTTCAGTCCATGTCAGTGTccTcGTGcTCcAGTc

-

T T T C T A C T C C T T C A G T C C A T G T C A G T G T C C A A G G G C C C T G G C C G
T C G T T T T A C A R C G T C G T G A C T G G G W C C C T G G C G T T A

GGCCCGCRCCGATCGCCCTTCCWCAGTTGCGCAGCCTATACGTACGGCAGTTTAAGGTTTACACCTATMGAGAGAGccGTTATcGTcTGTTT
G T G G A T G T A C A G A G T G A T A T T A T T G A C R C G C C G G G G C C C

TTTACCCGGTGGTGCATATCGGGGATGAARGCTGGCGCATGATGACCAccGATATGGCCAGTGTGccGGTcTccGTTATcGGGGAAmGTGGcTGA
T

C

T

C

A

G

C

C

A

C

C

G

C

G

A

A

A

R

T

G

A

C

A

T

C

~

C
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C

C

A

T

T
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C

C

TAGATCCTTTTCACGTAWGCCAGTCCGCAGAAACGGTGCTGACCCCGGATWTGTCAGCTACTGGGCTATCTGGAWGGGMCGWGCG
C A A R G A G A A A G C A G G T A G C T T G C A G T G G G C T T A C A T G G C G G C T G G G G C

GCCCTCTGGTAAGGTTGGGAAGCCCTGCAARGTAAACTGTGGCTTTCTTGCCGCCAAGGATCTGATGGCGCAGGGGA?CAAGCTCTGATWGAG
A C A G G A T G A G G A T C G T T T C G C A T G A T T G A A C A A G A T G G A C

AACAGAACATCGCTGCTCTGATGCGCGTGTCGCTGTCAGCGCAGGGcGcCGTTcTTTTGTcAAGGAcc~ccTGTcGTGccTAGAATGAAcTGm
GAACGGAAGGWl
TSS3
GCAGGCTTAACGW\TTCGCCCTTCGTATCTCTTCATAGCCTTATGCAGTGTCCTTTTCTACTCCTTCAGTCCATGTCAGTGTCCTCGTGCTCCAGTC
T T T C T A C T C C T T C A G T C C A T G T C A G T G T C C A A G G G C G A A T T G G C C G
TCGTTTTAWCGTCGTGACTGG~CCCTGGCGTTACcmcTTAATCGccTTGCAGCACATcCcccTTTcGccAGcTGGCGTAATAGcGAAGA
GGCCCGCACCGATCGCCCTTCCWCAGTTGCGCAGCCTATACGTACGGCAGTTTAAGGTTTACACCTATMGAGAGAGCCGTTATcGTcTGTTT
G T G G A T G T A C A G A G T G A T A T T A T T G A C A C G C C G G G G C G 4 C

TTTACCCGGTGGTGCATATCGGGGATGAAAGCTGGCGCATaTGAcCACcGATATGGcCAGTGTGccffiTcTccGTTATcGGGmGAAGTGGcTGA
T C T C A G C C A C C G C G A A A A T G A C A T C A L V A C G C C A T T A R C C C

TAGATCCTTTTCACGTAGAEAGCCAGTCCGCAGRRACGGTGCTaCCCCGGATaTGTCAGCTACTGGGCTATCTGGACAGGWCGCAGCGmG
AGRARGCAGTAGCTTGCAGTGGGCTTAACATGCGATAGCTAacTGGGCGTTTATGACAGcAGcGATcGATGCAGcTGGGGcGcccTcTGTTAGGTG
G A G C C T G C A G T A C T G G A T G C T T T C T G G C G C C A G G A T C T T G
TGGATGGCCRGGTTCCCGCGC?AGTGP.GGCATCCTAACTGCWGAATCGGGTCCTCTAGGCCGGTTCCGTTACCAGG
TSS4
C T C C A G A T T A C G A T T C G C C C T T G G A C A C T G A C A T G G A C T
TTTTCGTGAAAACCCTTACGGGOWGACCATCACCCTCGAGGTTGAACCCTCGWlTACGATAMTGCATAAGGCTATGAAGAGATACGAAGGGc

GAATTCGCGGCCGCTAAATTCAATTCGCCCTATAGTGAGTCGTATTAWTTCACTGGCCGTCGTTTTACAACGTCGTGACTGGWCCCTGGCG
TTACCCAACTTAATCGCCTTGCAGCACATCCCCCTTTCGCaGCTGGCGTAATAGCmGAGGCCCGaCCGATCGCCCTTCCWCAGTTGCGWG
CCTATACGTACGGCAGTTTRAGGTTTACACCTATAAAAGAGRGAGCCGTTATCGTCTGTTTGTGGATGTACAGAGTGATATTATTGACACGCCGGGG
C G A C G G A T G G T G A T C C C C C T G G C C A G T G C A C G T C T G C T G C T G G C
GCATGATGACCACCGATATGGCCAGTGTGCCGGTCTCCGTTATcGGGGAAGAAGTGGcTGATCTCAGcCAcCGcWTaCAT~cGccAT
TAACCTGATGTTCTGGGGAATATARATGTCAGGCATGAGATTAT~GGATCTTCACCTAGATCCTTTTCACGTAGAAAGCCAGTCCGCA~

CGGTGCTGACCCCGGATmTGTCAGCTACTGGGCTATCTGGAcmGGWcGCAAGCGCAARGA~GCAGGTAGcTTGCAGTGGGcTTAmT
GGCGATAGCTAGACTGGGCGGTTTTATGGACAGCAAGCGAACCGGAATTGCCAGCTGGGGCGCCCTCTGGTAAGGTTGGGGAGCCCTGCAAAGTARA
C T G G A T G G C T T T T C T T G C C G C A A G A T C T G A T G G C G C A G G G T G
ATGGCACGCAGTTTCTCGCCGCTGGGTGGAGAGGCCTATTCGCTATGACTTGGCACAACAWCATCGGCTGCCTmTGCGCGGTTCCGACTGTTC
AAGCCGAARGGAGCT
ACTaGATTACGAATTCGCCCTTGGAaCTGACATGGACTmGGAGTAGAAARTAcTTAcCTGGCAGGGGAGATACCATGATcAcGAAGGTGGTTT
T C C C A G G G C G A G G C T T A T C C A T T G C A C T C C G G A T G T G C T G T A

CGAAGGGCGAATTCGCGGCCGCTARATTCAATTCGCCCTATAGTGAGTCGTATTAWTTCACTGGCCGTCGTTTTAWCGTCGTGACTGGW
CCCTGGCGTTACCWCTTAATCGCCTTGCAGCACATCCCCCTTTCGCCAGCTGGCGTAATAGCGAAGRGGCCCGCACCaTCGCCCTTCCWCAG
TTGCGCAGCCTATACGTACGGCAGTTTRAGGTTTACACCTATMGAaGAGCCGTTATCGTCTGTTTGTGGATGTACAGAGTGATATTATTaCA
C G C C G G G G C G A C G G A T G G T G A T C C C C C T G G C C A G T G C A C G
AAGCTGGCGCATGATGACCACCGATATGGCCAGTGTGCCGGTCTccGTTATCGGGGAAGAAGTGGcTW\TcTCAGcCACcGcWTGACATm
A A C G C C A T T A A C C T G A T G T T C T G G G G R A T A T A A A T G T C A G T C

CGCAGRAACGGTGCTGACCCCGGATGI\ATGTCAGCTACTGGGCTATCTGGAWGGGAAARCGWGCGCAAAGAGRARGCAGGTAGCTTGCAGTGG

G C T T A C A T G G C G A T A G C T A G A C T G G G C G G G T T T A T G C
A G T A A A C T G G A T G G C T T T C T T G C G C A G G A T C T G A T G C G C G G
ATGCACGCAAGTCTCGACGCTGGGTGGAAGCTATCGGCTATGACTGGGCACGACATCGCTGCCTGATGCGCGGTTTCCCG
TSS6

CTTPATCTTACGRT?CGCCCTTCGTATCTCTTCATAGCCTTATGCAGTCGAGTTTCCCACATTTGGGWTCGCAGGGGTCAGCACATCCGGAGTG
W

T

G

G

A

T

A

A

G

C

C

T

C

G

C

C

C

T

G

G

~

C

C

A

C

C

T

T

C

G

T

G

A

T

C

CAAGGGCGAATTCGCGGCCGCTAAATTWTTCGCCCTATAGTGAGTcGTATTA~TTacTGGccGTcGTTTTAWcGTcGTGACTGGMc
CCTGGCGTTACCCAACTTAATCGCCTTGCAGCACATCCCCcTTTcGCcAGcTGGCGTmTAGCmGAGGcccGCAccGATcGcccTTccCAACAGT
TGCGCAGCCTATACGTACGGCAGTTTAAGGTTTACACCTATMGAGAGAGCCGTTATCGTCTGTTTGTGGATGTACAGAGTGATATTATTGACAC
GCCGGGGCGACGGATGGTGATCCCCCTGGCCAGTGCACGTCTGCTGTCAaTARAGTCTCCCGTGAACTTTACCCGGTGGTGCATATCGGGGATW
AGCTGGCGCATGATGACCACCGRTRTGGCCAGTGTGCCGGTcTcCGTTATcGGG~GAAGTGGcTaTcTCAGcCACCGC~TGACAT~
ACGCCATTAACCTGRTGTTCTGGGGAATATAAATGTCAGGcAT~ATTAT~GaTcTTcAccTAGATCC??TTCAcGTAGAEAGcCAGTcc
GCAGAAACGGTGCTGACCCCGGATGAATGTCAGCTACTGGGCTATCTGGAWGGWCGWGCGCaGAWGCAGGTAGCTTGCAGTGGG
C T T A C A T G G C G A T A G C T A G A C T G G G G C G G T T T T A T G C G C C C T G C A
A A G T R A A C T G G A T G G C T T T C T T G C G C A G R T C T G A T G C G C T G G

CAACGCAGTTCTCGGCCGCTGGTGGAGRGCCTATTCGCTTGRCTGGCAACAAMaTTCGTTGCCTTGATGCGCGGTTCGACGTTCAGGCAGGGAGT
G

TSS7
CGCAAGGTTACGATTCGCCCTTGGACACTGACATGGACTGAAGGAGTAGAAAGACTGGAGCACGAGGACACTGCATGGACTGAAGGRGTAGAAA
G A C T G G A G C A C G A G G A C A C T G C A T G G A C T G A A G G A G T A G A

CGAGGACACTGCATMGGCTATGAAGAGATACGAAGGGcGAATTcGcGGccGcTAAATTCAATTcGcccTATAGTGAGTcGTATTACAATTCAc
TGGCCGTCGTTTTACAACGTCGTGACTGG-CCCTGGCGTTACCCAACTTAATCGCCTTGCAGCACATCCCCCTTTCGCCAGCTGGCGTAA

TAGCWGAGGCCCGCACCGATCGCCCTTCCCAACAGTTGcGCAGccTATAcGTAcGGCAGTTTAAGGTTTACAccTAT~GAGAGAGccGT
TATCGTCTGTTTGTGGATGTACAGAGTGATATTATTGACACGCCGGGGCGACGGATGGTGATCCCCCTGGCCAGTGCACGTCTGCTGTCAGATA
A A G T C T C C C G T W L A C T T T A C C C G G T G G T G C A T A T C G G G G A T

CGGGWGRRGTGGCTGATCTCAGCCACCGC~TGXCATmCGCCATTAACCTGATGTTCTGGGGAATATAARTGTCAGGCATGAGA
T T A T C M G G A T C T T C A C C T A G A T C C T T T T C A C G T A G G C T A C T G G G C T A

TCTGGACAAGGGAAARCGCAAGCGmGAGARAGCAGGTAGCTTGCAGTGGGcTTACATGGcGATAGcTAGAcTGGGcGGTTTTATmCAGc
AAGCGAACCGGAATTGCCAGCTGGGGCGCCCTCTGGTAAGGTTGGGRAGCCCT~GTRRRCTGGATGGCTTTCTTKCGCCAAGGATCTGA

TGCGCAAGGGATCAAGCTCTGATCAAGAGACAGATGRGATCGTTCGCATGATGWCAGGATGATGCACGCAGTTTCTCCGCGCTGGGTGGAGA
GCCTATTCCGGCTATGAACTTGGWCAGACCAATCGGCCTGTCTCTGTGAATTGC
TSSB
CGTAGGGCTTAACGAAATTCGCCCTTGGACACTGACRTGGACTGAAGGAGTAwTACTTACCTGGCAGGGGAGATACCATGATCACGAAGG

TGGTTTTCCCAGGGCGAGGCTTATCULTTGCACTCCGGATGTGCTGACCCCTGCGATTTCCC~TGTGGGAAACTCGACTGCRTMGGCTAT
G A A G A G A T A C ~ G G G C W T T C G C G G C C G C T A A A T T C A A G T C G
TGACTGGG~CCCTGGCGTTACCCAACTTAATCGCCTTGCAGCACATCCCCCTTTCGCCAGCTGGCGTRATAGCGAAGAGGCCCGCACCGAT

CGCCCTTCCmCAGTTGCGCAGCCTATACGTACGGCAGTTTMGGTTTACACCTATAAAAGAGAGAGCCGTTATCGTCTGTTTGTGGATGTAc
AGAGTGATATTATTGACACGCCffiGGCGACGGATGGTGATCCCCCTffiCCAGTGCACGTCTKTGTCAGATAARGTCTCCCGTWCTTTACCC
GGTGGTGCATATCGGGGATGAAAGCTGGCGCATGATGACCACCGATATGGCCAGTGTGCCGGTCTCCGTTATCGGGGAAWGTGGCTGATcTc
AGCCACCGCGAAARTGACATWCGCCATTAACCTGATGTTCTGGGGAATATAARTGTCAGGCATGAGXTTATWGGATCTTCACCT

AGXTCCTTTTCACGTAGAAAGCCAGTCCGCAGAARCGGTGCTGAccccG~TWTGTCAGcTAcTGGGcTATCTGGACAAGGGAAARcGcAAG
CGmGAGAAAGCAGGTAGcTTGCAGTGGGCTTACATGGcGATAGcTAGAcTGGGcGGTTTTATGGACAGCAAGcGAAccGGAATTGcCAGcT
GGGGCGCCCTCTGGTAAGGTTGGGAAGCCCTG~GTAARCTGGATGGCTTTCTTGCCGCCAAGGATCTGATGGCGCAGGGGATCARGCTCTG
A T C A A G A G A C A G G A T G A G G R T C G T T T C G C A T G A T T G A A G G C T A T T C G G G C C T

ATGACTGGGCACRAACAWCATCGCTGCTCTGAATGGCGTCGTGTTCAGGCATGTTCCAGCGCGCACAATGAGCT
TSS9
C T C A G C T T A A C G G A T T C G C C C T T G R C T G C A T G A A G
G G C G A A T T C G C G G C C G C T R R R T T C A A T T C G C C C T A T A G T G C

CTGGCGTTACCCAACTTAATCGCCTTGCAGCACATCCCCCTTTCGCCAGCTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACA
G T T G C G C A G C C T A T A C G T A C G G C A G T T T A A G G T T T A C A C C T
GACACGCCGGGGCGACGGATGGTGATCCCCCTGGCCAGTGCACGTCTGCTGTCAGATAARGTCTCCCGTWCTTTACCCGGTGGTGCATATCG
GGGATGAAAGCTGGCGCATGATGACCACCGATATGGCCAGTGTGCCGGTCTCCGTTATCGGGWLAWLAGTGGCTGATCTCAGCCACCGC~
TGACATmCGCCATTAACCTGATGTTCTGGGGAATATAAATGTCAGGCATGAGATTAT~GGATcTTCAccTAGATccTTTTCAcG

TAGAAAGCCAGTCCGCAGRRACGGTGCTGACCCCGGATGAATGTCAGCTACTGGGCTATCTmCAAGGGAAARCGCAAGCGCAARGAGRAAGc
AGGTAGCTTGCAGTGGGCTTACATGGCGATAGCTAGACTGGCGGTTTTATGGACAGCAAGCGAACCGGAATTGCCAGCTGGGGCGCCCTCTGGT
AAGGTTGGGAAGCCCTGmGTAAACTGGRTGGCTTTCTTGccGcCAAGGATcTGXTGGcGCAGGGGATCAAGcTcTGATCAAGAGACAGGAT
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T C G G C T G C T C T G A T G C G C G T G T C G C T G T C A G C G C A G G G C
GCAGCCGTCTATGCCGTGACCTGCCACCGTGCCTGAGC
TSSlO
CTTAAGCTTACGATTCGCCCTTCGTATCTCTTCATAGCCTTATGCATCACCATCATAACTCTGAAGGTCCAGCAACACCAATCCATGTGGGTAA
ATTCTCAARTTGGCAARGCTGCCGTTCTTGTTTGTGTAGGTTGCTAAATAGCCATGGTCCTGCCAffiTGTGCACCGACTCCGCCATCCCCTGCT
CCTGGAAARTGGACTGGAGGCCTTTTAGAATGGTCTCACGCGTGCTGTGCCGTGCTGCTGCCAT
AGTGAGGCGAGGCCCTGTGCCATGCCTGGGGGXGCAGCCGCGGGAGACTGGGGGGCCGCGCGGCGTGTCAGGCTGCGGCCGGCTGGGXGTTTTc
TACTCCTTCAGTCCATGT~TGTCmGGGCWTTCGCGGccGCTAARTTCAATTcGcccTATAGTGAGTcGTATTACAATTCAcTGGccGTc
GTTTTACAACGTCGTGACTGGWCCCTGGCGTTACCCAACTTAATCGCCTTGCAGCACATCCCCCTTTCGCCAGCTGKGTMTAGCWG
AGGCCCGCACCGATCGCCCTTCCCAACRGTTGCGCAGCCTATACGTACGGCAGTTTAAGGTTTACACCTATAAAAGAGAGAGCCGTTATCGTCT
GTTTGTGGATGTACAGAGT~TATTATTGACACGCCGGGGcGAcGGXTGGTGATcccccTGGccAGTGCAcGTcTGcTGTCAGXTAARGTcTcc
CGTGAACTTTACCCGGTGGTGCATATCGGGGATGAAAGCTGGCGCATGATGACCACCGATATGGCCAGTGTGCCGGTCTCCGTTATCGGGGAAG
AAGTGGCTGATCTCAGCCACCGC~TGACATWCGCCATTAACCTGATGTTCTGGGGAATATAAATGTCAGGCATGAGATTATm
AAGGATCTTCACCTAGATCCTTTTCACGTAGAAAGCCAGTCCGCRGAACGGTGCTGACCCCGGGATGRRTGTCAGCTACTGGGCTATCTGGACA
G G G A A A A A C G C A A G C G C A A A G A A G A A A G C A G T A G C T T G C G

GCAAGCTGGGGCGCTCTGGT~GGTTGGTAGTCCTGCCARAGATARRACT
TSSll
C T C C A G C T T A A C G G A l i T T C G C C C T T C G T A T C T C T T C T C C
GGAGTGCAATGGATAAGCCTCGCCCT~CCACCTTCGTGATCATGGTATCTCCCCTGCCAGGTAAGTATTTTCTACTCCTTCAGTCCAT
G T C A G T G T C C A A G G G C G A A T T C G C G G C C G C T R R R T T C C C G T C G T

GXCTGG~CCCTGGCGTTACCCAACTTAATCGCCTTGCAGCAcATcccccTTTcGCCAGcTGGcGTAATAGcWGAGGcccGCAccGATc
GCCCTTCCCAACAGTTGCGCAGCCTATACGTACGGCAGTTTAAGGTTTACACCTATWGAGAGAGCCGTTATCGTCTGTTTGTGGATGTACR
GAGTGATATTATTGRCACGCCGGGGCGACGGATGGTGATCCCCCTffiCCAGTGCACGTCTGCTGTCAGATAAAGTCTCCCGTGAACTTTACccG
GTGGTGCATATCGGGGATGRRAGCTGGCGCATGATGACCACCGRTATGGCCAGTGTGCCGGTCTCCGTTATCGGGGAAGAAGTGGCTGATCTCA
GCCACCGCGAAARTGACATWCGCmTTAACCTGATGTTCTGGGGAATATRRRTGTCAGGCATGAGATTAT~GGATCTTCACcTA
GATCCTTTTCACGTAGRRAGCCAGTCCGCAGAAACGGTGCTGRCCCCGGATWTGTCAGCTACTGGGCTATCTGGACAAGG-CGCAAGC

GmGAGARAGCAGGTAGCTTGCAGTGGGCTTAmTGGcGATAGcTAGAcTGGGcGGTTTTATGGACA~GcGAAccGGAATTGcCAGcTG
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TCAGAGACAGGATGAGGGATCGTTTCGCATGXTTGACAGATGGATTGCACGCAGGTCCTCCGCGCTGGGTGGAGXGGCTATCGGCTATGACTGA

CACACAGACATCGGCTGCTCTGATGCGCGATATTCGGCCGGATCAGCGCGCACAAGXGC
TSS12
CGTCAGGCTTMCGAATTCGCCCTTCGTATCTCTTCATAGCCTTATGCAGTGTCCTCGTGTTTCTACTCCTTCAGTCCATGTCAGTGTCCTCGT
GTTTCTACTCCTTCAGTCCATGTCAGTGGTCCTCGTGCTTTTcTAcTCcTTCAGTcCATGTCRGTGTcmGGGcGAATTcKGGccGcTRRRT
TCAATTCGCCCTATAGTGAGTCGTATTACAATTCAcTGGCcGTcGTTTTAcAAcGTcGTGAcTGGwcccTGGcGTTACcCAAcTTRATcG

CCTTGCAGCACATCCCCCTTTCGCCAGCTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAGTTGCGCAGCCTATACGTACGG
CAGTTTI\RGGTTTACRCCTATAAAAGAGAGAGCCGTTATcGTcTGTTTGTGGATGTACAGAGTGATATTATTGACAcKcGffiGcGAcGGATGG
TGATCCCCCTGGCCAGTGCACGTCTGCTGTCAGATAARGTCTCCCGTWCTTTACCCGGTGGTGCATATCffiGGATWGCTGGCGCATGAT
GACCACCGATATGGCCAGTGTGCCGGTCTCCGTTATCGGGWWGTGGCTGATCTCAGCCRCCGC-TGACATWCGCCATTAAC
CTGATGTTCTGGGGAATATAAATGTCAGGCATGAGATTATc~GGXTcTTCACcTAGATccTTTTCAcGTAGAAAGcCAGTccGCAGAARc

GGTGCTGACCCCGGATGAATGTCAGCTACTGGGCTATcTGGAmGG~cGCAAGcG~GAGAAAGCRGGTAGcTTGCAGTGGGcTTAc
ATGGCGATAGCTAGACTGGGCGGTTTTATGGACAG~GCGRRCCGGRRTTGCCAGCTGGGGCGCCCTCTGGTAAGGTTGGWGCCCTG~
GTAAACTGGRTGGCTTCTTGCCGCCAAGGATCTGATGGCGCAGGGRTCAAGCTCTGATCAGAGACAGGATGAGGATCGTTTCGCATGATTGAAC
A A G A T G G A T T G C A C G C A G G T T C T C G G C C G C T G G G G T G C T G
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